{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "38f1c792",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "thilan\n"
     ]
    }
   ],
   "source": [
    "print(\"thilan\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "9ed5aa58",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from langchain import PromptTemplate\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain.embeddings import HuggingFaceBgeEmbeddings\n",
    "from langchain.vectorstores import Pinecone\n",
    "import pinecone\n",
    "from langchain.document_loaders import PyPDFLoader,DirectoryLoader\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain.prompts import PromptTemplate\n",
    "from langchain.llms import ctransformers\n",
    "from langchain_community.document_loaders import PyPDFLoader, DirectoryLoader\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "8d052f42",
   "metadata": {},
   "outputs": [],
   "source": [
    "PINECONE_API_KEY = \"pcsk_4kdMmd_LSyLr9FYWARVseBiXahi4q28hE1t3Hpt73vA9mi39yMDP57H18QsPL9Gi7xDzJw\"\n",
    "PINECONE_API_ENV = \"quickstart\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "4f04f93f",
   "metadata": {},
   "outputs": [],
   "source": [
    "def load_pdf(data):\n",
    "    loader = DirectoryLoader(data,\n",
    "                             glob = \"*.pdf\",\n",
    "                             loader_cls=PyPDFLoader)\n",
    "    document = loader.load()\n",
    "    return document"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "1d8ccc6e",
   "metadata": {},
   "outputs": [],
   "source": [
    "extracted_data = load_pdf(\"data/\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "177c2956",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 0, 'page_label': '1'}, page_content='WHO/NCD/NCS/99.2\\nOriginal: English\\nDistr.: General\\nDefinition, Diagnosis\\nand Classification\\nof Diabetes Mellitus\\nand its Complications\\nReport of a WHO Consultation\\nPart 1: Diagnosis and Classification of\\nDiabetes Mellitus\\nWorld Health Organization\\nDepartment of Noncommunicable Disease Surveillance\\nGeneva'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 1, 'page_label': '2'}, page_content='© World Health Organization 1999\\nThis document is not a formal publication of the World\\nHealth Organization (WHO), and all rights are reserved by\\nthe Organization. The document may, however, be freely\\nreviewed, abstracted, reproduced and translated, in part or\\nin whole, but not for sale nor for use in conjunction with\\ncommercial purposes.\\nThe views expressed in documents by named authors are\\nsolely the responsibility of those authors'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 2, 'page_label': '3'}, page_content='Contents\\n1.  Introduction 1\\n2.  Definition and diagnostic criteria for diabetes mellitus and\\nother categories of glucose intolerance 2\\n2.1  Definition 2\\n2.2  Diagnosis and diagnostic criteria 3\\n2.2.1  Diagnosis 3\\n2.2.2  Diabetes in children 4\\n2.3  Diagnostic criteria 4\\n2.3.1  Change in diagnostic value for fasting\\nplasma/blood glucose concentrations 5\\n2.3.2  Epidemiological studies 6\\n2.3.3  Individual diagnosis 7\\n3.  Classification 8\\n3.1  Earlier classifications 8\\n3.2  Revised classification 9\\n3.2.1  Application of the new classification 9\\n3.3  Terminology (Table 2) 11\\n4.  Clinical staging of diabetes mellitus and other categories\\nof glucose tolerance (Figure 2) 14\\n4.1  Diabetes mellitus 14\\n4.2  Impaired glucose regulation - Impaired Glucose\\nTolerance and Impaired Fasting Glycaemia 14\\n4.3  Normoglycaemia 16\\n5.  Aetiological types (see also section 7. and Table 2) 17\\n5.1  Type 1 17\\n5.2  Type 2 18\\n5.3  Other specific types (Table 3) 18\\n6.  Gestational Hyperglycaemia and Diabetes 19\\n6.1  Diagnosis of gestational diabetes 20'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 3, 'page_label': '4'}, page_content='7.  Description of aetiological types 21\\n7.1  Type 1 (beta-cell destruction, usually leading to       \\nabsolute insulin deficiency) 21\\n7.1.1  Autoimmune Diabetes Mellitus 21\\n7.1.2  Idiopathic 22\\n7.2  Type 2 (predominantly insulin resistance with relative\\ninsulin deficiency or predominantly an insulin\\nsecretory defect with/without insulin resistance) 23\\n7.3  Other Specific Types 25\\n7.3.1  Genetic defects of beta-cell function 25\\n7.3.2  Genetic defects in insulin action 26\\n7.3.3  Diseases of the exocrine pancreas 27\\n7.3.4  Endocrinopathies 27\\n7.3.5  Drug- or chemical-induced diabetes 28\\n7.3.6  Infections 28\\n7.3.7  Uncommon but specific forms of\\nimmune-mediated diabetes mellitus 29\\n7.3.8  Other genetic syndromes sometimes\\nassociated with diabetes 30\\n8.  The Metabolic Syndrome 31\\n8.1  Definition 32\\n8.2  Future needs 33\\nReferences 34\\nAnnex 1  The Oral Glucose Tolerance Test 48\\nAnnex 2  Methods for measuring substances in blood and urine 49'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 4, 'page_label': '5'}, page_content=\"Members\\nKGMM Alberti, University of Newcastle upon Tyne, UK       (Co–\\nChairman)\\nP Aschner, ACD and Javerlana University, Bogota, Colombia\\nJ–P Assal, University Hospital, Geneva, Switzerland\\nPH Bennett, NIDDK, Phoenix, AZ, USA\\nL Groop, University of Lund, Malmö, Sweden\\nJ Jervell, Rikshospitalet, Oslo, Norway\\nY Kanazawa, Jichi Medical School, Omiya, Japan\\nH Keen, Guy's Hospital and Medical School, London, UK\\nR Klein, University of Wisconsin Medical School, Madison, WI, USA\\nJ–C Mbanya, Centre Hospitalier et Universitaire de Yaoundé,\\nCameroon\\nD McCarty, International Diabetes Institute, Caulfield, Australia\\n(Rapporteur)\\nA Motala, University of Natal, Congella, South Africa\\nPan X–R, China–Japan Friendship Hospital, Beijing, China PR\\n(deceased 8 July 1997)\\nA Ramachandran, Diabetes Research Centre, Madras, India\\nN Samad, Dow Medical College & Civil Hospital, Karachi, Pakistan\\nN Unwin, University of Newcastle upon Tyne, UK (Rapporteur)\\nP Vardi, Schneider Children's Centre, Petah–Tikvah, Israel\\nPZ Zimmet, International Diabetes Institute, Caulfield, Australia (Co–\\nChairman)\\nSecretariat\\nA Alwan, World Health Organization, Geneva, Switzerland\\nH King, World Health Organization, Geneva, Switzerland\"),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 5, 'page_label': '6'}, page_content='Observers\\nM Berrens, Bayer, Germany\\nR Kahn, American Diabetes Association, USA\\nJ Nolan, Institute for Diabetes Discovery, USA\\nS Pramming, Novo Nordisk, Denmark\\nRA Rizza, American Diabetes Association, USA'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 6, 'page_label': '7'}, page_content='1\\n1. Introduction\\nIn the late 1970s both WHO (1) and the National Diabetes\\nData Group (2) produced new diagnostic criteria and a new\\nclassification system for diabetes mellitus. This brought order\\nto a chaotic situation in which nomenclature varied and\\ndiagnostic criteria showed enormous variations using\\ndifferent oral glucose loads. In 1985 WHO slightly modified\\ntheir criteria to coincide more closely with the NDDG values\\n(3). There are now many data available, and also much more\\naetiological information has appeared. It seemed timely to re–\\nexamine the issues and to update and refine both the\\nclassification and the criteria, and to include a definition of\\nthe “Metabolic Syndrome”.\\nAn American Diabetes Association (ADA) expert group was\\nconvened to discuss these issues. It published its\\nrecommendations in 1997 (4). WHO convened a\\nConsultation on the same subject in London, United\\nKingdom, in December 1996. In general, the ADA and WHO\\ngroups reached similar conclusions.\\nThe provisional report of the WHO Consultation (5) solicited\\ncomments which were considered in preparing the present\\nreport. Both the provisional and the present report were\\nprepared by Professor K.G.M.M. Alberti and Professor P.Z.\\nZimmet on behalf of the members of the Consultation.  The\\nmeeting was made possible with financial support from\\nBayer, UK; Bayer, Germany; Novo Nordisk, Copenhagen,\\nDenmark; and The Institute for Diabetes Discovery, New\\nHaven, USA.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 7, 'page_label': '8'}, page_content='2\\n2. Definition and diagnostic criteria for\\ndiabetes mellitus and other categories\\nof glucose intolerance\\n2.1 Definition\\nThe term diabetes mellitus describes a metabolic disorder of\\nmultiple aetiology characterized by chronic hyperglycaemia\\nwith disturbances of carbohydrate, fat and protein\\nmetabolism resulting from defects in insulin secretion, insulin\\naction, or both. The effects of diabetes mellitus include long–\\nterm damage, dysfunction and failure of various organs.\\nDiabetes mellitus may present with characteristic symptoms\\nsuch as thirst, polyuria, blurring of vision, and weight loss. In\\nits most severe forms, ketoacidosis or a non–ketotic\\nhyperosmolar state may develop and lead to stupor, coma\\nand, in absence of effective treatment, death. Often symptoms\\nare not severe, or may be absent, and consequently\\nhyperglycaemia sufficient to cause pathological and\\nfunctional changes may be present for a long time before the\\ndiagnosis is made. The long–term effects of diabetes mellitus\\ninclude progressive development of the specific\\ncomplications of retinopathy with potential blindness,\\nnephropathy that may lead to renal failure, and/or neuropathy\\nwith risk of foot ulcers, amputation, Charcot joints, and\\nfeatures of autonomic dysfunction, including sexual\\ndysfunction. People with diabetes are at increased risk of\\ncardiovascular, peripheral vascular and cerebrovascular\\ndisease.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 8, 'page_label': '9'}, page_content='3\\nSeveral pathogenetic processes are involved in the\\ndevelopment of diabetes. These include processes which\\ndestroy the beta cells of the pancreas with consequent insulin\\ndeficiency, and others that result in resistance to insulin\\naction. The abnormalities of carbohydrate, fat and protein\\nmetabolism are due to deficient action of insulin on target\\ntissues resulting from insensitivity or lack of insulin.\\n2.2 Diagnosis and diagnostic criteria\\n2.2.1 Diagnosis\\nIf a diagnosis of diabetes is made, the clinician must feel\\nconfident that the diagnosis is fully established since the\\nconsequences for the individual are considerable and lifelong.\\nThe requirements for diagnostic confirmation for a person\\npresenting with severe symptoms and gross hyperglycaemia\\ndiffer from those for the asymptomatic person with blood\\nglucose values found to be just above the diagnostic cut–off\\nvalue. Severe hyperglycaemia detected under conditions of\\nacute infective, traumatic, circulatory or other stress may be\\ntransitory and should not in itself be regarded as diagnostic of\\ndiabetes. The diagnosis of diabetes in an asymptomatic\\nsubject should never be made on the basis of a single\\nabnormal blood glucose value. For the asymptomatic person,\\nat least one additional plasma/blood glucose test result with a\\nvalue in the diabetic range is essential, either fasting, from a\\nrandom (casual) sample, or from the oral glucose tolerance\\ntest (OGTT). If such samples fail to confirm the diagnosis of\\ndiabetes mellitus, it will usually be advisable to maintain\\nsurveillance with periodic re–testing until the diagnostic\\nsituation becomes clear. In these circumstances, the clinician'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 9, 'page_label': '10'}, page_content='4\\nshould take into consideration such additional factors as\\nethnicity, family history, age, adiposity, and concomitant\\ndisorders, before deciding on a diagnostic or therapeutic\\ncourse of action. An alternative to blood glucose estimation\\nor the OGTT has long been sought to simplify the diagnosis\\nof diabetes. Glycated haemoglobin, reflecting average\\nglycaemia over a period of weeks, was thought to provide\\nsuch a test. Although in certain cases it gives equal or almost\\nequal sensitivity and specificity to glucose measurement (6),\\nit is not available in many parts of the world and is not well\\nenough standardized for its use to be recommended at this\\ntime.\\n2.2.2 Diabetes in children\\nDiabetes in children usually presents with severe symptoms,\\nvery high blood glucose levels, marked glycosuria, and\\nketonuria. In most children the diagnosis is confirmed\\nwithout delay by blood glucose measurements, and treatment\\n(including insulin injection) is initiated immediately, often as\\na life–saving measure. An OGTT is neither necessary nor\\nappropriate for diagnosis in such circumstances. A small\\nproportion of children and adolescents, however, present with\\nless severe symptoms and may require fasting blood glucose\\nmeasurement and/or an OGTT for diagnosis.\\n2.3 Diagnostic criteria\\nThe clinical diagnosis of diabetes is often prompted by\\nsymptoms such as increased thirst and urine volume,\\nrecurrent infections, unexplained weight loss and, in severe\\ncases, drowsiness and coma; high levels of glycosuria are\\nusually present. A single blood glucose estimation in excess'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 10, 'page_label': '11'}, page_content='5\\nof the diagnostic values indicated in Figure 1 (black zone)\\nestablishes the diagnosis in such cases. Figure 1 also defines\\nlevels of blood glucose below which a diagnosis of diabetes is\\nunlikely in non–pregnant individuals. These criteria are as in\\nthe 1985 report (3). For clinical purposes, an OGTT to\\nestablish diagnostic status need only be considered if casual\\nblood glucose values lie in the uncertain range (i.e. between\\nthe levels that establish or exclude diabetes) and fasting blood\\nglucose levels are below those which establish the diagnosis of\\ndiabetes. If an OGTT is performed, it is sufficient to measure\\nthe blood glucose values while fasting and at 2 hours after a 75\\ng oral glucose load (Annexes 1 and 2). For children the oral\\nglucose load is related to body weight: 1.75 g per kg. The\\ndiagnostic criteria in children are the same as for adults.\\nDiagnostic interpretations of the fasting and 2–h post–load\\nconcentrations in non–pregnant subjects are shown in Table 1.\\n2.3.1 Change in diagnostic value for fasting\\nplasma/blood glucose concentrations\\nThe major change recommended in the diagnostic criteria for\\ndiabetes mellitus is the lowering of the diagnostic value of the\\nfasting plasma glucose concentration to 7.0 mmol l –1 (126 mg\\ndl–1) and above (3), from the former level of 7.8 mmol l –1 (140\\nmg dl–1) and above. For whole blood the proposed new level is\\n6.1 mmol l –1 (110 mg dl –1) and above, from the former 6.7\\nmmol l–1 (120 mg dl–1).\\nThe new fasting criterion is chosen to represent a value which\\nis at the upper end of the range that corresponds in diagnostic\\nsignificance in many persons to that of the 2–h post–load\\nconcentration, which is not changed. This equivalence has'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 11, 'page_label': '12'}, page_content='6\\nbeen established from several population–based studies (6–\\n8) and it also represents an optimal cut–off point to separate\\nthe components of bimodal frequency distributions of\\nfasting plasma glucose concentrations seen in several\\npopulations. Furthermore, several studies have shown\\nincreased risk of microvascular disease in persons with\\nfasting plasma glucose concentrations of 7.0 mmol l –1 (126\\nmg dl –1) and over (6), and of macrovascular disease in\\npersons with such fasting concentrations, even in those with\\n2–h values of < 7.8 mmol l-1 (140 mg dl–1) (9). Nevertheless,\\nin less obese subjects, in some ethnic groups and in the\\nelderly lower fasting glucose levels may be seen in persons\\nwho have 2–h post–load glucose values that are diagnostic\\nfor diabetes.\\n2.3.2 Epidemiological studies\\nFor population studies of glucose intolerance and diabetes,\\nindividuals have been classified by their blood glucose\\nconcentration measured after an overnight fast and/or 2 h\\nafter a 75 g oral glucose load. Since it may be difficult to be\\nsure of the fasting state, and because of the strong\\ncorrelation between fasting and 2–h values, epidemiological\\nstudies or diagnostic screening have in the past been\\nrestricted to the 2–h values only (Table 1). Whilst this\\nremains the single best choice, if it is not possible to\\nperform the OGTT (e.g. for logistical or economic reasons),\\nthe fasting plasma glucose alone may be used for\\nepidemiological purposes. It has now been clearly shown,\\nhowever, that some of the individuals identified by the new\\nfasting values differ from those identified by 2–h post\\nglucose challenge values (10,11). The latter include the\\nelderly (12) and those with less obesity, such as many Asian\\npopulations. On the other hand, middle-aged, more obese'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 12, 'page_label': '13'}, page_content='7\\npatients are more likely to have diagnostic fasting values\\n(10). Overall population prevalence may (13) or may not\\n(7,10,14) be found to differ when estimates using fasting\\nand 2–h values are compared.\\n2.3.3 Individual diagnosis\\nThe requirements for individual diagnosis differ from those\\nof population studies. The diagnosis should not be based on\\na single glucose determination but requires confirmatory\\nsymptoms or blood/plasma determination. Diagnosis\\nrequires the identification of people at risk for development\\nof complications in whom early preventive strategies are\\nindicated. Ideally therefore both the 2–h and the fasting\\nvalue should be used. These recommendations contrast with\\nthose of the ADA Expert Committee which gives primacy to\\nthe fasting plasma glucose (4).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 13, 'page_label': '14'}, page_content='8\\n3. Classification\\n3.1 Earlier classifications\\nThe first widely accepted classification of diabetes mellitus\\nwas published by WHO in 1980 (1) and, in modified form, in\\n1985 (3). The 1980 and 1985 classifications of diabetes\\nmellitus and allied categories of glucose intolerance included\\nclinical classes and two statistical risk classes. The 1980\\nExpert Committee proposed two major classes of diabetes\\nmellitus and named them, IDDM or Type 1, and NIDDM or\\nType 2. In the 1985 Study Group Report the terms Type 1\\nand Type 2 were omitted, but the classes IDDM and NIDDM\\nwere retained, and a class of Malnutrition–related Diabetes\\nMellitus (MRDM) was introduced. In both the 1980 and 1985\\nreports other classes of diabetes included Other Types and\\nImpaired Glucose Tolerance (IGT) as well as Gestational\\nDiabetes Mellitus (GDM). These were reflected in the\\nsubsequent International Nomenclature of Diseases (IND) in\\n1991, and the tenth revision of the International Classification\\nof Diseases (ICD–10) in 1992. The 1985 classification was\\nwidely accepted and is used internationally. It represented a\\ncompromise between clinical and aetiological classification\\nand allowed classification of individual subjects and patients\\nin a clinically useful manner even when the specific cause or\\naetiology was unknown. The recommended classification\\nincludes both staging of diabetes mellitus based on clinical\\ndescriptive criteria and a complementary aetiological\\nclassification.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 14, 'page_label': '15'}, page_content='9\\n3.2 Revised classification\\nThe classification encompasses both clinical stages and\\naetiological types of diabetes mellitus and other categories of\\nhyperglycaemia, as suggested by Kuzuya and Matsuda (15).\\nThe clinical staging reflects that diabetes, regardless of its\\naetiology, progresses through several clinical stages during\\nits natural history. Moreover, individual subjects may move\\nfrom stage to stage in either direction. Persons who have, or\\nwho are developing, diabetes mellitus can be categorized by\\nstage according to the clinical characteristics, even in the\\nabsence of information concerning the underlying aetiology.\\nThe classification by aetiological type results from improved\\nunderstanding of the causes of diabetes mellitus.\\n3.2.1 Application of the new classification\\nThe new classification contains stages which reflect the\\nvarious degrees of hyperglycaemia in individual subjects with\\nany of the disease processes which may lead to diabetes\\nmellitus.\\nAll subjects with diabetes mellitus can be categorized\\naccording to clinical stage, and this is achievable in all\\ncircumstances. The stage of glycaemia may change over time\\ndepending on the extent of the underlying disease processes\\n(Figure 2). The disease process may be present but may not\\nhave progressed far enough to cause hyperglycaemia. The\\naetiological classification reflects the fact that the defect or'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 15, 'page_label': '16'}, page_content='10\\nprocess which may lead to diabetes may be identifiable at any\\nstage in the development of diabetes – even at the stage of\\nnormoglycaemia. Thus the presence of islet cell antibodies in\\na normoglycaemic individual makes it likely that that person\\nhas the Type 1 autoimmune process. Unfortunately, there are\\nfew sensitive or highly specific indicators of the Type 2\\nprocess at present, although these are likely to be revealed as\\naetiology is more clearly defined. The same disease processes\\ncan cause impaired fasting glycaemia and/or impaired\\nglucose tolerance without fulfilling the criteria for the\\ndiagnosis of diabetes mellitus. In some individuals with\\ndiabetes, adequate glycaemic control can be achieved with\\nweight reduction, exercise and/or oral agents. These\\nindividuals, therefore, do not require insulin and may even\\nrevert to IGT or normoglycaemia. Other individuals require\\ninsulin for adequate glycaemic control but can survive\\nwithout it. These individuals, by definition, have some\\nresidual insulin secretion. Individuals with extensive beta–\\ncell destruction, and therefore no residual insulin secretion,\\nrequire insulin for survival. The severity of the metabolic\\nabnormality can either regress (e.g. with weight reduction),\\nprogress (e.g. with weight gain), or stay the same.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 16, 'page_label': '17'}, page_content='11\\n3.3 Terminology (Table 2)\\nIt is recommended that the terms “insulin–dependent diabetes\\nmellitus” and “non–insulin–dependent diabetes mellitus” and\\ntheir acronyms “IDDM” and “NIDDM” no longer be used.\\nThese terms have been confusing and frequently resulted in\\npatients being classified on the basis of treatment rather than\\npathogenesis.\\nC The terms Type 1 and Type 2 should be reintroduced.\\nThe aetiological type named Type 1 encompasses the\\nmajority of cases which are primarily due to pancreatic\\nislet beta–cell destruction and are prone to\\nketoacidosis. Type 1 includes those cases attributable\\nto an autoimmune process, as well as those with beta–\\ncell destruction and who are prone to ketoacidosis for\\nwhich neither an aetiology nor a pathogenesis is\\nknown (idiopathic). It does not include those forms of\\nbeta–cell destruction or failure to which specific\\ncauses can be assigned (e.g. cystic fibrosis,\\nmitochondrial defects, etc.). Some subjects with this\\ntype can be identified at earlier clinical stages than\\n“diabetes mellitus”.\\nC The type named Type 2 includes the common major\\nform of diabetes which results from defect(s) in insulin\\nsecretion, almost always with a major contribution\\nfrom insulin resistance. It has been argued that a lean\\nphenotype of Type 2 diabetes mellitus in adults found\\nin the Indian sub–continent may be very distinct from\\nthe more characteristic form of Type 2 found in'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 17, 'page_label': '18'}, page_content='12\\nCaucasians. Not enough information is available,\\nhowever, to characterize such subjects separately.\\nC A recent international workshop reviewed the evidence\\nfor, and characteristics of, diabetes mellitus seen in\\nundernourished populations (16,17). Whilst it appears\\nthat malnutrition may influence the expression of\\nseveral types of diabetes, the evidence that diabetes\\ncan be caused by malnutrition or protein deficiency per\\nse is not convincing. Therefore, it is recommended that\\nthe class “Malnutrition–related diabetes” (MRDM) be\\ndeleted. The former subtype of MRDM, Protein–\\ndeficient Pancreatic Diabetes (PDPD or PDDM), may\\nbe considered as a malnutrition modulated or modified\\nform of diabetes mellitus for which more studies are\\nneeded. The other former subtype of MRDM,\\nFibrocalculous Pancreatic Diabetes (FCPD), is now\\nclassified as a disease of the exocrine pancreas,\\nfibrocalculous pancreatopathy, which may lead to\\ndiabetes mellitus.\\nC The class “Impaired Glucose Tolerance” is now\\nclassified as a stage of impaired glucose regulation,\\nsince it can be observed in any hyperglycaemic\\ndisorder, and is itself not diabetes.\\nC A clinical stage of Impaired Fasting Glycaemia has\\nbeen introduced to classify individuals who have\\nfasting glucose values above the normal range, but\\nbelow those diagnostic of diabetes.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 18, 'page_label': '19'}, page_content='13\\nC Gestational Diabetes is retained but now encompasses\\nthe groups formerly classified as Gestational Impaired\\nGlucose Tolerance (GIGT) and Gestational Diabetes\\nMellitus (GDM).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 19, 'page_label': '20'}, page_content='14\\n4. Clinical staging of diabetes mellitus\\nand other categories of glucose\\ntolerance (Figure 2)\\n4.1 Diabetes mellitus\\nDiabetes mellitus, regardless of underlying cause, is sub–\\ndivided into: Insulin requiring for survival  (corresponding to\\nthe former clinical class of “Insulin Dependent Diabetes\\nMellitus – IDDM”), e.g. C–peptide deficient; Insulin\\nrequiring for control , i.e. metabolic control, rather than for\\nsurvival, e.g. some endogenous insulin secretion but\\ninsufficient to achieve normoglycaemia without added\\nexogenous insulin; and Not insulin requiring , i.e. those who\\nmay be controlled satisfactorily by non–pharmacological\\nmethods or drugs other than insulin. Together, the latter two\\nsub–divisions constitute the former class of NIDDM.\\n4.2 Impaired glucose regulation – Impaired\\nGlucose Tolerance (IGT) and Impaired Fasting\\nGlycaemia (IFG)\\nImpaired glucose regulation (IGT and IFG) refers to a\\nmetabolic state intermediate between normal glucose\\nhomeostasis and diabetes. It should be stated unequivocally,\\nhowever, that IFG and IGT are not interchangeable and\\nrepresent different abnormalities of glucose regulation, one in\\nthe fasting state and one post–prandial.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 20, 'page_label': '21'}, page_content='15\\nIGT, rather than being a class as in the previous\\nclassification, is categorized as a stage in the natural history\\nof disordered carbohydrate metabolism. A stage of IFG is\\nalso recognized because such subjects, like those with IGT,\\nhave increased risks of progressing to diabetes and\\nmacrovascular disease, although prospective data are sparse\\nand early data suggest a lower risk of progression than IGT\\n(18), although a similar CVD risk factor profile has been\\nshown in IFG and IGT subjects (19). IFG refers to fasting\\nglucose concentrations which are lower than those required to\\ndiagnose diabetes mellitus but higher than the “normal”\\nreference range.\\nThe values for IFG are a fasting plasma glucose\\nconcentration of 6.1 mmol l–1 (110 mg dl–1) or greater (whole\\nblood 5.6 mmol l –1; 100 mg dl–1), but less than 7.0 mmol l –1\\n(126 mg dl–1) (whole blood 6.1 mmol l –1; 110 mg dl–1). If an\\nOGTT is performed, some individuals with IFG will have\\nIGT or diabetes, but this cannot be determined without an\\nOGTT. If resources allow, it is recommended that all those\\nwith IFG have an OGTT to exclude the diagnosis of diabetes.\\nIndividuals who meet criteria for IGT or IFG may be\\neuglycaemic in their daily lives as shown by normal or near–\\nnormal glycated haemoglobin levels. IGT and IFG are not\\nclinical entities in their own right, but rather risk categories\\nfor future diabetes and/or cardiovascular disease (20,21).\\nThey can occur as an intermediate stage in any of the disease\\nprocesses listed in Table 2. IGT is often associated with the\\nMetabolic Syndrome (Insulin Resistance Syndrome) (22).\\nThus, IGT may not be directly involved in the pathogenesis\\nof cardiovascular disease, but rather may serve as an\\nindicator or marker of enhanced risk by virtue of its\\ncorrelation with the other elements of the Metabolic'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 21, 'page_label': '22'}, page_content='16\\nSyndrome that are cardiovascular risk factors. Self–evidently,\\nthose individuals with IGT manifest glucose intolerance only\\nwhen challenged with an oral glucose load.\\n4.3 Normoglycaemia\\nA fasting venous plasma glucose concentration of less than\\n6.1 mmol l –1 (110 mg dl S1) has been chosen as “normal”\\n(Table 1). Although this choice is arbitrary, such values are\\nobserved in people with proven normal glucose tolerance,\\nalthough some may have IGT if an OGTT is performed.\\nValues above this are associated with a progressively greater\\nrisk of developing micro– and macrovascular complications\\n(8,9,21,23).\\nThe pathological or aetiological processes which often lead to\\ndiabetes mellitus begin, and may be recognizable, in some\\nsubjects who have normal glucose tolerance. Recognition of\\nthe pathological process at an early stage may be useful if\\nprogression to more advanced stages can be prevented.\\nConversely, effective treatments, or occasionally the natural\\nhistory of some forms of diabetes mellitus, may result in\\nreversion of hyperglycaemia to a state of normoglycaemia.\\nThe proposed classification includes a stage of\\nnormoglycaemia in which persons who have evidence of the\\npathological processes which may lead to diabetes mellitus,\\nor in whom a reversal of the hyperglycaemia has occurred,\\nare classified.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 22, 'page_label': '23'}, page_content='17\\n5. Aetiological types\\n (see also section 7 and Table 2)\\nThe aetiological types designate defects, disorders or\\nprocesses which often result in diabetes mellitus.\\n5.1 Type 1\\nType 1 indicates the processes of beta–cell destruction that\\nmay ultimately lead to diabetes mellitus in which “insulin is\\nrequired for survival” to prevent the development of\\nketoacidosis, coma and death. An individual with a Type 1\\nprocess may be metabolically normal before the disease is\\nclinically manifest, but the process of beta–cell destruction\\ncan be detected. Type 1 is usually characterized by the\\npresence of anti–GAD, islet cell or insulin antibodies which\\nidentify the autoimmune processes that lead to beta–cell\\ndestruction. In some subjects with this clinical form of\\ndiabetes, particularly non–Caucasians, no evidence of an\\nautoimmune disorder is demonstrable and these are classified\\nas “Type 1 idiopathic”. Aetiological classification may be\\npossible in some circumstances and not in others. Thus, the\\naetiological Type 1 process can be identified and sub–\\ncategorized if appropriate antibody determinations are\\nperformed. It is recognized that such measurements may be\\navailable only in certain centres at the present time. If these\\nmeasurements are performed, then the classification of\\nindividual patients should reflect this.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 23, 'page_label': '24'}, page_content='18\\n5.2 Type 2\\nType 2 is the most common form of diabetes and is\\ncharacterized by disorders of insulin action and insulin\\nsecretion, either of which may be the predominant feature.\\nBoth are usually present at the time that this form of diabetes\\nis clinically manifest. By definition, the specific reasons for\\nthe development of these abnormalities are not yet known.\\n5.3 Other specific types (Table 3)\\nOther specific types are currently less common causes of\\ndiabetes mellitus, but are those in which the underlying\\ndefect or disease process can be identified in a relatively\\nspecific manner. They include, for example, fibrocalculous\\npancreatopathy, a form of diabetes which was formerly\\nclassified as one type of malnutrition–related diabetes\\nmellitus.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 24, 'page_label': '25'}, page_content='19\\n6. Gestational Hyperglycaemia and\\nDiabetes\\nGestational diabetes is carbohydrate intolerance resulting in\\nhyperglycaemia of variable severity with onset or first\\nrecognition during pregnancy. It does not exclude the\\npossibility that the glucose intolerance may antedate\\npregnancy but has been previously unrecognized. The\\ndefinition applies irrespective of whether or not insulin is\\nused for treatment or the condition persists after pregnancy.\\nWomen who become pregnant and who are known to have\\ndiabetes mellitus which antedates pregnancy do not have\\ngestational diabetes but have “diabetes mellitus and\\npregnancy” and should be treated accordingly before, during,\\nand after the pregnancy.\\nIn the early part of pregnancy (e.g. first trimester and first\\nhalf of second trimester) fasting and postprandial glucose\\nconcentrations are normally lower than in normal, non–\\npregnant women. Elevated fasting or postprandial plasma\\nglucose levels at this time in pregnancy may well reflect the\\npresence of diabetes which has antedated pregnancy, but\\ncriteria for designating abnormally high glucose\\nconcentrations at this time have not yet been established. The\\noccurrence of higher than usual plasma glucose levels at this\\ntime in pregnancy mandates careful management and may be\\nan indication for carrying out an OGTT (Annex 1).\\nNevertheless, normal glucose tolerance in the early part of'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 25, 'page_label': '26'}, page_content='20\\npregnancy does not itself establish that gestational diabetes\\nmay not develop later.\\nIndividuals at high risk for gestational diabetes include older\\nwomen, those with previous history of glucose intolerance,\\nthose with a history of large for gestational age babies,\\nwomen from certain high–risk ethnic groups, and any\\npregnant woman who has elevated fasting, or casual, blood\\nglucose levels. It may be appropriate to screen pregnant\\nwomen belonging to high–risk populations during the first\\ntrimester of pregnancy in order to detect previously\\nundiagnosed diabetes mellitus. Formal systematic testing for\\ngestational diabetes is usually done between 24 and 28 weeks\\nof gestation.\\n6.1 Diagnosis of gestational diabetes\\nTo determine if gestational diabetes is present in pregnant\\nwomen, a standard OGTT should be performed after\\novernight fasting (8–14 hours) by giving 75 g anhydrous\\nglucose in 250–300 ml water (Annex 1). Plasma glucose is\\nmeasured fasting and after 2 hours. Pregnant women who\\nmeet WHO criteria for diabetes mellitus or IGT are classified\\nas having Gestational Diabetes Mellitus (GDM). After the\\npregnancy ends, the woman should be re–classified as having\\neither diabetes mellitus, or IGT, or normal glucose tolerance\\nbased on the results of a 75 g OGTT six weeks or more after\\ndelivery. It should be emphasized that such women,\\nregardless of the 6–week post–pregnancy result, are at\\nincreased risk of subsequently developing diabetes. The\\nsignificance of IFG in pregnancy remains to be established.\\nAny woman with IFG, however, should have a 75 g OGTT.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 26, 'page_label': '27'}, page_content='21\\n7. Description of aetiological types\\nPatients with any form of diabetes may require insulin\\ntreatment at some stage of their disease. Such use of insulin\\ndoes not, of itself, define the aetiological class.\\n7.1 Type 1 (beta–cell destruction, usually\\nleading to absolute insulin deficiency)\\n7.1.1 Autoimmune Diabetes Mellitus\\nThis form of diabetes, previously encompassed by the terms\\ninsulin–dependent diabetes, Type 1 diabetes, or juvenile–\\nonset diabetes, results from autoimmune mediated\\ndestruction of the beta cells of the pancreas. The rate of\\ndestruction is quite variable, being rapid in some\\nindividuals and slow in others (24). The rapidly progressive\\nform is commonly observed in children, but also may occur\\nin adults (25). The slowly progressive form generally\\noccurs in adults and is sometimes referred to as latent\\nautoimmune diabetes in adults (LADA). Some patients,\\nparticularly children and adolescents, may present with\\nketoacidosis as the first manifestation of the disease (26).\\nOthers have modest fasting hyperglycaemia that can rapidly\\nchange to severe hyperglycaemia and/or ketoacidosis in the\\npresence of infection or other stress. Still others,\\nparticularly adults, may retain residual beta–cell function,\\nsufficient to prevent ketoacidosis, for many years (27).\\nIndividuals with this form of Type 1 diabetes often become\\ndependent on insulin for survival eventually and are at risk\\nfor ketoacidosis (28). At this stage of the disease, there'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 27, 'page_label': '28'}, page_content='22\\nis little or no insulin secretion as manifested by low or\\nundetectable levels of plasma C–peptide (29).\\nMarkers of immune destruction, including islet cell\\nautoantibodies, and/or autoantibodies to insulin, and\\nautoantibodies to glutamic acid decarboxylase (GAD) are\\npresent in 85–90 % of individuals with Type 1 diabetes\\nmellitus when fasting diabetic hyperglycaemia is initially\\ndetected (30). The peak incidence of this form of Type 1\\ndiabetes occurs in childhood and adolescence, but the onset\\nmay occur at any age, ranging from childhood to the ninth\\ndecade of life (31). There is a genetic predisposition to\\nautoimmune destruction of beta cells, and it is also related\\nto environmental factors that are still poorly defined.\\nAlthough patients are usually not obese when they present\\nwith this type of diabetes, the presence of obesity is not\\nincompatible with the diagnosis. These patients may also\\nhave other autoimmune disorders such as Graves’ disease,\\nHashimoto’s thyroiditis, and Addison’s disease (32).\\n7.1.2 Idiopathic\\nThere are some forms of Type 1 diabetes which have no\\nknown aetiology. Some of these patients have permanent\\ninsulinopenia and are prone to ketoacidosis, but have no\\nevidence of autoimmunity (33). This form of diabetes is\\nmore common among individuals of African and Asian\\norigin. In another form found in Africans an absolute\\nrequirement for insulin replacement therapy in affected\\npatients may come and go, and patients periodically\\ndevelop ketoacidosis (34).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 28, 'page_label': '29'}, page_content='23\\n7.2 Type 2 (predominantly insulin resistance with\\nrelative insulin deficiency or predominantly an\\ninsulin secretory defect with/without insulin\\nresistance)\\nDiabetes mellitus of this type previously encompassed non–\\ninsulin–dependent diabetes, or adult–onset diabetes. It is a\\nterm used for individuals who have relative (rather than\\nabsolute) insulin deficiency. People with this type of diabetes\\nfrequently are resistant to the action of insulin (35,36). At\\nleast initially, and often throughout their lifetime, these\\nindividuals do not need insulin treatment to survive. This\\nform of diabetes is frequently undiagnosed for many years\\nbecause the hyperglycaemia is often not severe enough to\\nprovoke noticeable symptoms of diabetes (37,38).\\nNevertheless, such patients are at increased risk of\\ndeveloping macrovascular and microvascular complications\\n(37,38). There are probably several different mechanisms\\nwhich result in this form of diabetes, and it is likely that the\\nnumber of people in this category will decrease in the future\\nas identification of specific pathogenetic processes and\\ngenetic defects permits better differentiation and a more\\ndefinitive classification with movement into “Other types”.\\nAlthough the specific aetiologies of this form of diabetes are\\nnot known, by definition autoimmune destruction of the\\npancreas does not occur and patients do not have other\\nknown specific causes of diabetes listed in Tables 3–5.\\nThe majority of patients with this form of diabetes are obese,\\nand obesity itself causes or aggravates insulin resistance\\n(39,40). Many of those who are not obese by traditional\\nweight criteria may have an increased percentage of body fat\\ndistributed predominantly in the abdominal region (41).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 29, 'page_label': '30'}, page_content='24\\nKetoacidosis is infrequent in this type of diabetes; when seen\\nit usually arises in association with the stress of another\\nillness such as infection (42,43). Whereas patients with this\\nform of diabetes may have insulin levels that appear normal\\nor elevated, the high blood glucose levels in these diabetic\\npatients would be expected to result in even higher insulin\\nvalues had their beta–cell function been normal (44). Thus,\\ninsulin secretion is defective and insufficient to compensate\\nfor the insulin resistance. On the other hand, some individuals\\nhave essentially normal insulin action, but markedly impaired\\ninsulin secretion. Insulin sensitivity may be increased by\\nweight reduction, increased physical activity, and/or\\npharmacological treatment of hyperglycaemia but is not\\nrestored to normal (45,46). The risk of developing Type 2\\ndiabetes increases with age, obesity, and lack of physical\\nactivity (47,48). It occurs more frequently in women with\\nprior GDM and in individuals with hypertension or\\ndyslipidaemia. Its frequency varies in different racial/ethnic\\nsubgroups (47–50). It is often associated with strong familial,\\nlikely genetic, predisposition (49–51). However, the genetics\\nof this form of diabetes are complex and not clearly defined.\\nSome patients who present with a clinical picture consistent\\nwith Type 2 diabetes have autoantibodies similar to those\\nfound in Type 1 diabetes, and may masquerade as Type 2\\ndiabetes if antibody determinations are not made. Patients\\nwho are non–obese or who have relatives with Type 1\\ndiabetes and who are of Northern European origin may be\\nsuspected of having late onset Type 1 diabetes.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 30, 'page_label': '31'}, page_content='25\\n7.3 Other Specific Types\\n7.3.1 Genetic defects of beta–cell function\\nSeveral forms of the diabetic state may be associated with\\nmonogenic defects in beta–cell function, frequently\\ncharacterized by onset of mild hyperglycaemia at an early\\nage (generally before age 25 years). They are usually\\ninherited in an autosomal dominant pattern. Patients with\\nthese forms of diabetes, formerly referred to as maturity–\\nonset diabetes of the young (MODY), have impaired insulin\\nsecretion with minimal or no defect in insulin action (52,53).\\nAbnormalities at three genetic loci on different\\nchromosomes have now been characterized. The most\\ncommon form is associated with mutations on chromosome\\n12 in a hepatic nuclear transcription factor referred to as\\nHNF1\" (54). A second form is associated with mutations in\\nthe glucokinase gene on chromosome 7p (55,56).\\nGlucokinase converts glucose to glucose–6–phosphate, the\\nmetabolism of which in turn stimulates insulin secretion by\\nthe beta cell. Thus, glucokinase serves as the “glucose\\nsensor” for the beta cell. Because of defects in the\\nglucokinase gene, increased levels of glucose are necessary\\nto elicit normal levels of insulin secretion. A third form is\\nassociated with a mutation in the HNF4 \" gene on\\nchromosome 20q (57). HNF4\" is a transcription factor which\\nis involved in the regulation of the expression of HNF1 \". A\\nfourth variant has recently been ascribed to mutations in\\nanother transcription factor gene, IPF–1, which in its\\nhomozygous form leads to total pancreatic agenesis (58).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 31, 'page_label': '32'}, page_content='26\\nSpecific genetic defects in other individuals who have a\\nsimilar clinical presentation are currently being defined.\\nPoint mutations in mitochondrial DNA have been found to be\\nassociated with diabetes mellitus and deafness (59). The most\\ncommon mutation occurs at position 3243 in the tRNA\\nleucine gene, leading to an A to G substitution. An identical\\nlesion occurs in the MELAS syndrome (Mitochondrial\\nmyopathy, Encephalopathy, Lactic Acidosis, and Stroke–like\\nsyndrome); however, diabetes is not part of this syndrome,\\nsuggesting for unknown reasons different phenotypic\\nexpressions of this genetic lesion (60).\\nGenetic abnormalities that result in the inability to convert\\nproinsulin to insulin have been identified in a few families.\\nSuch traits are usually inherited in an autosomal dominant\\npattern (61,62) and the resultant carbohydrate intolerance is\\nmild. Similarly, mutant insulin molecules with impaired\\nreceptor binding have been identified in a few families. These\\nare also associated with autosomal inheritance and either\\nnormal or only mildly impaired carbohydrate metabolism\\n(63,64).\\n7.3.2 Genetic defects in insulin action\\nThere are some unusual causes of diabetes which result from\\ngenetically determined abnormalities of insulin action. The\\nmetabolic abnormalities associated with mutations of the\\ninsulin receptor may range from hyperinsulinaemia and\\nmodest hyperglycaemia to symptomatic diabetes (65,66).\\nSome individuals with these mutations have acanthosis\\nnigricans. Women may have virilization and have enlarged,'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 32, 'page_label': '33'}, page_content='27\\ncystic ovaries. In the past, this syndrome was termed Type A\\ninsulin resistance (65). Leprechaunism and Rabson–\\nMendenhall syndrome are two paediatric syndromes that\\nhave mutations in the insulin receptor gene with subsequent\\nalterations in insulin receptor function and extreme insulin\\nresistance (66). The former has characteristic facial features\\nwhile the latter is associated with abnormalities of teeth and\\nnails and pineal gland hyperplasia.\\n7.3.3 Diseases of the exocrine pancreas\\nAny process that diffusely injures the pancreas can cause\\ndiabetes. Acquired processes include pancreatitis, trauma,\\ninfection, pancreatic carcinoma, and pancreatectomy (67,68).\\nWith the exception of cancer, damage to the pancreas must be\\nextensive for diabetes to occur. However, adenocarcinomas\\nthat involve only a small portion of the pancreas have been\\nassociated with diabetes. This implies a mechanism other\\nthan simple reduction in beta–cell mass (69). If extensive\\nenough, cystic fibrosis and haemochromatosis will also\\ndamage beta cells and impair insulin secretion (70,71).\\nFibrocalculous pancreatopathy may be accompanied by\\nabdominal pain radiating to the back and pancreatic\\ncalcification on X–ray and ductal dilatation (72). Pancreatic\\nfibrosis and calcified stones in the exocrine ducts are found at\\nautopsy.\\n7.3.4 Endocrinopathies\\nSeveral hormones (e.g. growth hormone, cortisol, glucagon,\\nepinephrine) antagonize insulin action. Diseases associated\\nwith excess secretion of these hormones can cause diabetes\\n(e.g. Acromegaly, Cushing’s Syndrome, Glucagonoma and'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 33, 'page_label': '34'}, page_content='28\\nPhaeochromocytoma) (73). These forms of hyperglycaemia\\ntypically resolve when the hormone excess is removed.\\nSomatostatinoma, and aldosteronoma–induced hypokalaemia,\\ncan cause diabetes, at least in part by inhibiting insulin\\nsecretion (74,75). Hyperglycaemia generally resolves\\nfollowing successful removal of the tumour.\\n7.3.5 Drug– or chemical–induced diabetes\\nMany drugs can impair insulin secretion. These drugs may\\nnot, by themselves, cause diabetes but they may precipitate\\ndiabetes in persons with insulin resistance (76,77). In such\\ncases, the classification is ambiguous, as the primacy of beta–\\ncell dysfunction or insulin resistance is unknown. Certain\\ntoxins such as Vacor (a rat poison) and pentamidine can\\npermanently destroy pancreatic beta cells (78–80).\\nFortunately, such drug reactions are rare. There are also many\\ndrugs and hormones which can impair insulin action.\\nExamples include nicotinic acid and glucocorticoids (71,72).\\nThe list shown in Table 4 is not all–inclusive, but reflects the\\nmore commonly recognized drug–, hormone–, or toxin–\\ninduced forms of diabetes and hyperglycaemia.\\n7.3.6 Infections\\nCertain viruses have been associated with beta–cell\\ndestruction. Diabetes occurs in some patients with congenital\\nrubella (81). In addition, Coxsackie B, cytomegalovirus and\\nother viruses (e.g. adenovirus and mumps) have been\\nimplicated in inducing the disease (82–84).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 34, 'page_label': '35'}, page_content='29\\n7.3.7 Uncommon but specific forms of immune–\\nmediated diabetes mellitus\\nDiabetes may be associated with several immunological\\ndiseases with a pathogenesis or aetiology different from that\\nwhich leads to the Type 1 diabetes process. Postprandial\\nhyperglycaemia of a severity sufficient to fulfil the criteria\\nfor diabetes has been reported in rare individuals who\\nspontaneously develop insulin autoantibodies (85,86).\\nHowever, these individuals generally present with symptoms\\nof hypoglycaemia rather than hyperglycaemia. The “stiff man\\nsyndrome” is an autoimmune disorder of the central nervous\\nsystem, characterized by stiffness of the axial muscles with\\npainful spasms (87). Affected people usually have high titres\\nof the GAD autoantibodies and approximately one-half will\\ndevelop diabetes. Patients receiving interferon alpha have\\nbeen reported to develop diabetes associated with islet cell\\nautoantibodies and, in certain instances, severe insulin\\ndeficiency (88).\\nAnti–insulin receptor antibodies can cause diabetes by\\nbinding to the insulin receptor, thereby reducing the binding\\nof insulin to target tissues (89). However, these antibodies\\nalso can act as an insulin agonist after binding to the receptor\\nand can thereby cause hypoglycaemia (90). Anti–insulin\\nreceptor antibodies are occasionally found in patients with\\nsystemic lupus erythematosus and other autoimmune diseases\\n(91). As in other states of extreme insulin resistance, patients\\nwith anti–insulin receptor antibodies often have acanthosis\\nnigricans. In the past, this syndrome was termed Type B\\ninsulin resistance.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 35, 'page_label': '36'}, page_content='30\\n7.3.8 Other genetic syndromes sometimes\\nassociated with diabetes\\nMany genetic syndromes are accompanied by an increased\\nincidence of diabetes mellitus. These include the\\nchromosomal abnormalities of Down’s syndrome,\\nKlinefelter’s syndrome and Turner’s syndrome. Wolfram’s\\nsyndrome is an autosomal recessive disorder characterized by\\ninsulin–deficient diabetes and the absence of beta cells at\\nautopsy (92). Additional manifestations include diabetes\\ninsipidus, hypogonadism, optic atrophy, and neural deafness.\\nThese and other similar disorders are listed in Table 5.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 36, 'page_label': '37'}, page_content='31\\n8. The Metabolic Syndrome\\nA major classification, diagnostic and therapeutic challenge\\nis the person with hypertension, central (upper body) obesity,\\nand dyslipidaemia, with or without hyperglycaemia. This\\ngroup of people is at high risk of macrovascular disease (22).\\nOften a person with abnormal glucose tolerance (IGT or\\ndiabetes) will be found to have at least one or more of the\\nother cardiovascular disease (CVD) risk components (22).\\nThis clustering has been labelled variously as Syndrome X\\n(22), the Insulin Resistance Syndrome (47), or the Metabolic\\nSyndrome (47).\\nEpidemiological studies confirm that this syndrome occurs\\ncommonly in a wide variety of ethnic groups including\\nCaucasians, Afro–Americans, Mexican–Americans, Asian\\nIndians, Chinese, Australian Aborigines, Polynesians and\\nMicronesians (47,93). In 1988 Reaven focused attention on\\nthis cluster, naming it Syndrome X (22). Central obesity was\\nnot included in the original description so the term Metabolic\\nSyndrome is now favoured.\\nEvidence is accumulating that insulin resistance may be the\\ncommon aetiological factor for the individual components of\\nthe Metabolic Syndrome (47,93,94), although there appears\\nto be heterogeneity in the strength of the insulin resistance\\nrelationship with different components between, and even\\nwithin, populations. Alone, each component of the cluster\\nconveys increased CVD risk, but as a combination they'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 37, 'page_label': '38'}, page_content='32\\nbecome much more powerful (95). This means that the\\nmanagement of persons with hyperglycaemia and other\\nfeatures of the Metabolic Syndrome should focus not only on\\nblood glucose control but also include strategies for reduction\\nof the other CVD risk factors (96).\\nIt is well documented that the features of the Metabolic\\nSyndrome can be present for up to 10 years before detection\\nof the glycaemic disorders (97). This is important in relation\\nto the aetiology of the hyperglycaemia and the associated\\nCVD risk, and the potential to prevent CVD and its morbidity\\nand mortality in persons with glucose intolerance.\\nThe Metabolic Syndrome with normal glucose tolerance\\nidentifies the subject as a member of a group at very high risk\\nof future diabetes. Thus, vigorous early management of the\\nsyndrome may have a significant impact on the prevention of\\nboth diabetes and cardiovascular disease (98).\\n8.1 Definition\\nThere is no internationally agreed definition for the\\nMetabolic Syndrome. The following, which does not imply\\ncausal relationships, is suggested as a working definition to\\nbe improved upon in due course: glucose intolerance, IGT or\\ndiabetes mellitus and/or insulin resistance together with two\\nor more of the other components listed below:\\n• Impaired glucose regulation or diabetes (see Table 1)'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 38, 'page_label': '39'}, page_content='33\\n• Insulin resistance (under hyperinsulinaemic, euglycaemic\\nconditions, glucose uptake below lowest quartile for\\nbackground population under investigation)\\n• Raised arterial pressure ≥ 140/90 mmHg\\n• Raised plasma triglycerides (≥ 1.7 mmol l –1; 150 mg dl–1)\\nand/or low HDL–cholesterol (< 0.9 mmol l –1, 35 mg dl –1\\nmen; < 1.0 mmol l–1, 39 mg dl–1 women)\\n• Central obesity (males: waist to hip ratio > 0.90; females:\\nwaist to hip ratio > 0.85) and/or BMI > 30 kg m–2\\n• Microalbuminuria (urinary albumin excretion rate ≥ 20\\nµg min–1 or albumin:creatinine ratio  ≥ 30 mg g–1)\\nSeveral other components of the Metabolic Syndrome have\\nbeen described (e.g. hyperuricaemia, coagulation disorders,\\nraised PAI–1, etc.) but they are not necessary for the\\nrecognition of the condition.\\n8.2 Future needs\\nA clear description of the essential components of the\\nsyndrome is needed together with data to support the relative\\nimportance of each component. Internationally agreed criteria\\nfor central obesity, insulin resistance and hyperinsulinaemia\\nwould be of major assistance.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 39, 'page_label': '40'}, page_content='34\\nReferences\\n1. WHO Expert Committee on Diabete s Mellitus. Second\\nReport. Geneva: WHO, 1980. Technical Report Series\\n646.\\n2. National Diabetes Data Group. Classification and\\ndiagnosis of diabetes mellitus and other categories of\\nglucose intolerance. Diabetes 1979; 28: 1039–57.\\n3. World Health Organizat ion. Diabetes Mellitus: Report\\nof a WHO Study Group . Geneva: WHO, 1985.\\nTechnical Report Series 727.\\n4. The Expert Committee on the Diagnosis and\\nClassification of Diabetes Mellitus. Report of the Expert\\nCommittee on the Diagnosis and Classification of\\nDiabetes Mellitus. Diabetes Care 1997; 20: 1183–97.\\n5. Alberti KGMM, Zimmet PZ for the WHO Consultation.\\nDefinition, diagnosis and classification of diabetes\\nmellitus and its complications. Part 1: diagnosis and\\nclassification of diabetes mellitus. Provisional report of\\na WHO Consultation. Diabetic Medicine  1998; 15:\\n539–553.\\n6. McCance DR, Hanson RL, Charles MA, Jacobsson\\nLTH, Pettitt DJ, Bennett PH et al. Comparison of tests\\nfor glycated haemoglobin and fasting and two hour\\nplasma glucose concentrations as diagnostic methods\\nfor diabetes. BMJ 1994; 308: 1323–28.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 40, 'page_label': '41'}, page_content='35\\n7. Finch CF, Zimmet PZ, Alberti KGMM. Determining\\ndiabetes prevalence: a rational basis for the use of\\nfasting plasma glucose concentrations?  Diabetic\\nMedicine 1990; 7: 603–10.\\n8. Engelgau MM, Thompson TJ, Herman WH, Boyle JP,\\nAubert RE, Kenny SJ et al. Comparison of fasting and\\n2–hour glucose and HbA1c levels for diagnosing\\ndiabetes: diagnostic criteria and performance revisited.\\nDiabetes Care 1997; 20: 785–91.\\n9. Charles MA, Balkau B, Vauzelle–Kervoeden F, Thibult\\nN, Eschwège E. Revision of diagnostic criteria for\\ndiabetes (Letter). Lancet 1996; 348: 1657–58.\\n10. DECODE Study Group on behalf of the European\\nDiabetes Epidemiology Study Group. Will new\\ndiagnostic criteria for diabetes mellitus change\\nphenotype of patients with diabetes? Reanalysis of\\nEuropean epidemiological data. BMJ 1998; 317: 371–\\n375.\\n11. De Vegt F, Dekker JM, Stehouwer CDA, Nijpels G,\\nBouter LM, Heine RJ. The 1997 American Diabetes\\nAssociation criteria versus the 1985 World Health\\nOrganization criteria for the diagnosis of abnormal\\nglucose tolerance: poor agreement in the Hoorn Study.\\nDiabetes Care 1998; 21: 1686–1690.\\n12. Wahl PW, Savage PJ, Psaty BM, Orchard TJ, Robbins\\nJA, Tracy RP. Diabetes in older adults: comparison of\\n1997 American Diabetes Association classification of\\ndiabetes mellitus with 1985 WHO classification. Lancet\\n1998; 352: 1012–1015.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 41, 'page_label': '42'}, page_content='36\\n13. Harris MI, Eastman RC, Cowie CC, Flegal KM,\\nEberhardt MS. Comparison of diabetes diagnostic\\ncategories in the US population according to 1997\\nAmerican Diabetes Association and 1980–1985 World\\nHealth Organization diagnostic criteria. Diabetes Care\\n1997; 20: 1859–62.\\n14. Ramachandran A, Snehalatha C, Latha E, Vijay V.\\nEvaluation of the use of fasting plasma glucose as a\\nnew diagnostic criterion for diabetes in Asian Indian\\npopulation (Letter). Diabetes Care 1998; 21: 666–67.\\n15. Kuzuya T, Matsuda A. Classification of diabetes on the\\nbasis of etiologies versus degree of insulin deficiency.\\nDiabetes Care 1997; 20: 219–20.\\n16. Hoet JJ, Tripathy BB, Rao RH, Yajnik CS. Malnutrition\\nand diabetes in the tropics. Diabetes Care 1996; 19:\\n1014–17.\\n17. Tripathy BB, Samal KC. Overview and consensus\\nstatement on diabetes in tropical areas. Diabetes\\nMetab Rev 1997; 13: 63–76.\\n18. Shaw JE, Zimmet PZ, de Courten M, Dowse GK,\\nGareeboo H, Hemraj F et al. IFG or IGT: what best\\npredicts future diabetes?  A view of the new ADA\\nrecommendations. Diabetes Care 1999 (In press)\\n19. Larsson H, Berglund G, Lindgärde F, Ahrén B.\\nComparison of ADA and WHO criteria for diagnosis of\\ndiabetes and glucose intolerance. Diabetologia  1998;\\n41: 1124–1125.\\n20. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H.\\nCoronary heart disease risk and impaired glucose\\ntolerance: the Whitehall Study. Lancet 1980; i: 1373–\\n76.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 42, 'page_label': '43'}, page_content='37\\n21. Alberti KGMM. The clinical implications of Impaired\\nGlucose Tolerance. Diabet Med 1996; 13: 927–37.\\n22. Reaven GM. Role of insulin resistance in human\\ndisease. Diabetes 1988; 37: 1595–607.\\n23. McCance DR, Hanson RL, Pettitt DJ, Bennett PH,\\nHadden DR, Knowler WC. Diagnosing diabetes\\nmellitus – do we need new criteria?  Diabetologia\\n1997; 40: 247–55.\\n24. Zimmet PZ, Tuomi T, Mackay R, Rowley MJ, Knowles\\nW, Cohen M et al. Latent autoimmune diabetes\\nmellitus in adults (LADA): the role of antibodies to\\nglutamic acid decarboxylase in diagnosis and\\nprediction of insulin dependency. Diabetic Med  1994;\\n11: 299–303.\\n25. Humphrey ARG, McCarty DJ, Mackay IR, Rowley MJ,\\nDwyer T, Zimmet P. Autoantibodies to glutamic acid\\ndecarboxylase and phenotypic features associated\\nwith early insulin treatment in individuals with adult–\\nonset diabetes mellitus. Diabetic Med  1998; 15: 113–\\n19.\\n26. Japan and Pittsburgh Childhood Diabetes Research\\nGroups. Coma at onset of young insulin–dependent\\ndiabetes in Japan: the result of a nationwide survey.\\nDiabetes 1985; 34: 1241–46.\\n27. Zimmet PZ. The pathogenesis and prevention of\\ndiabetes in adults. Diabetes Care 1995; 18: 1050–64.\\n28. Willis JA, Scott RS, Brown LJ, Forbes LV, Schmidli RS,\\nZimmet PZ et al. Islet cell antibodies and antibodies\\nagainst glutamic acid decarboxylase in newly\\ndiagnosed adult–onset diabetes mellitus. Diabetes Res\\nClin Pract 1996; 33: 89–97.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 43, 'page_label': '44'}, page_content='38\\n29. Hother–Nielsen O, Faber O, Sørensen NS, Beck–\\nNielsen H. Classification of newly diagnosed diabetic\\npatients as insulin–requiring or non–insulin–requiring\\nbased on clinical and biochemical variables. Diabetes\\nCare 1988; 11: 531–37.\\n30. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo\\nM, Jackson RA et al. Predicting type I diabetes in first–\\ndegree relatives using a combination of insulin, GAD,\\nand ICA512bdc/IA–2 autoantibodies. Diabetes 1996;\\n45: 926–33.\\n31. Mølbak AG, Christau B, Marner B, Borch–Johnsen K,\\nNerup J. Incidence of insulin–dependent diabetes\\nmellitus in age groups over 30 years in Denmark.\\nDiabet Med 1994; 11: 650–55.\\n32. Betterle C, Zanette F, Pedini B, Presotto F, Rapp LB,\\nMonsciotti CM et al. Clinical and subclinical organ–\\nspecific autoimmune manifestations in type 1 (insulin–\\ndependent) diabetic patients and their first–degree\\nrelatives. Diabetologia  1983; 26: 431–36.\\n33. McLarty DG, Athaide I, Bottazzo GF, Swai ABM,\\nAlberti KGMM. Islet cell antibodies are not specifically\\nassociated with insulin–dependent diabetes in rural\\nTanzanian Africans. Diabetes Res Clin Pract  1990; 9:\\n219–24.\\n34. Ahrén B, Corrigan CB. Intermittent need for insulin in a\\nsubgroup of diabetic patients in Tanzania. Diabet Med\\n1984; 2: 262–64.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 44, 'page_label': '45'}, page_content='39\\n35. DeFronzo RA, Bonadonna RC, Ferrannini E.\\nPathogenesis of NIDDM. In: Alberti KGMM, Zimmet P,\\nDeFronzo RA, eds. International Textbook of Diabetes\\nMellitus. 2nd edn. Chichester: John Wiley, 1997: pp\\n635–712.\\n36. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE,\\nRavussin E et al. Insulin resistance and insulin\\nsecretory dysfunction as precursors of non–insulin–\\ndependent diabetes. Prospective Study of Pima\\nIndians. N Engl J Med 1993; 329: 1988–92.\\n37. Mooy JM, Grootenhuis PA, de Vries H, Valkenburg HA,\\nBouter LM, Kostense PJ et al. Prevalence and\\ndeterminants of glucose intolerance in a Dutch\\npopulation. The Hoorn Study. Diabetes Care 1995; 18:\\n1270–73.\\n38. Harris MI. Undiagnosed NIDDM; clinical and public\\nhealth issues. Diabetes Care 1993; 16: 642–52.\\n39. Campbell PJ, Carlson MG. Impact of obesity on insulin\\naction in NIDDM. Diabetes 1993; 42: 405–10.\\n40. Bogardus C, Lillioja S, Mott DM, Hollenbeck C, Reaven\\nG. Relationship between degree of obesity and in vivo\\ninsulin action in man. Am J Physiol  1985; 248: E286–\\nE291.\\n41. Kissebah AH, Vydelingum N, Murray R, Evans DF,\\nHartz AJ, Kalkhoff RK et al. Relationship of body fat\\ndistribution to metabolic complications of obesity. J Clin\\nEndocrinol Metab  1982; 54: 254–60.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 45, 'page_label': '46'}, page_content='40\\n42. Banerji MA, Chaiken RI, Huey H, Tuomi T, Norin AJ,\\nMacKay IR et al. GAD antibody negative NIDDM in\\nadult black subjects with diabetic ketoacidosis and\\nincreased frequency of human leukocyte antigen DR3\\nand DR4: flatbush diabetes. Diabetes 1994; 43: 741–\\n45.\\n43. Umpierrez GE, Casals MMC, Gebhardt SSP, Mixon\\nPS, Clark WS, Phillips LS. Diabetic ketoacidosis in\\nobese African–Americans. Diabetes 1995; 44: 790–95.\\n44. Polonsky KS, Sturis J, Bell GI. Non–insulin–dependent\\ndiabetes mellitus: a genetically programmed failure of\\nthe beta cell to compensate for insulin resistance. N\\nEngl J Med 1996; 334: 777–84.\\n45. Simonson DC, Ferrannini E, Bevilacqua S, Smith D,\\nBarrett E, Carlson R et al. Mechanism of improvement\\nin glucose metabolism after chronic glyburide therapy.\\nDiabetes 1984; 33: 838–45.\\n46. Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe\\nR, Bergman RN. Caloric restriction per se is a\\nsignificant factor in improvements in glycemic control\\nand insulin sensitivity during weight loss in obese\\nNIDDM patients. Diabetes Care 1994; 17: 30–36.\\n47. Zimmet PZ. Kelly West Lecture 1991: challenges in\\ndiabetes epidemiology: from West to the rest. Diabetes\\nCare 1992; 15: 232–52.\\n48. Harris MI, Cowie CC, Stern MP, Boyko E S, Reiber GE,\\nBennett PH, eds. Diabetes in America . 2nd edn.\\nWashington DC: US Government Printing Office, 1995\\n(NIH publ. No. 95–1468).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 46, 'page_label': '47'}, page_content='41\\n49. Valle T, Tuomilehto J, Eriksson J. Epidemiology of\\nNIDDM in Europids. In: Alberti KGMM, Zimmet P,\\nDeFronzo RA, eds. International Textbook of Diabetes\\nMellitus. 2nd edn. Chichester: John Wiley, 1997: pp\\n125–42.\\n50. de Courten M, Bennett PH, Tuomilehto J, Zimmet P.\\nEpidemiology of NIDDM in Non–Europids. In: Alberti\\nKGMM, Zimmet P, DeFronzo RA, eds. International\\nTextbook of Diabetes Mellitus . 2nd edn. Chichester:\\nJohn Wiley, 1997: pp 143–70.\\n51. Knowler WC, Nelson RG, Saad M, Bennett PH, Pettitt\\nDJ. Determinants of diabetes mellitus in the Pima\\nIndians. Diabetes Care 1993; 16: 216–27.\\n52. Byrne MM, Sturis J, Menzel S, Y amagata K, Fajans\\nSS, Dronsfield MJ et al. Altered insulin secretory\\nresponse to glucose in diabetic and nondiabetic\\nsubjects with mutations in the diabetes susceptibility\\ngene MODY 3 on chromosome 20. Diabetes 1996; 45:\\n1503–10.\\n53. Clement K, Pueyo ME, V axillaire M, Rakotoambinina\\nB, Thuillier F, Passa P et al. Assessment of insulin\\nsensitivity in glucokinase–deficient subjects.\\nDiabetologia  1996; 39: 82–90.\\n54. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H,\\nVaxillaire M et al. Mutations in the hepatocyte nuclear\\nfactor–1\" gene in maturity–onset diabetes of the young\\n(MODY 3). Nature 1996; 384: 455–58.\\n55. Froguel P, Vaxillaire M, Sun F, Velho G, Zouali H,\\nButel MO et al. Close linkage of glucokinase locus on\\nchromosome 7p to early–onset non–insulin–dependent\\ndiabetes. Nature 1992; 356: 162–64.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 47, 'page_label': '48'}, page_content='42\\n56. Vionnet N, Stoffel M, Takeda J, Yasuda K, Bell GI,\\nZouali H et al. Nonsense mutation in the glucokinase\\ngene causes early–onset non–insulin–dependent\\ndiabetes. Nature 1992; 356: 721–22.\\n57. Yamagata K, Furuta H, Oda N, Kaisaki PJ, Menzel S,\\nCox NJ et al. Mutations in the hepatocyte nuclear\\nfactor–4\" gene in maturity–onset diabetes of the young\\n(MODY 1). Nature 1996; 384: 458–60.\\n58. Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early–\\nonset type–II diabetes mellitus (MODY4) linked to\\nIPF1. Nature Genetics  1997; 117: 138–39.\\n59. Walker M, Turnbull DM.  Mitochondrial related diabetes:\\na clinical perspective. Diabet Med 1997; 14: 1007–09.\\n60. Johns DR. Mitochondrial DNA and disease. N Engl J\\nMed 1995; 333: 638–44.\\n61. Gruppuso PA, Gorden P, Kahn CR, Cornblath M,\\nZeller WP, Schwartz R. Familial hyperproinsulinemia\\ndue to a proposed defect in conversion of proinsulin to\\ninsulin. N Engl J Med  1984; 311: 629–34.\\n62. Robbins DC, Shoelson SE, Rubenstein AH, Tager HS.\\nFamilial hyperproinsulinemia: two cohorts secreting\\nindistinguishable type II intermediates of proinsulin\\nconversion. J Clin Invest 1984; 73: 714–19.\\n63. Haneda M, Polonsky KS, Bergenstal RM, Jaspan JB,\\nShoelson SE, Blix PM et al. Familial hyperinsulinemia\\ndue to a structurally abnormal insulin. Definition of an\\nemerging new clinical syndrome. N Engl J Med  1984;\\n310: 1288–94.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 48, 'page_label': '49'}, page_content='43\\n64. Sanz N, Karam JH, Horita S, Bell GI. Prevalence of\\ninsulin–gene mutations in non–insulin–dependent\\ndiabetes mellitus. N Engl J Med  1986; 314: 1322–23.\\n65. Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P,\\nMartin MM et al. The syndromes of insulin resistance\\nand acanthosis nigricans. N Engl J Med  1976; 294:\\n739–45.\\n66. Taylor SI. Lilly Lecture: molecular mechanisms of\\ninsulin resistance: lessons from patients with mutations\\nin the insulin–receptor gene. Diabetes 1992; 41: 1473–\\n90.\\n67. Gullo L, Pezzilli R, Morselli–Labate AM, and the Italian\\nPancreatic Cancer Study Group. Diabetes and the risk\\nof pancreatic cancer. N Engl J Med  1994; 331: 81–84.\\n68. Larsen S, Hilsted J, Tronier B, Worning H. Metabolic\\ncontrol and B cell function in patients with insulin–\\ndependent diabetes mellitus secondary to chronic\\npancreatitis. Metabolism  1987; 36: 964–67.\\n69. Permert J, Larsson J, Westermark GT, Herrington MK,\\nChristmanson L, Pour PM et al. Islet amyloid\\npolypeptide in patients with pancreatic cancer and\\ndiabetes. N Engl J Med 1994; 330: 313–18.\\n70. Moran A, Pyzdrowski KL, Weinreb J, Kahn BB, Smith\\nSA, Adams KS et al. Insulin sensitivity in cystic fibrosis.\\nDiabetes 1994; 43: 1020–26.\\n71. Phelps G, Chapman I, Hall P, Braund W, Mackinnon\\nM. Prevalence of genetic haemochromatosis among\\ndiabetic patients. Lancet 1989; ii: 233–34.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 49, 'page_label': '50'}, page_content='44\\n72. Yajnik CS, Shelgikar KM, Naik SS, Kanitkar SV,\\nOrskov H, Alberti KGMM et al. The ketoacidosis–\\nresistance in fibro–calculous–pancreatic–diabetes.\\nDiabetes Res Clin Pract 1992; 15: 149–56.\\n73. MacFarlane IA. Endocrine diseases and diabetes\\nmellitus. In: Pickup JC, Williams G, eds. Textbook of\\nDiabetes. 2nd edn. Oxford: Blackwell, 1997: pp 64.1–\\n64.20.\\n74. Krejs GJ, Orci L, Conlon JM, Ravazzola M, Davis GR,\\nRaskin P et al. Somatostatinoma syndrome. N Engl J\\nMed 1979; 301: 285–92.\\n75. Conn JW. Hypertension, the potassium ion and\\nimpaired carbohydrate tolerance. N Engl J Med  1965;\\n273: 1135–43.\\n76. Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris\\nAN. Drug–induced disorders of glucose tolerance. Ann\\nIntern Med 1993; 118: 529–40.\\n77. O’Byrne S, Feely J. Effects of drugs on glucose\\ntolerance in non–insulin–dependent diabetes (parts I\\nand II). Drugs 1990; 40: 203–19.\\n78. Gallanosa AG, Spyker DA, Curnow RT. Diabetes\\nmellitus associated with autonomic and peripheral\\nneuropathy after Vacor poisoning: a review. Clin\\nToxicol 1981; 18: 441–49.\\n79. Esposti MD, Ngo A, Myers MA. Inhibition of\\nmitochondrial complex I may account for IDDM induced\\nby intoxication with rodenticide Vacor. Diabetes 1996;\\n45: 1531–34.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 50, 'page_label': '51'}, page_content='45\\n80. Assan R, Perronne C, Assan D, Chotard L, Mayaud C,\\nMatheron S et al. Pentamidine–induced derangements\\nof glucose homeostasis. Diabetes Care 1995; 18: 47–\\n55.\\n81. Forrest JA, Menser MA, Burgess JA. High frequency of\\ndiabetes mellitus in young patients with congenital\\nrubella. Lancet 1971; ii: 332–34.\\n82. King ML, Bidwell D, Shaikh A, Voller A, Banatvala JE.\\nCoxsackie–B–virus–specific IgM responses in children\\nwith insulin–dependent (juvenile–onset; type 1)\\ndiabetes mellitus. Lancet 1983; i: 1397–99.\\n83. Karjalainen J, Knip M, Hyoty H, Linikki P, Ilonen J,\\nKaar M–L et al. Relationship between serum insulin\\nantibodies, islet cell antibodies and Coxsackie–B4 and\\nmumps virus–specific antibodies at the clinical\\nmanifestation of type 1 (insulin–dependent) diabetes.\\nDiabetologia  1988; 31: 146–52.\\n84. Pak CY, Eun H, McArthur RG, Yoon J. Association of\\ncytomegalovirus infection with autoimmune type 1\\ndiabetes. Lancet 1988; ii: 1–4.\\n85. Hirata Y, Ishizu H, Ouchi N et al. Insulin autoimmunity\\nin a case of spontaneous hypoglycaemia. J Jpn Diabet\\nSoc 1970; 13: 312–20.\\n86. Bodansky HJ, Grant PJ, Dean BM, McNally J, Bottazzo\\nGF, Hambling MH et al. Islet–cell antibodies and insulin\\nautoantibodies in association with common viral\\ninfections. Lancet 1986; ii: 1351–53.\\n87. Solimena M, De Camilli P. Autoimmunity to glutamic\\nacid decarboxylase (GAD) in Stiff–Man syndrome and\\ninsulin–dependent diabetes mellitus. Trends Neurosci\\n1991; 14: 452–57.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 51, 'page_label': '52'}, page_content='46\\n88. Fabris P, Betterle C, Floreani A, Greggio NA, de\\nLazzari F, Naccarato R et al. Development of type 1\\ndiabetes mellitus during interferon alfa therapy for\\nchronic HCV hepatitis (Letter). Lancet 1992; 340: 548.\\n89. Flier JS. Lilly Lecture: syndromes of insulin resistance:\\nfrom patient to gene and back again. Diabetes 1992;\\n41: 1207–19.\\n90. Kahn CR, Baird KL, Flier JS, Jarrett DB. Effects of\\nautoantibodies to the insulin receptor on isolated\\nadipocytes. J Clin Invest 1977; 60: 1094–106.\\n91. Tsokos GC, Gorden P, Antonovych T, Wilson CB,\\nBalow JE. Lupus nephritis and other autoimmune\\nfeatures in patients with diabetes mellitus due to\\nautoantibody to insulin receptors. Ann Intern Med\\n1985; 102: 176–81.\\n92. Barrett TG, Bundey SE, Macleod AF.\\nNeurodegeneration and diabetes: UK nationwide study\\nof Wolfram (DIDMOAD) syndrome. Lancet 1995; 346:\\n1458–63.\\n93. Stern MP. The insulin resistance syndrome. In: Alberti\\nKGMM, Zimmet P, DeFronzo RA, eds. International\\nTextbook of Diabetes Mellitus . 2nd edn. Chichester:\\nJohn Wiley, 1997: pp 255–83.\\n94. Haffner SM, Valdez RA, Hazuda HP , Mitchell BD,\\nMorales PA, Stern MP. Prospective analysis of the\\ninsulin resistance syndrome (Syndrome X). Diabetes\\n1992; 41: 715–22.\\n95. Kaplan NM. The deadly quartet: upper body adiposity,\\nglucose intolerance, hypertriglyceridaemia and\\nhypertension. Arch Intern Med  1989; 149: 1514–20.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 52, 'page_label': '53'}, page_content='47\\n96. European Arterial Risk Policy Group on behalf of the\\nInternational Diabetes Federation (European Region).\\nA strategy for arterial risk assessment and\\nmanagement in Type 2 (non–insulin–dependent)\\ndiabetes. Diabet Med 1997; 14: 611–21.\\n97. Mykkänen L, Kuusisto J, Pyörälä K, Laakso M.\\nCardiovascular disease risk factors as predictors of\\nType 2 (non–insulin–dependent) diabetes mellitus in\\nelderly subjects. Diabetologia  1993; 36: 553–59.\\n98. Eriksson KF, Lindegärde F. Prevent ion of Type 2 (non–\\ninsulin–dependent) diabetes mellitus by diet and\\nphysical exercise. Diabetologia  1991; 34: 891–98.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 53, 'page_label': '54'}, page_content='48\\nAnnex 1\\nThe Oral Glucose Tolerance Test\\nThe oral glucose tolerance test (OGTT) is principally used for\\ndiagnosis when blood glucose levels are equivocal, during\\npregnancy, or in epidemiological studies.\\nThe OGTT should be administered in the morning after at least\\nthree days of unrestricted diet (greater than 150 g of carbohydrate\\ndaily) and usual physical activity. Recent evidence suggests that a\\nreasonable (30–50g) carbohydrate containing meal should be\\nconsumed on the evening before the test. The test should be\\npreceded by an overnight fast of 8–14 hours, during which water\\nmay be drunk. Smoking is not permitted during the test. The\\npresence of factors that influence interpretation of the results of the\\ntest must be recorded (e.g. medications, inactivity, infection, etc.).\\nAfter collection of the fasting blood sample, the subject should\\ndrink 75 g of anhydrous glucose or 82.5 g of glucose monohydrate\\n(or partial hydrolysates of starch of the equivalent carbohydrate\\ncontent) in 250–300 ml of water over the course of 5 minutes. For\\nchildren, the test load should be 1.75 g of glucose per kg body\\nweight up to a total of 75 g of glucose. Timing of the test is from the\\nbeginning of the drink. Blood samples must be collected 2 hours\\nafter the test load.\\nUnless the glucose concentration can be determined immediately,\\nthe blood sample should be collected in a tube containing sodium\\nfluoride (6 mg per ml whole blood) and immediately centrifuged to\\nseparate the plasma; the plasma should be frozen until the glucose\\nconcentration can be estimated. For interpretation of results, refer\\nto Table 1.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 54, 'page_label': '55'}, page_content='49\\nAnnex 2\\nMethods for measuring substances in blood and urine\\nMeasurement of glucose in blood\\nReductiometric methods (the Somogyi–Nelson, the ferricyanide\\nand neocuprine autoanalyser methods) are still in use for blood\\nglucose measurement. The o–toluidine method also remains in use\\nbut enzyme–based methods are widely available, for both\\nlaboratory and near–patient use. Highly accurate and rapid (1–2\\nmin) devices are now available based on immobilized glucose\\noxidase electrodes. Hexokinase and glucose dehydrogenase\\nmethods are used for reference.\\nWhole blood samples preserved with fluoride show an initial rapid\\nfall in glucose of up to 10 % at room temperature, but subsequent\\ndecline is slow; centrifugation prevents the initial fall. Whole blood\\nglucose values are 15 % lower than corresponding plasma values\\nin patients with a normal haematocrit reading, and arterial values\\nare about 7 % higher than corresponding venous values.\\nThe use of reagent–strip glucose oxidase methods has made\\nbedside estimation of blood glucose very popular. However, the\\ncost of the reagent–strips remains high. Some methods still require\\npunctilious technique, accurate timing, and storage of strips in\\nairtight containers. Reasonably quantitative results can be obtained\\neven with visual colour–matching techniques. Electrochemical and\\nreflectance meters can give coefficients of variation of well under 5\\n%. Reagent–strip methods have been validated under tropical\\nconditions, but are sensitive to extreme climatic conditions.\\nDiabetes may be strongly suspected from the results of reagent–\\nstrip glucose estimation, but the diagnosis cannot be confidently\\nexcluded by the use of this method. Confirmation of diagnosis\\nrequires estimation by laboratory methods.\\nPatients can easily collect small blood samples themselves (either\\nin specially prepared plastic or glass capillary tubes or on'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 55, 'page_label': '56'}, page_content='50\\nfilter–paper), and self–monitoring using glucose reagent–strips\\nwith direct colour–matching or meters is now widely practised.\\nPatients should be properly trained in the appropriate techniques\\nto avoid inaccurate or misleading results.\\nThe insulin–treated patient is commonly requested to build up a\\n“glycaemic profile” by self–measurement of blood glucose at\\nspecific times of the day (and night). A “7–point profile” is useful,\\nwith samples taken before and 90 min after breakfast, before\\nand 90 min after lunch, before and 90 min after an evening\\nmeal, and just before going to bed. Occasionally patients may\\narrange to wake at 0300 h to collect and measure a nocturnal\\nsample. The complete profile rarely needs to be collected within\\na single 24–hour period, and it may be compiled from samples\\ncollected at different times over several days.\\nMeasurement of glucose in urine\\nInsulin–treated patients who do not have access to facilities for\\nself–measurement of blood glucose should test urine samples\\npassed after rising, before main meals, and before going to bed.\\nNon–insulin–dependent patients do not need to monitor their\\nurine so frequently. Urine tests are of somewhat limited value,\\nhowever, because of the great variation in urine glucose\\nconcentration for given levels of blood glucose. The correlation\\nbetween blood and urine glucose may be improved a little by\\ncollecting short–term fractions (15–30 min) of the urine output.\\nBenedict’s quantitative solution or self–boiling, caustic\\nsoda/copper sulphate tablets may be used or the more\\nconvenient, but costly, semi–quantitative enzyme–based test–\\nstrips.\\nKetone bodies in urine and blood\\nThe appearance of persistent ketonuria associated with\\nhyperglycaemia or high levels of glycosuria in the diabetic\\npatient points to an unacceptably severe level of metabolic\\ndisturbance and indicates an urgent need for corrective action.\\nThe patient should be advised to test for ketone bodies (acetone\\nand aceto–acetic acid) when tests for glucose are'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 56, 'page_label': '57'}, page_content='51\\nrepeatedly positive, or when there is substantial disturbance of\\nhealth, particularly with infections. Rothera’s sodium nitroprusside\\ntest may be used or, alternatively, reagent–strips that are sensitive\\nto ketones. In emergency situations such as diabetic ketoacidosis,\\na greatly raised concentration of plasma ketones can be detected\\nwith a reagent–strip and roughly quantified by serial 1 in 2 dilution\\nof plasma with water.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 57, 'page_label': '58'}, page_content='52\\nTable 1.   Values for diagnosis of diabetes mellitus and other categories of hyperglycaemia\\nGlucose concentration, mmol l–1  (mg dl–1 )\\nWhole blood Plasma*\\nVenous Capillary Venous\\n Diabetes Mellitus:\\n   Fasting  ≥ 6.1 (≥ 110)  ≥ 6.1 (≥ 110)  ≥ 7.0 (≥ 126)\\n   or\\n   2-h post glucose load\\n   or both\\n ≥ 10.0 (≥ 180)  ≥ 11.1 (≥ 200)  ≥ 11.1 (≥ 200)\\n   or both\\n Impaired Glucose Tolerance (IGT):\\n   Fasting (if measured)  < 6.1 (< 110)  < 6.1 (< 110)  < 7.0 (< 126)\\n   and\\n   2-h post glucose load  ≥ 6.7 (≥ 120) and  ≥ 7.8 (≥ 140) and  ≥ 7.8 (≥ 140) and\\n   < 10.0 (< 180)    < 11.1 (< 200)    < 11.1 (< 200)\\n Impaired Fasting Glycaemia (IFG):\\n   Fasting  ≥ 5.6 (≥ 100) and  ≥ 5.6 (≥ 100) and  ≥ 6.1 (≥ 110) and\\n   < 6.1 (< 110)    < 6.1 (< 110)    < 7.0 (< 126)\\n   and (if measured)\\n   2-h post glucose load  < 6.7 (< 120)  < 7.8 (< 140)  < 7.8 (< 140)\\n* Corresponding values for capillary plasma are: for Diabetes Mellitus, fasting ≥ 7.0 (≥ 126), 2-h ≥ 12.2 (≥ 220); for Impaired Glucose Tolerance,fasting < 7.0 (< 126) and\\n2-h ≥ 8.9 (≥ 160) and < 12.2 (< 220); and for Impaired Fasting Glycaemia ≥ 6.1 (≥ 110) and < 7.0 (< 126) and if measured, 2-h < 8.9 (< 160).\\nFor epidemiological or population screening purposes, the fasting or 2-h value after 75 g oral glucose may be used alone. For clinical purposes, the diagnosis of diabetes\\nshould always be confirmed by repeating the test on another day unless there is unequivocal hyperglycaemia with acute metabolic decompensation or obvious\\nsymptoms.\\nGlucose concentrations should not be determined on serum unless red cells are immediately removed, otherwise glycolysis will result in an\\nunpredictable under-estimation of the true concentrations. It should be stressed that glucose preservatives do not totally prevent glycolysis.\\nIf whole blood is used, the sample should be kept at 0-4 °C or centrifuged immediately, or assayed immediately.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 58, 'page_label': '59'}, page_content='53\\nTable 2. Aetiological Classification of Disorders of\\nGlycaemia*\\n––––––––––––––––––––––––––––––––––––––––––––––––\\nType 1 (beta-cell destruction, usually leading to absolute\\ninsulin deficiency)\\nAutoimmune\\nIdiopathic\\nType 2  (may range from predominantly insulin resistance\\nwith relative insulin deficiency to a predominantly\\nsecretory defect with or without insulin resistance)\\nOther specific types   (see Table 3)\\nGenetic defects of beta-cell function\\nGenetic defects in insulin action\\nDiseases of the exocrine pancreas\\nEndocrinopathies\\nDrug- or chemical-induced\\nInfections\\nUncommon forms of immun e-mediated diabetes\\nOther genetic syndromes sometimes associated with\\ndiabetes\\nGestational diabetes**\\n––––––––––––––––––––––––––––––––––––––––––––––––\\n*As additional subtypes are discovered it is anticipated that\\nthey will be reclassified within their own specific category.\\n**Includes the former categories of gestational impaired\\nglucose tolerance and gestational diabetes.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 59, 'page_label': '60'}, page_content=\"54\\nTable 3 Other Specific Types of Diabetes\\n––––––––––––––––––––––––––––––––––––––––––––––––\\nGenetic defects of beta-cell function\\nChromosome 20, HNF4 α (MODY1)\\nChromosome 7, glucokinase (MODY2)\\nChromosome 12, HNF1 α (MODY3)\\nChromosome 13, IPF-1 (MODY4)\\nMitochondrial DNA 3243 mutation\\nOthers\\nGenetic defects in insulin action\\nType A insulin resistance\\nLeprechaunism\\nRabson-Mendenhall syndrome\\nLipoatrophic diabetes\\nOthers\\nDiseases of the exocrine pancreas\\nFibrocalculous pancreatopathy\\nPancreatitis\\nTrauma / pancreatectomy\\nNeoplasia\\nCystic fibrosis\\nHaemochromatosis\\nOthers\\nEndocrinopathies\\nCushing's syndrome\\nAcromegaly\\nPhaeochromocytoma\\nGlucagonoma\\nHyperthyroidism\\nSomatostatinoma\\nOthers\\n––––––––––––––––––––––––––––––––––––––––––––––––\\n(Continued on page 55 )\"),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 60, 'page_label': '61'}, page_content='55\\nTable 3 (continued)\\n––––––––––––––––––––––––––––––––––––––––––––––––\\nDrug- or chem ical-induced  (see Table 4)\\nInfections\\nCongenital rubella\\nCytomegalovirus\\nOthers\\nUncommon forms of immune-mediated diabetes\\nInsulin autoimmune syndrome (antibodies to insulin)\\nAnti-insulin receptor antibodies\\n\"Stiff Man\" syndrome\\nOthers\\nOther genetic syndromes   (see Table 5)\\n––––––––––––––––––––––––––––––––––––––––––––––––'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 61, 'page_label': '62'}, page_content='56\\nTable 4. Drug- or Chemical-induced Diabetes\\n–––––––––––––––––––––––––––––––––––––––––––––––\\nNicotinic acid\\nGlucocorticoids\\nThyroid hormone\\nAlpha-adrenergic agonists\\nBeta-adrenergic agonists\\nThiazides\\nDilantin\\nPentamidine\\nVacor\\nInterferon-alpha therapy\\nOthers\\n–––––––––––––––––––––––––––––––––––––––––––––––'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 62, 'page_label': '63'}, page_content=\"57\\nTable 5. Other Genetic Syndromes Sometimes\\nAssociated with Diabetes\\n–––––––––––––––––––––––––––––––––––––––––––––––\\nDown's syndrome\\nFriedreich's ataxia\\nHuntington's chorea\\nKlinefelter's syndrome\\nLawrence-Moon-Biedel syndrome\\nMyotonic dystrophy\\nPorphyria\\nPrader-Willi syndrome\\nTurner's syndrome\\nWolfram's syndrome\\nOthers\\n–––––––––––––––––––––––––––––––––––––––––––––––\"),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 63, 'page_label': '64'}, page_content='58\\nFigure 1:   Unstandardized (casual, random) blood glucose values in the diagnosis of diabetes in\\nmmol l-1 (mg dl-1).  Taken from the 1985 WHO Study Group Report (3).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 64, 'page_label': '65'}, page_content='59\\nFigure 2:  Disorders of glycaemia: aetiological types and clinical stages.\\nStages Normoglycaemia Hyperglycaemia\\nNormal glucose\\ntolerance\\nImpaired glucose\\nregulation\\nDiabetes Mellitus\\nTypes\\nIGT and/or IFG Not\\ninsulin\\nrequiring\\nInsulin\\nrequiring\\nfor\\ncontrol\\nInsulin\\nrequiring\\nfor\\nsurvival\\nType 1\\n• Autoimmune\\n• Idiopathic\\nType 2*\\n• Predominantly\\ninsulin resistance\\n• Predominantly\\ninsulin secretory\\ndefects\\nOther specific\\ntypes*\\nGestational\\ndiabetes*\\n* In rare instances patients in these categories (e.g. Vacor Toxicity, Type 1\\npresenting in pregnancy, etc.) may require insulin for survival.')]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "extracted_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "5d5bab3d",
   "metadata": {},
   "outputs": [],
   "source": [
    "#Split create text chunks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "e41be2cc",
   "metadata": {},
   "outputs": [],
   "source": [
    "def text_split(extracted_data):\n",
    "    text_splitter = RecursiveCharacterTextSplitter(chunk_size=500,chunk_overlap = 20)\n",
    "    text_chunks = text_splitter.split_documents(extracted_data)\n",
    "\n",
    "    return text_chunks\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "8b29a4e4",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Length of my chunk: 192\n"
     ]
    }
   ],
   "source": [
    "text_chunks = text_split(extracted_data)\n",
    "print(\"Length of my chunk:\",len(text_chunks))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "fc5d5496",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 0, 'page_label': '1'}, page_content='WHO/NCD/NCS/99.2\\nOriginal: English\\nDistr.: General\\nDefinition, Diagnosis\\nand Classification\\nof Diabetes Mellitus\\nand its Complications\\nReport of a WHO Consultation\\nPart 1: Diagnosis and Classification of\\nDiabetes Mellitus\\nWorld Health Organization\\nDepartment of Noncommunicable Disease Surveillance\\nGeneva'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 1, 'page_label': '2'}, page_content='© World Health Organization 1999\\nThis document is not a formal publication of the World\\nHealth Organization (WHO), and all rights are reserved by\\nthe Organization. The document may, however, be freely\\nreviewed, abstracted, reproduced and translated, in part or\\nin whole, but not for sale nor for use in conjunction with\\ncommercial purposes.\\nThe views expressed in documents by named authors are\\nsolely the responsibility of those authors'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 2, 'page_label': '3'}, page_content='Contents\\n1.  Introduction 1\\n2.  Definition and diagnostic criteria for diabetes mellitus and\\nother categories of glucose intolerance 2\\n2.1  Definition 2\\n2.2  Diagnosis and diagnostic criteria 3\\n2.2.1  Diagnosis 3\\n2.2.2  Diabetes in children 4\\n2.3  Diagnostic criteria 4\\n2.3.1  Change in diagnostic value for fasting\\nplasma/blood glucose concentrations 5\\n2.3.2  Epidemiological studies 6\\n2.3.3  Individual diagnosis 7\\n3.  Classification 8\\n3.1  Earlier classifications 8\\n3.2  Revised classification 9'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 2, 'page_label': '3'}, page_content='3.2.1  Application of the new classification 9\\n3.3  Terminology (Table 2) 11\\n4.  Clinical staging of diabetes mellitus and other categories\\nof glucose tolerance (Figure 2) 14\\n4.1  Diabetes mellitus 14\\n4.2  Impaired glucose regulation - Impaired Glucose\\nTolerance and Impaired Fasting Glycaemia 14\\n4.3  Normoglycaemia 16\\n5.  Aetiological types (see also section 7. and Table 2) 17\\n5.1  Type 1 17\\n5.2  Type 2 18\\n5.3  Other specific types (Table 3) 18\\n6.  Gestational Hyperglycaemia and Diabetes 19'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 2, 'page_label': '3'}, page_content='6.1  Diagnosis of gestational diabetes 20'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 3, 'page_label': '4'}, page_content='7.  Description of aetiological types 21\\n7.1  Type 1 (beta-cell destruction, usually leading to       \\nabsolute insulin deficiency) 21\\n7.1.1  Autoimmune Diabetes Mellitus 21\\n7.1.2  Idiopathic 22\\n7.2  Type 2 (predominantly insulin resistance with relative\\ninsulin deficiency or predominantly an insulin\\nsecretory defect with/without insulin resistance) 23\\n7.3  Other Specific Types 25\\n7.3.1  Genetic defects of beta-cell function 25\\n7.3.2  Genetic defects in insulin action 26'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 3, 'page_label': '4'}, page_content='7.3.3  Diseases of the exocrine pancreas 27\\n7.3.4  Endocrinopathies 27\\n7.3.5  Drug- or chemical-induced diabetes 28\\n7.3.6  Infections 28\\n7.3.7  Uncommon but specific forms of\\nimmune-mediated diabetes mellitus 29\\n7.3.8  Other genetic syndromes sometimes\\nassociated with diabetes 30\\n8.  The Metabolic Syndrome 31\\n8.1  Definition 32\\n8.2  Future needs 33\\nReferences 34\\nAnnex 1  The Oral Glucose Tolerance Test 48\\nAnnex 2  Methods for measuring substances in blood and urine 49'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 4, 'page_label': '5'}, page_content=\"Members\\nKGMM Alberti, University of Newcastle upon Tyne, UK       (Co–\\nChairman)\\nP Aschner, ACD and Javerlana University, Bogota, Colombia\\nJ–P Assal, University Hospital, Geneva, Switzerland\\nPH Bennett, NIDDK, Phoenix, AZ, USA\\nL Groop, University of Lund, Malmö, Sweden\\nJ Jervell, Rikshospitalet, Oslo, Norway\\nY Kanazawa, Jichi Medical School, Omiya, Japan\\nH Keen, Guy's Hospital and Medical School, London, UK\\nR Klein, University of Wisconsin Medical School, Madison, WI, USA\"),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 4, 'page_label': '5'}, page_content='J–C Mbanya, Centre Hospitalier et Universitaire de Yaoundé,\\nCameroon\\nD McCarty, International Diabetes Institute, Caulfield, Australia\\n(Rapporteur)\\nA Motala, University of Natal, Congella, South Africa\\nPan X–R, China–Japan Friendship Hospital, Beijing, China PR\\n(deceased 8 July 1997)\\nA Ramachandran, Diabetes Research Centre, Madras, India\\nN Samad, Dow Medical College & Civil Hospital, Karachi, Pakistan\\nN Unwin, University of Newcastle upon Tyne, UK (Rapporteur)'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 4, 'page_label': '5'}, page_content=\"P Vardi, Schneider Children's Centre, Petah–Tikvah, Israel\\nPZ Zimmet, International Diabetes Institute, Caulfield, Australia (Co–\\nChairman)\\nSecretariat\\nA Alwan, World Health Organization, Geneva, Switzerland\\nH King, World Health Organization, Geneva, Switzerland\"),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 5, 'page_label': '6'}, page_content='Observers\\nM Berrens, Bayer, Germany\\nR Kahn, American Diabetes Association, USA\\nJ Nolan, Institute for Diabetes Discovery, USA\\nS Pramming, Novo Nordisk, Denmark\\nRA Rizza, American Diabetes Association, USA'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 6, 'page_label': '7'}, page_content='1\\n1. Introduction\\nIn the late 1970s both WHO (1) and the National Diabetes\\nData Group (2) produced new diagnostic criteria and a new\\nclassification system for diabetes mellitus. This brought order\\nto a chaotic situation in which nomenclature varied and\\ndiagnostic criteria showed enormous variations using\\ndifferent oral glucose loads. In 1985 WHO slightly modified\\ntheir criteria to coincide more closely with the NDDG values\\n(3). There are now many data available, and also much more'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 6, 'page_label': '7'}, page_content='aetiological information has appeared. It seemed timely to re–\\nexamine the issues and to update and refine both the\\nclassification and the criteria, and to include a definition of\\nthe “Metabolic Syndrome”.\\nAn American Diabetes Association (ADA) expert group was\\nconvened to discuss these issues. It published its\\nrecommendations in 1997 (4). WHO convened a\\nConsultation on the same subject in London, United\\nKingdom, in December 1996. In general, the ADA and WHO\\ngroups reached similar conclusions.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 6, 'page_label': '7'}, page_content='The provisional report of the WHO Consultation (5) solicited\\ncomments which were considered in preparing the present\\nreport. Both the provisional and the present report were\\nprepared by Professor K.G.M.M. Alberti and Professor P.Z.\\nZimmet on behalf of the members of the Consultation.  The\\nmeeting was made possible with financial support from\\nBayer, UK; Bayer, Germany; Novo Nordisk, Copenhagen,\\nDenmark; and The Institute for Diabetes Discovery, New\\nHaven, USA.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 7, 'page_label': '8'}, page_content='2\\n2. Definition and diagnostic criteria for\\ndiabetes mellitus and other categories\\nof glucose intolerance\\n2.1 Definition\\nThe term diabetes mellitus describes a metabolic disorder of\\nmultiple aetiology characterized by chronic hyperglycaemia\\nwith disturbances of carbohydrate, fat and protein\\nmetabolism resulting from defects in insulin secretion, insulin\\naction, or both. The effects of diabetes mellitus include long–\\nterm damage, dysfunction and failure of various organs.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 7, 'page_label': '8'}, page_content='Diabetes mellitus may present with characteristic symptoms\\nsuch as thirst, polyuria, blurring of vision, and weight loss. In\\nits most severe forms, ketoacidosis or a non–ketotic\\nhyperosmolar state may develop and lead to stupor, coma\\nand, in absence of effective treatment, death. Often symptoms\\nare not severe, or may be absent, and consequently\\nhyperglycaemia sufficient to cause pathological and\\nfunctional changes may be present for a long time before the'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 7, 'page_label': '8'}, page_content='diagnosis is made. The long–term effects of diabetes mellitus\\ninclude progressive development of the specific\\ncomplications of retinopathy with potential blindness,\\nnephropathy that may lead to renal failure, and/or neuropathy\\nwith risk of foot ulcers, amputation, Charcot joints, and\\nfeatures of autonomic dysfunction, including sexual\\ndysfunction. People with diabetes are at increased risk of\\ncardiovascular, peripheral vascular and cerebrovascular\\ndisease.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 8, 'page_label': '9'}, page_content='3\\nSeveral pathogenetic processes are involved in the\\ndevelopment of diabetes. These include processes which\\ndestroy the beta cells of the pancreas with consequent insulin\\ndeficiency, and others that result in resistance to insulin\\naction. The abnormalities of carbohydrate, fat and protein\\nmetabolism are due to deficient action of insulin on target\\ntissues resulting from insensitivity or lack of insulin.\\n2.2 Diagnosis and diagnostic criteria\\n2.2.1 Diagnosis'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 8, 'page_label': '9'}, page_content='2.2.1 Diagnosis\\nIf a diagnosis of diabetes is made, the clinician must feel\\nconfident that the diagnosis is fully established since the\\nconsequences for the individual are considerable and lifelong.\\nThe requirements for diagnostic confirmation for a person\\npresenting with severe symptoms and gross hyperglycaemia\\ndiffer from those for the asymptomatic person with blood\\nglucose values found to be just above the diagnostic cut–off\\nvalue. Severe hyperglycaemia detected under conditions of'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 8, 'page_label': '9'}, page_content='acute infective, traumatic, circulatory or other stress may be\\ntransitory and should not in itself be regarded as diagnostic of\\ndiabetes. The diagnosis of diabetes in an asymptomatic\\nsubject should never be made on the basis of a single\\nabnormal blood glucose value. For the asymptomatic person,\\nat least one additional plasma/blood glucose test result with a\\nvalue in the diabetic range is essential, either fasting, from a\\nrandom (casual) sample, or from the oral glucose tolerance'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 8, 'page_label': '9'}, page_content='test (OGTT). If such samples fail to confirm the diagnosis of\\ndiabetes mellitus, it will usually be advisable to maintain\\nsurveillance with periodic re–testing until the diagnostic\\nsituation becomes clear. In these circumstances, the clinician'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 9, 'page_label': '10'}, page_content='4\\nshould take into consideration such additional factors as\\nethnicity, family history, age, adiposity, and concomitant\\ndisorders, before deciding on a diagnostic or therapeutic\\ncourse of action. An alternative to blood glucose estimation\\nor the OGTT has long been sought to simplify the diagnosis\\nof diabetes. Glycated haemoglobin, reflecting average\\nglycaemia over a period of weeks, was thought to provide\\nsuch a test. Although in certain cases it gives equal or almost'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 9, 'page_label': '10'}, page_content='equal sensitivity and specificity to glucose measurement (6),\\nit is not available in many parts of the world and is not well\\nenough standardized for its use to be recommended at this\\ntime.\\n2.2.2 Diabetes in children\\nDiabetes in children usually presents with severe symptoms,\\nvery high blood glucose levels, marked glycosuria, and\\nketonuria. In most children the diagnosis is confirmed\\nwithout delay by blood glucose measurements, and treatment'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 9, 'page_label': '10'}, page_content='(including insulin injection) is initiated immediately, often as\\na life–saving measure. An OGTT is neither necessary nor\\nappropriate for diagnosis in such circumstances. A small\\nproportion of children and adolescents, however, present with\\nless severe symptoms and may require fasting blood glucose\\nmeasurement and/or an OGTT for diagnosis.\\n2.3 Diagnostic criteria\\nThe clinical diagnosis of diabetes is often prompted by\\nsymptoms such as increased thirst and urine volume,'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 9, 'page_label': '10'}, page_content='recurrent infections, unexplained weight loss and, in severe\\ncases, drowsiness and coma; high levels of glycosuria are\\nusually present. A single blood glucose estimation in excess'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 10, 'page_label': '11'}, page_content='5\\nof the diagnostic values indicated in Figure 1 (black zone)\\nestablishes the diagnosis in such cases. Figure 1 also defines\\nlevels of blood glucose below which a diagnosis of diabetes is\\nunlikely in non–pregnant individuals. These criteria are as in\\nthe 1985 report (3). For clinical purposes, an OGTT to\\nestablish diagnostic status need only be considered if casual\\nblood glucose values lie in the uncertain range (i.e. between\\nthe levels that establish or exclude diabetes) and fasting blood'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 10, 'page_label': '11'}, page_content='glucose levels are below those which establish the diagnosis of\\ndiabetes. If an OGTT is performed, it is sufficient to measure\\nthe blood glucose values while fasting and at 2 hours after a 75\\ng oral glucose load (Annexes 1 and 2). For children the oral\\nglucose load is related to body weight: 1.75 g per kg. The\\ndiagnostic criteria in children are the same as for adults.\\nDiagnostic interpretations of the fasting and 2–h post–load\\nconcentrations in non–pregnant subjects are shown in Table 1.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 10, 'page_label': '11'}, page_content='2.3.1 Change in diagnostic value for fasting\\nplasma/blood glucose concentrations\\nThe major change recommended in the diagnostic criteria for\\ndiabetes mellitus is the lowering of the diagnostic value of the\\nfasting plasma glucose concentration to 7.0 mmol l –1 (126 mg\\ndl–1) and above (3), from the former level of 7.8 mmol l –1 (140\\nmg dl–1) and above. For whole blood the proposed new level is\\n6.1 mmol l –1 (110 mg dl –1) and above, from the former 6.7\\nmmol l–1 (120 mg dl–1).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 10, 'page_label': '11'}, page_content='The new fasting criterion is chosen to represent a value which\\nis at the upper end of the range that corresponds in diagnostic\\nsignificance in many persons to that of the 2–h post–load\\nconcentration, which is not changed. This equivalence has'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 11, 'page_label': '12'}, page_content='6\\nbeen established from several population–based studies (6–\\n8) and it also represents an optimal cut–off point to separate\\nthe components of bimodal frequency distributions of\\nfasting plasma glucose concentrations seen in several\\npopulations. Furthermore, several studies have shown\\nincreased risk of microvascular disease in persons with\\nfasting plasma glucose concentrations of 7.0 mmol l –1 (126\\nmg dl –1) and over (6), and of macrovascular disease in'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 11, 'page_label': '12'}, page_content='persons with such fasting concentrations, even in those with\\n2–h values of < 7.8 mmol l-1 (140 mg dl–1) (9). Nevertheless,\\nin less obese subjects, in some ethnic groups and in the\\nelderly lower fasting glucose levels may be seen in persons\\nwho have 2–h post–load glucose values that are diagnostic\\nfor diabetes.\\n2.3.2 Epidemiological studies\\nFor population studies of glucose intolerance and diabetes,\\nindividuals have been classified by their blood glucose'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 11, 'page_label': '12'}, page_content='concentration measured after an overnight fast and/or 2 h\\nafter a 75 g oral glucose load. Since it may be difficult to be\\nsure of the fasting state, and because of the strong\\ncorrelation between fasting and 2–h values, epidemiological\\nstudies or diagnostic screening have in the past been\\nrestricted to the 2–h values only (Table 1). Whilst this\\nremains the single best choice, if it is not possible to\\nperform the OGTT (e.g. for logistical or economic reasons),'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 11, 'page_label': '12'}, page_content='the fasting plasma glucose alone may be used for\\nepidemiological purposes. It has now been clearly shown,\\nhowever, that some of the individuals identified by the new\\nfasting values differ from those identified by 2–h post\\nglucose challenge values (10,11). The latter include the\\nelderly (12) and those with less obesity, such as many Asian\\npopulations. On the other hand, middle-aged, more obese'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 12, 'page_label': '13'}, page_content='7\\npatients are more likely to have diagnostic fasting values\\n(10). Overall population prevalence may (13) or may not\\n(7,10,14) be found to differ when estimates using fasting\\nand 2–h values are compared.\\n2.3.3 Individual diagnosis\\nThe requirements for individual diagnosis differ from those\\nof population studies. The diagnosis should not be based on\\na single glucose determination but requires confirmatory\\nsymptoms or blood/plasma determination. Diagnosis'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 12, 'page_label': '13'}, page_content='requires the identification of people at risk for development\\nof complications in whom early preventive strategies are\\nindicated. Ideally therefore both the 2–h and the fasting\\nvalue should be used. These recommendations contrast with\\nthose of the ADA Expert Committee which gives primacy to\\nthe fasting plasma glucose (4).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 13, 'page_label': '14'}, page_content='8\\n3. Classification\\n3.1 Earlier classifications\\nThe first widely accepted classification of diabetes mellitus\\nwas published by WHO in 1980 (1) and, in modified form, in\\n1985 (3). The 1980 and 1985 classifications of diabetes\\nmellitus and allied categories of glucose intolerance included\\nclinical classes and two statistical risk classes. The 1980\\nExpert Committee proposed two major classes of diabetes\\nmellitus and named them, IDDM or Type 1, and NIDDM or'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 13, 'page_label': '14'}, page_content='Type 2. In the 1985 Study Group Report the terms Type 1\\nand Type 2 were omitted, but the classes IDDM and NIDDM\\nwere retained, and a class of Malnutrition–related Diabetes\\nMellitus (MRDM) was introduced. In both the 1980 and 1985\\nreports other classes of diabetes included Other Types and\\nImpaired Glucose Tolerance (IGT) as well as Gestational\\nDiabetes Mellitus (GDM). These were reflected in the\\nsubsequent International Nomenclature of Diseases (IND) in'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 13, 'page_label': '14'}, page_content='1991, and the tenth revision of the International Classification\\nof Diseases (ICD–10) in 1992. The 1985 classification was\\nwidely accepted and is used internationally. It represented a\\ncompromise between clinical and aetiological classification\\nand allowed classification of individual subjects and patients\\nin a clinically useful manner even when the specific cause or\\naetiology was unknown. The recommended classification\\nincludes both staging of diabetes mellitus based on clinical'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 13, 'page_label': '14'}, page_content='descriptive criteria and a complementary aetiological\\nclassification.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 14, 'page_label': '15'}, page_content='9\\n3.2 Revised classification\\nThe classification encompasses both clinical stages and\\naetiological types of diabetes mellitus and other categories of\\nhyperglycaemia, as suggested by Kuzuya and Matsuda (15).\\nThe clinical staging reflects that diabetes, regardless of its\\naetiology, progresses through several clinical stages during\\nits natural history. Moreover, individual subjects may move\\nfrom stage to stage in either direction. Persons who have, or'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 14, 'page_label': '15'}, page_content='who are developing, diabetes mellitus can be categorized by\\nstage according to the clinical characteristics, even in the\\nabsence of information concerning the underlying aetiology.\\nThe classification by aetiological type results from improved\\nunderstanding of the causes of diabetes mellitus.\\n3.2.1 Application of the new classification\\nThe new classification contains stages which reflect the\\nvarious degrees of hyperglycaemia in individual subjects with'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 14, 'page_label': '15'}, page_content='any of the disease processes which may lead to diabetes\\nmellitus.\\nAll subjects with diabetes mellitus can be categorized\\naccording to clinical stage, and this is achievable in all\\ncircumstances. The stage of glycaemia may change over time\\ndepending on the extent of the underlying disease processes\\n(Figure 2). The disease process may be present but may not\\nhave progressed far enough to cause hyperglycaemia. The\\naetiological classification reflects the fact that the defect or'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 15, 'page_label': '16'}, page_content='10\\nprocess which may lead to diabetes may be identifiable at any\\nstage in the development of diabetes – even at the stage of\\nnormoglycaemia. Thus the presence of islet cell antibodies in\\na normoglycaemic individual makes it likely that that person\\nhas the Type 1 autoimmune process. Unfortunately, there are\\nfew sensitive or highly specific indicators of the Type 2\\nprocess at present, although these are likely to be revealed as\\naetiology is more clearly defined. The same disease processes'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 15, 'page_label': '16'}, page_content='can cause impaired fasting glycaemia and/or impaired\\nglucose tolerance without fulfilling the criteria for the\\ndiagnosis of diabetes mellitus. In some individuals with\\ndiabetes, adequate glycaemic control can be achieved with\\nweight reduction, exercise and/or oral agents. These\\nindividuals, therefore, do not require insulin and may even\\nrevert to IGT or normoglycaemia. Other individuals require\\ninsulin for adequate glycaemic control but can survive'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 15, 'page_label': '16'}, page_content='without it. These individuals, by definition, have some\\nresidual insulin secretion. Individuals with extensive beta–\\ncell destruction, and therefore no residual insulin secretion,\\nrequire insulin for survival. The severity of the metabolic\\nabnormality can either regress (e.g. with weight reduction),\\nprogress (e.g. with weight gain), or stay the same.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 16, 'page_label': '17'}, page_content='11\\n3.3 Terminology (Table 2)\\nIt is recommended that the terms “insulin–dependent diabetes\\nmellitus” and “non–insulin–dependent diabetes mellitus” and\\ntheir acronyms “IDDM” and “NIDDM” no longer be used.\\nThese terms have been confusing and frequently resulted in\\npatients being classified on the basis of treatment rather than\\npathogenesis.\\nC The terms Type 1 and Type 2 should be reintroduced.\\nThe aetiological type named Type 1 encompasses the\\nmajority of cases which are primarily due to pancreatic'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 16, 'page_label': '17'}, page_content='islet beta–cell destruction and are prone to\\nketoacidosis. Type 1 includes those cases attributable\\nto an autoimmune process, as well as those with beta–\\ncell destruction and who are prone to ketoacidosis for\\nwhich neither an aetiology nor a pathogenesis is\\nknown (idiopathic). It does not include those forms of\\nbeta–cell destruction or failure to which specific\\ncauses can be assigned (e.g. cystic fibrosis,\\nmitochondrial defects, etc.). Some subjects with this'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 16, 'page_label': '17'}, page_content='type can be identified at earlier clinical stages than\\n“diabetes mellitus”.\\nC The type named Type 2 includes the common major\\nform of diabetes which results from defect(s) in insulin\\nsecretion, almost always with a major contribution\\nfrom insulin resistance. It has been argued that a lean\\nphenotype of Type 2 diabetes mellitus in adults found\\nin the Indian sub–continent may be very distinct from\\nthe more characteristic form of Type 2 found in'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 17, 'page_label': '18'}, page_content='12\\nCaucasians. Not enough information is available,\\nhowever, to characterize such subjects separately.\\nC A recent international workshop reviewed the evidence\\nfor, and characteristics of, diabetes mellitus seen in\\nundernourished populations (16,17). Whilst it appears\\nthat malnutrition may influence the expression of\\nseveral types of diabetes, the evidence that diabetes\\ncan be caused by malnutrition or protein deficiency per\\nse is not convincing. Therefore, it is recommended that'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 17, 'page_label': '18'}, page_content='the class “Malnutrition–related diabetes” (MRDM) be\\ndeleted. The former subtype of MRDM, Protein–\\ndeficient Pancreatic Diabetes (PDPD or PDDM), may\\nbe considered as a malnutrition modulated or modified\\nform of diabetes mellitus for which more studies are\\nneeded. The other former subtype of MRDM,\\nFibrocalculous Pancreatic Diabetes (FCPD), is now\\nclassified as a disease of the exocrine pancreas,\\nfibrocalculous pancreatopathy, which may lead to\\ndiabetes mellitus.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 17, 'page_label': '18'}, page_content='diabetes mellitus.\\nC The class “Impaired Glucose Tolerance” is now\\nclassified as a stage of impaired glucose regulation,\\nsince it can be observed in any hyperglycaemic\\ndisorder, and is itself not diabetes.\\nC A clinical stage of Impaired Fasting Glycaemia has\\nbeen introduced to classify individuals who have\\nfasting glucose values above the normal range, but\\nbelow those diagnostic of diabetes.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 18, 'page_label': '19'}, page_content='13\\nC Gestational Diabetes is retained but now encompasses\\nthe groups formerly classified as Gestational Impaired\\nGlucose Tolerance (GIGT) and Gestational Diabetes\\nMellitus (GDM).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 19, 'page_label': '20'}, page_content='14\\n4. Clinical staging of diabetes mellitus\\nand other categories of glucose\\ntolerance (Figure 2)\\n4.1 Diabetes mellitus\\nDiabetes mellitus, regardless of underlying cause, is sub–\\ndivided into: Insulin requiring for survival  (corresponding to\\nthe former clinical class of “Insulin Dependent Diabetes\\nMellitus – IDDM”), e.g. C–peptide deficient; Insulin\\nrequiring for control , i.e. metabolic control, rather than for\\nsurvival, e.g. some endogenous insulin secretion but'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 19, 'page_label': '20'}, page_content='insufficient to achieve normoglycaemia without added\\nexogenous insulin; and Not insulin requiring , i.e. those who\\nmay be controlled satisfactorily by non–pharmacological\\nmethods or drugs other than insulin. Together, the latter two\\nsub–divisions constitute the former class of NIDDM.\\n4.2 Impaired glucose regulation – Impaired\\nGlucose Tolerance (IGT) and Impaired Fasting\\nGlycaemia (IFG)\\nImpaired glucose regulation (IGT and IFG) refers to a\\nmetabolic state intermediate between normal glucose'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 19, 'page_label': '20'}, page_content='homeostasis and diabetes. It should be stated unequivocally,\\nhowever, that IFG and IGT are not interchangeable and\\nrepresent different abnormalities of glucose regulation, one in\\nthe fasting state and one post–prandial.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 20, 'page_label': '21'}, page_content='15\\nIGT, rather than being a class as in the previous\\nclassification, is categorized as a stage in the natural history\\nof disordered carbohydrate metabolism. A stage of IFG is\\nalso recognized because such subjects, like those with IGT,\\nhave increased risks of progressing to diabetes and\\nmacrovascular disease, although prospective data are sparse\\nand early data suggest a lower risk of progression than IGT\\n(18), although a similar CVD risk factor profile has been'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 20, 'page_label': '21'}, page_content='shown in IFG and IGT subjects (19). IFG refers to fasting\\nglucose concentrations which are lower than those required to\\ndiagnose diabetes mellitus but higher than the “normal”\\nreference range.\\nThe values for IFG are a fasting plasma glucose\\nconcentration of 6.1 mmol l–1 (110 mg dl–1) or greater (whole\\nblood 5.6 mmol l –1; 100 mg dl–1), but less than 7.0 mmol l –1\\n(126 mg dl–1) (whole blood 6.1 mmol l –1; 110 mg dl–1). If an\\nOGTT is performed, some individuals with IFG will have'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 20, 'page_label': '21'}, page_content='IGT or diabetes, but this cannot be determined without an\\nOGTT. If resources allow, it is recommended that all those\\nwith IFG have an OGTT to exclude the diagnosis of diabetes.\\nIndividuals who meet criteria for IGT or IFG may be\\neuglycaemic in their daily lives as shown by normal or near–\\nnormal glycated haemoglobin levels. IGT and IFG are not\\nclinical entities in their own right, but rather risk categories\\nfor future diabetes and/or cardiovascular disease (20,21).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 20, 'page_label': '21'}, page_content='They can occur as an intermediate stage in any of the disease\\nprocesses listed in Table 2. IGT is often associated with the\\nMetabolic Syndrome (Insulin Resistance Syndrome) (22).\\nThus, IGT may not be directly involved in the pathogenesis\\nof cardiovascular disease, but rather may serve as an\\nindicator or marker of enhanced risk by virtue of its\\ncorrelation with the other elements of the Metabolic'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 21, 'page_label': '22'}, page_content='16\\nSyndrome that are cardiovascular risk factors. Self–evidently,\\nthose individuals with IGT manifest glucose intolerance only\\nwhen challenged with an oral glucose load.\\n4.3 Normoglycaemia\\nA fasting venous plasma glucose concentration of less than\\n6.1 mmol l –1 (110 mg dl S1) has been chosen as “normal”\\n(Table 1). Although this choice is arbitrary, such values are\\nobserved in people with proven normal glucose tolerance,\\nalthough some may have IGT if an OGTT is performed.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 21, 'page_label': '22'}, page_content='Values above this are associated with a progressively greater\\nrisk of developing micro– and macrovascular complications\\n(8,9,21,23).\\nThe pathological or aetiological processes which often lead to\\ndiabetes mellitus begin, and may be recognizable, in some\\nsubjects who have normal glucose tolerance. Recognition of\\nthe pathological process at an early stage may be useful if\\nprogression to more advanced stages can be prevented.\\nConversely, effective treatments, or occasionally the natural'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 21, 'page_label': '22'}, page_content='history of some forms of diabetes mellitus, may result in\\nreversion of hyperglycaemia to a state of normoglycaemia.\\nThe proposed classification includes a stage of\\nnormoglycaemia in which persons who have evidence of the\\npathological processes which may lead to diabetes mellitus,\\nor in whom a reversal of the hyperglycaemia has occurred,\\nare classified.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 22, 'page_label': '23'}, page_content='17\\n5. Aetiological types\\n (see also section 7 and Table 2)\\nThe aetiological types designate defects, disorders or\\nprocesses which often result in diabetes mellitus.\\n5.1 Type 1\\nType 1 indicates the processes of beta–cell destruction that\\nmay ultimately lead to diabetes mellitus in which “insulin is\\nrequired for survival” to prevent the development of\\nketoacidosis, coma and death. An individual with a Type 1\\nprocess may be metabolically normal before the disease is'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 22, 'page_label': '23'}, page_content='clinically manifest, but the process of beta–cell destruction\\ncan be detected. Type 1 is usually characterized by the\\npresence of anti–GAD, islet cell or insulin antibodies which\\nidentify the autoimmune processes that lead to beta–cell\\ndestruction. In some subjects with this clinical form of\\ndiabetes, particularly non–Caucasians, no evidence of an\\nautoimmune disorder is demonstrable and these are classified\\nas “Type 1 idiopathic”. Aetiological classification may be'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 22, 'page_label': '23'}, page_content='possible in some circumstances and not in others. Thus, the\\naetiological Type 1 process can be identified and sub–\\ncategorized if appropriate antibody determinations are\\nperformed. It is recognized that such measurements may be\\navailable only in certain centres at the present time. If these\\nmeasurements are performed, then the classification of\\nindividual patients should reflect this.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 23, 'page_label': '24'}, page_content='18\\n5.2 Type 2\\nType 2 is the most common form of diabetes and is\\ncharacterized by disorders of insulin action and insulin\\nsecretion, either of which may be the predominant feature.\\nBoth are usually present at the time that this form of diabetes\\nis clinically manifest. By definition, the specific reasons for\\nthe development of these abnormalities are not yet known.\\n5.3 Other specific types (Table 3)\\nOther specific types are currently less common causes of'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 23, 'page_label': '24'}, page_content='diabetes mellitus, but are those in which the underlying\\ndefect or disease process can be identified in a relatively\\nspecific manner. They include, for example, fibrocalculous\\npancreatopathy, a form of diabetes which was formerly\\nclassified as one type of malnutrition–related diabetes\\nmellitus.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 24, 'page_label': '25'}, page_content='19\\n6. Gestational Hyperglycaemia and\\nDiabetes\\nGestational diabetes is carbohydrate intolerance resulting in\\nhyperglycaemia of variable severity with onset or first\\nrecognition during pregnancy. It does not exclude the\\npossibility that the glucose intolerance may antedate\\npregnancy but has been previously unrecognized. The\\ndefinition applies irrespective of whether or not insulin is\\nused for treatment or the condition persists after pregnancy.\\nWomen who become pregnant and who are known to have'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 24, 'page_label': '25'}, page_content='diabetes mellitus which antedates pregnancy do not have\\ngestational diabetes but have “diabetes mellitus and\\npregnancy” and should be treated accordingly before, during,\\nand after the pregnancy.\\nIn the early part of pregnancy (e.g. first trimester and first\\nhalf of second trimester) fasting and postprandial glucose\\nconcentrations are normally lower than in normal, non–\\npregnant women. Elevated fasting or postprandial plasma\\nglucose levels at this time in pregnancy may well reflect the'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 24, 'page_label': '25'}, page_content='presence of diabetes which has antedated pregnancy, but\\ncriteria for designating abnormally high glucose\\nconcentrations at this time have not yet been established. The\\noccurrence of higher than usual plasma glucose levels at this\\ntime in pregnancy mandates careful management and may be\\nan indication for carrying out an OGTT (Annex 1).\\nNevertheless, normal glucose tolerance in the early part of'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 25, 'page_label': '26'}, page_content='20\\npregnancy does not itself establish that gestational diabetes\\nmay not develop later.\\nIndividuals at high risk for gestational diabetes include older\\nwomen, those with previous history of glucose intolerance,\\nthose with a history of large for gestational age babies,\\nwomen from certain high–risk ethnic groups, and any\\npregnant woman who has elevated fasting, or casual, blood\\nglucose levels. It may be appropriate to screen pregnant\\nwomen belonging to high–risk populations during the first'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 25, 'page_label': '26'}, page_content='trimester of pregnancy in order to detect previously\\nundiagnosed diabetes mellitus. Formal systematic testing for\\ngestational diabetes is usually done between 24 and 28 weeks\\nof gestation.\\n6.1 Diagnosis of gestational diabetes\\nTo determine if gestational diabetes is present in pregnant\\nwomen, a standard OGTT should be performed after\\novernight fasting (8–14 hours) by giving 75 g anhydrous\\nglucose in 250–300 ml water (Annex 1). Plasma glucose is'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 25, 'page_label': '26'}, page_content='measured fasting and after 2 hours. Pregnant women who\\nmeet WHO criteria for diabetes mellitus or IGT are classified\\nas having Gestational Diabetes Mellitus (GDM). After the\\npregnancy ends, the woman should be re–classified as having\\neither diabetes mellitus, or IGT, or normal glucose tolerance\\nbased on the results of a 75 g OGTT six weeks or more after\\ndelivery. It should be emphasized that such women,\\nregardless of the 6–week post–pregnancy result, are at'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 25, 'page_label': '26'}, page_content='increased risk of subsequently developing diabetes. The\\nsignificance of IFG in pregnancy remains to be established.\\nAny woman with IFG, however, should have a 75 g OGTT.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 26, 'page_label': '27'}, page_content='21\\n7. Description of aetiological types\\nPatients with any form of diabetes may require insulin\\ntreatment at some stage of their disease. Such use of insulin\\ndoes not, of itself, define the aetiological class.\\n7.1 Type 1 (beta–cell destruction, usually\\nleading to absolute insulin deficiency)\\n7.1.1 Autoimmune Diabetes Mellitus\\nThis form of diabetes, previously encompassed by the terms\\ninsulin–dependent diabetes, Type 1 diabetes, or juvenile–\\nonset diabetes, results from autoimmune mediated'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 26, 'page_label': '27'}, page_content='destruction of the beta cells of the pancreas. The rate of\\ndestruction is quite variable, being rapid in some\\nindividuals and slow in others (24). The rapidly progressive\\nform is commonly observed in children, but also may occur\\nin adults (25). The slowly progressive form generally\\noccurs in adults and is sometimes referred to as latent\\nautoimmune diabetes in adults (LADA). Some patients,\\nparticularly children and adolescents, may present with'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 26, 'page_label': '27'}, page_content='ketoacidosis as the first manifestation of the disease (26).\\nOthers have modest fasting hyperglycaemia that can rapidly\\nchange to severe hyperglycaemia and/or ketoacidosis in the\\npresence of infection or other stress. Still others,\\nparticularly adults, may retain residual beta–cell function,\\nsufficient to prevent ketoacidosis, for many years (27).\\nIndividuals with this form of Type 1 diabetes often become\\ndependent on insulin for survival eventually and are at risk'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 26, 'page_label': '27'}, page_content='for ketoacidosis (28). At this stage of the disease, there'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 27, 'page_label': '28'}, page_content='22\\nis little or no insulin secretion as manifested by low or\\nundetectable levels of plasma C–peptide (29).\\nMarkers of immune destruction, including islet cell\\nautoantibodies, and/or autoantibodies to insulin, and\\nautoantibodies to glutamic acid decarboxylase (GAD) are\\npresent in 85–90 % of individuals with Type 1 diabetes\\nmellitus when fasting diabetic hyperglycaemia is initially\\ndetected (30). The peak incidence of this form of Type 1\\ndiabetes occurs in childhood and adolescence, but the onset'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 27, 'page_label': '28'}, page_content='may occur at any age, ranging from childhood to the ninth\\ndecade of life (31). There is a genetic predisposition to\\nautoimmune destruction of beta cells, and it is also related\\nto environmental factors that are still poorly defined.\\nAlthough patients are usually not obese when they present\\nwith this type of diabetes, the presence of obesity is not\\nincompatible with the diagnosis. These patients may also\\nhave other autoimmune disorders such as Graves’ disease,'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 27, 'page_label': '28'}, page_content='Hashimoto’s thyroiditis, and Addison’s disease (32).\\n7.1.2 Idiopathic\\nThere are some forms of Type 1 diabetes which have no\\nknown aetiology. Some of these patients have permanent\\ninsulinopenia and are prone to ketoacidosis, but have no\\nevidence of autoimmunity (33). This form of diabetes is\\nmore common among individuals of African and Asian\\norigin. In another form found in Africans an absolute\\nrequirement for insulin replacement therapy in affected'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 27, 'page_label': '28'}, page_content='patients may come and go, and patients periodically\\ndevelop ketoacidosis (34).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 28, 'page_label': '29'}, page_content='23\\n7.2 Type 2 (predominantly insulin resistance with\\nrelative insulin deficiency or predominantly an\\ninsulin secretory defect with/without insulin\\nresistance)\\nDiabetes mellitus of this type previously encompassed non–\\ninsulin–dependent diabetes, or adult–onset diabetes. It is a\\nterm used for individuals who have relative (rather than\\nabsolute) insulin deficiency. People with this type of diabetes\\nfrequently are resistant to the action of insulin (35,36). At'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 28, 'page_label': '29'}, page_content='least initially, and often throughout their lifetime, these\\nindividuals do not need insulin treatment to survive. This\\nform of diabetes is frequently undiagnosed for many years\\nbecause the hyperglycaemia is often not severe enough to\\nprovoke noticeable symptoms of diabetes (37,38).\\nNevertheless, such patients are at increased risk of\\ndeveloping macrovascular and microvascular complications\\n(37,38). There are probably several different mechanisms'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 28, 'page_label': '29'}, page_content='which result in this form of diabetes, and it is likely that the\\nnumber of people in this category will decrease in the future\\nas identification of specific pathogenetic processes and\\ngenetic defects permits better differentiation and a more\\ndefinitive classification with movement into “Other types”.\\nAlthough the specific aetiologies of this form of diabetes are\\nnot known, by definition autoimmune destruction of the\\npancreas does not occur and patients do not have other'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 28, 'page_label': '29'}, page_content='known specific causes of diabetes listed in Tables 3–5.\\nThe majority of patients with this form of diabetes are obese,\\nand obesity itself causes or aggravates insulin resistance\\n(39,40). Many of those who are not obese by traditional\\nweight criteria may have an increased percentage of body fat\\ndistributed predominantly in the abdominal region (41).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 29, 'page_label': '30'}, page_content='24\\nKetoacidosis is infrequent in this type of diabetes; when seen\\nit usually arises in association with the stress of another\\nillness such as infection (42,43). Whereas patients with this\\nform of diabetes may have insulin levels that appear normal\\nor elevated, the high blood glucose levels in these diabetic\\npatients would be expected to result in even higher insulin\\nvalues had their beta–cell function been normal (44). Thus,\\ninsulin secretion is defective and insufficient to compensate'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 29, 'page_label': '30'}, page_content='for the insulin resistance. On the other hand, some individuals\\nhave essentially normal insulin action, but markedly impaired\\ninsulin secretion. Insulin sensitivity may be increased by\\nweight reduction, increased physical activity, and/or\\npharmacological treatment of hyperglycaemia but is not\\nrestored to normal (45,46). The risk of developing Type 2\\ndiabetes increases with age, obesity, and lack of physical\\nactivity (47,48). It occurs more frequently in women with'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 29, 'page_label': '30'}, page_content='prior GDM and in individuals with hypertension or\\ndyslipidaemia. Its frequency varies in different racial/ethnic\\nsubgroups (47–50). It is often associated with strong familial,\\nlikely genetic, predisposition (49–51). However, the genetics\\nof this form of diabetes are complex and not clearly defined.\\nSome patients who present with a clinical picture consistent\\nwith Type 2 diabetes have autoantibodies similar to those\\nfound in Type 1 diabetes, and may masquerade as Type 2'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 29, 'page_label': '30'}, page_content='diabetes if antibody determinations are not made. Patients\\nwho are non–obese or who have relatives with Type 1\\ndiabetes and who are of Northern European origin may be\\nsuspected of having late onset Type 1 diabetes.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 30, 'page_label': '31'}, page_content='25\\n7.3 Other Specific Types\\n7.3.1 Genetic defects of beta–cell function\\nSeveral forms of the diabetic state may be associated with\\nmonogenic defects in beta–cell function, frequently\\ncharacterized by onset of mild hyperglycaemia at an early\\nage (generally before age 25 years). They are usually\\ninherited in an autosomal dominant pattern. Patients with\\nthese forms of diabetes, formerly referred to as maturity–\\nonset diabetes of the young (MODY), have impaired insulin'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 30, 'page_label': '31'}, page_content='secretion with minimal or no defect in insulin action (52,53).\\nAbnormalities at three genetic loci on different\\nchromosomes have now been characterized. The most\\ncommon form is associated with mutations on chromosome\\n12 in a hepatic nuclear transcription factor referred to as\\nHNF1\" (54). A second form is associated with mutations in\\nthe glucokinase gene on chromosome 7p (55,56).\\nGlucokinase converts glucose to glucose–6–phosphate, the\\nmetabolism of which in turn stimulates insulin secretion by'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 30, 'page_label': '31'}, page_content='the beta cell. Thus, glucokinase serves as the “glucose\\nsensor” for the beta cell. Because of defects in the\\nglucokinase gene, increased levels of glucose are necessary\\nto elicit normal levels of insulin secretion. A third form is\\nassociated with a mutation in the HNF4 \" gene on\\nchromosome 20q (57). HNF4\" is a transcription factor which\\nis involved in the regulation of the expression of HNF1 \". A\\nfourth variant has recently been ascribed to mutations in'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 30, 'page_label': '31'}, page_content='another transcription factor gene, IPF–1, which in its\\nhomozygous form leads to total pancreatic agenesis (58).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 31, 'page_label': '32'}, page_content='26\\nSpecific genetic defects in other individuals who have a\\nsimilar clinical presentation are currently being defined.\\nPoint mutations in mitochondrial DNA have been found to be\\nassociated with diabetes mellitus and deafness (59). The most\\ncommon mutation occurs at position 3243 in the tRNA\\nleucine gene, leading to an A to G substitution. An identical\\nlesion occurs in the MELAS syndrome (Mitochondrial\\nmyopathy, Encephalopathy, Lactic Acidosis, and Stroke–like'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 31, 'page_label': '32'}, page_content='syndrome); however, diabetes is not part of this syndrome,\\nsuggesting for unknown reasons different phenotypic\\nexpressions of this genetic lesion (60).\\nGenetic abnormalities that result in the inability to convert\\nproinsulin to insulin have been identified in a few families.\\nSuch traits are usually inherited in an autosomal dominant\\npattern (61,62) and the resultant carbohydrate intolerance is\\nmild. Similarly, mutant insulin molecules with impaired'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 31, 'page_label': '32'}, page_content='receptor binding have been identified in a few families. These\\nare also associated with autosomal inheritance and either\\nnormal or only mildly impaired carbohydrate metabolism\\n(63,64).\\n7.3.2 Genetic defects in insulin action\\nThere are some unusual causes of diabetes which result from\\ngenetically determined abnormalities of insulin action. The\\nmetabolic abnormalities associated with mutations of the\\ninsulin receptor may range from hyperinsulinaemia and'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 31, 'page_label': '32'}, page_content='modest hyperglycaemia to symptomatic diabetes (65,66).\\nSome individuals with these mutations have acanthosis\\nnigricans. Women may have virilization and have enlarged,'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 32, 'page_label': '33'}, page_content='27\\ncystic ovaries. In the past, this syndrome was termed Type A\\ninsulin resistance (65). Leprechaunism and Rabson–\\nMendenhall syndrome are two paediatric syndromes that\\nhave mutations in the insulin receptor gene with subsequent\\nalterations in insulin receptor function and extreme insulin\\nresistance (66). The former has characteristic facial features\\nwhile the latter is associated with abnormalities of teeth and\\nnails and pineal gland hyperplasia.\\n7.3.3 Diseases of the exocrine pancreas'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 32, 'page_label': '33'}, page_content='Any process that diffusely injures the pancreas can cause\\ndiabetes. Acquired processes include pancreatitis, trauma,\\ninfection, pancreatic carcinoma, and pancreatectomy (67,68).\\nWith the exception of cancer, damage to the pancreas must be\\nextensive for diabetes to occur. However, adenocarcinomas\\nthat involve only a small portion of the pancreas have been\\nassociated with diabetes. This implies a mechanism other\\nthan simple reduction in beta–cell mass (69). If extensive'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 32, 'page_label': '33'}, page_content='enough, cystic fibrosis and haemochromatosis will also\\ndamage beta cells and impair insulin secretion (70,71).\\nFibrocalculous pancreatopathy may be accompanied by\\nabdominal pain radiating to the back and pancreatic\\ncalcification on X–ray and ductal dilatation (72). Pancreatic\\nfibrosis and calcified stones in the exocrine ducts are found at\\nautopsy.\\n7.3.4 Endocrinopathies\\nSeveral hormones (e.g. growth hormone, cortisol, glucagon,\\nepinephrine) antagonize insulin action. Diseases associated'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 32, 'page_label': '33'}, page_content='with excess secretion of these hormones can cause diabetes\\n(e.g. Acromegaly, Cushing’s Syndrome, Glucagonoma and'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 33, 'page_label': '34'}, page_content='28\\nPhaeochromocytoma) (73). These forms of hyperglycaemia\\ntypically resolve when the hormone excess is removed.\\nSomatostatinoma, and aldosteronoma–induced hypokalaemia,\\ncan cause diabetes, at least in part by inhibiting insulin\\nsecretion (74,75). Hyperglycaemia generally resolves\\nfollowing successful removal of the tumour.\\n7.3.5 Drug– or chemical–induced diabetes\\nMany drugs can impair insulin secretion. These drugs may\\nnot, by themselves, cause diabetes but they may precipitate'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 33, 'page_label': '34'}, page_content='diabetes in persons with insulin resistance (76,77). In such\\ncases, the classification is ambiguous, as the primacy of beta–\\ncell dysfunction or insulin resistance is unknown. Certain\\ntoxins such as Vacor (a rat poison) and pentamidine can\\npermanently destroy pancreatic beta cells (78–80).\\nFortunately, such drug reactions are rare. There are also many\\ndrugs and hormones which can impair insulin action.\\nExamples include nicotinic acid and glucocorticoids (71,72).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 33, 'page_label': '34'}, page_content='The list shown in Table 4 is not all–inclusive, but reflects the\\nmore commonly recognized drug–, hormone–, or toxin–\\ninduced forms of diabetes and hyperglycaemia.\\n7.3.6 Infections\\nCertain viruses have been associated with beta–cell\\ndestruction. Diabetes occurs in some patients with congenital\\nrubella (81). In addition, Coxsackie B, cytomegalovirus and\\nother viruses (e.g. adenovirus and mumps) have been\\nimplicated in inducing the disease (82–84).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 34, 'page_label': '35'}, page_content='29\\n7.3.7 Uncommon but specific forms of immune–\\nmediated diabetes mellitus\\nDiabetes may be associated with several immunological\\ndiseases with a pathogenesis or aetiology different from that\\nwhich leads to the Type 1 diabetes process. Postprandial\\nhyperglycaemia of a severity sufficient to fulfil the criteria\\nfor diabetes has been reported in rare individuals who\\nspontaneously develop insulin autoantibodies (85,86).\\nHowever, these individuals generally present with symptoms'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 34, 'page_label': '35'}, page_content='of hypoglycaemia rather than hyperglycaemia. The “stiff man\\nsyndrome” is an autoimmune disorder of the central nervous\\nsystem, characterized by stiffness of the axial muscles with\\npainful spasms (87). Affected people usually have high titres\\nof the GAD autoantibodies and approximately one-half will\\ndevelop diabetes. Patients receiving interferon alpha have\\nbeen reported to develop diabetes associated with islet cell\\nautoantibodies and, in certain instances, severe insulin\\ndeficiency (88).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 34, 'page_label': '35'}, page_content='deficiency (88).\\nAnti–insulin receptor antibodies can cause diabetes by\\nbinding to the insulin receptor, thereby reducing the binding\\nof insulin to target tissues (89). However, these antibodies\\nalso can act as an insulin agonist after binding to the receptor\\nand can thereby cause hypoglycaemia (90). Anti–insulin\\nreceptor antibodies are occasionally found in patients with\\nsystemic lupus erythematosus and other autoimmune diseases\\n(91). As in other states of extreme insulin resistance, patients'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 34, 'page_label': '35'}, page_content='with anti–insulin receptor antibodies often have acanthosis\\nnigricans. In the past, this syndrome was termed Type B\\ninsulin resistance.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 35, 'page_label': '36'}, page_content='30\\n7.3.8 Other genetic syndromes sometimes\\nassociated with diabetes\\nMany genetic syndromes are accompanied by an increased\\nincidence of diabetes mellitus. These include the\\nchromosomal abnormalities of Down’s syndrome,\\nKlinefelter’s syndrome and Turner’s syndrome. Wolfram’s\\nsyndrome is an autosomal recessive disorder characterized by\\ninsulin–deficient diabetes and the absence of beta cells at\\nautopsy (92). Additional manifestations include diabetes'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 35, 'page_label': '36'}, page_content='insipidus, hypogonadism, optic atrophy, and neural deafness.\\nThese and other similar disorders are listed in Table 5.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 36, 'page_label': '37'}, page_content='31\\n8. The Metabolic Syndrome\\nA major classification, diagnostic and therapeutic challenge\\nis the person with hypertension, central (upper body) obesity,\\nand dyslipidaemia, with or without hyperglycaemia. This\\ngroup of people is at high risk of macrovascular disease (22).\\nOften a person with abnormal glucose tolerance (IGT or\\ndiabetes) will be found to have at least one or more of the\\nother cardiovascular disease (CVD) risk components (22).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 36, 'page_label': '37'}, page_content='This clustering has been labelled variously as Syndrome X\\n(22), the Insulin Resistance Syndrome (47), or the Metabolic\\nSyndrome (47).\\nEpidemiological studies confirm that this syndrome occurs\\ncommonly in a wide variety of ethnic groups including\\nCaucasians, Afro–Americans, Mexican–Americans, Asian\\nIndians, Chinese, Australian Aborigines, Polynesians and\\nMicronesians (47,93). In 1988 Reaven focused attention on\\nthis cluster, naming it Syndrome X (22). Central obesity was'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 36, 'page_label': '37'}, page_content='not included in the original description so the term Metabolic\\nSyndrome is now favoured.\\nEvidence is accumulating that insulin resistance may be the\\ncommon aetiological factor for the individual components of\\nthe Metabolic Syndrome (47,93,94), although there appears\\nto be heterogeneity in the strength of the insulin resistance\\nrelationship with different components between, and even\\nwithin, populations. Alone, each component of the cluster\\nconveys increased CVD risk, but as a combination they'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 37, 'page_label': '38'}, page_content='32\\nbecome much more powerful (95). This means that the\\nmanagement of persons with hyperglycaemia and other\\nfeatures of the Metabolic Syndrome should focus not only on\\nblood glucose control but also include strategies for reduction\\nof the other CVD risk factors (96).\\nIt is well documented that the features of the Metabolic\\nSyndrome can be present for up to 10 years before detection\\nof the glycaemic disorders (97). This is important in relation'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 37, 'page_label': '38'}, page_content='to the aetiology of the hyperglycaemia and the associated\\nCVD risk, and the potential to prevent CVD and its morbidity\\nand mortality in persons with glucose intolerance.\\nThe Metabolic Syndrome with normal glucose tolerance\\nidentifies the subject as a member of a group at very high risk\\nof future diabetes. Thus, vigorous early management of the\\nsyndrome may have a significant impact on the prevention of\\nboth diabetes and cardiovascular disease (98).\\n8.1 Definition'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 37, 'page_label': '38'}, page_content='8.1 Definition\\nThere is no internationally agreed definition for the\\nMetabolic Syndrome. The following, which does not imply\\ncausal relationships, is suggested as a working definition to\\nbe improved upon in due course: glucose intolerance, IGT or\\ndiabetes mellitus and/or insulin resistance together with two\\nor more of the other components listed below:\\n• Impaired glucose regulation or diabetes (see Table 1)'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 38, 'page_label': '39'}, page_content='33\\n• Insulin resistance (under hyperinsulinaemic, euglycaemic\\nconditions, glucose uptake below lowest quartile for\\nbackground population under investigation)\\n• Raised arterial pressure ≥ 140/90 mmHg\\n• Raised plasma triglycerides (≥ 1.7 mmol l –1; 150 mg dl–1)\\nand/or low HDL–cholesterol (< 0.9 mmol l –1, 35 mg dl –1\\nmen; < 1.0 mmol l–1, 39 mg dl–1 women)\\n• Central obesity (males: waist to hip ratio > 0.90; females:\\nwaist to hip ratio > 0.85) and/or BMI > 30 kg m–2'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 38, 'page_label': '39'}, page_content='• Microalbuminuria (urinary albumin excretion rate ≥ 20\\nµg min–1 or albumin:creatinine ratio  ≥ 30 mg g–1)\\nSeveral other components of the Metabolic Syndrome have\\nbeen described (e.g. hyperuricaemia, coagulation disorders,\\nraised PAI–1, etc.) but they are not necessary for the\\nrecognition of the condition.\\n8.2 Future needs\\nA clear description of the essential components of the\\nsyndrome is needed together with data to support the relative'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 38, 'page_label': '39'}, page_content='importance of each component. Internationally agreed criteria\\nfor central obesity, insulin resistance and hyperinsulinaemia\\nwould be of major assistance.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 39, 'page_label': '40'}, page_content='34\\nReferences\\n1. WHO Expert Committee on Diabete s Mellitus. Second\\nReport. Geneva: WHO, 1980. Technical Report Series\\n646.\\n2. National Diabetes Data Group. Classification and\\ndiagnosis of diabetes mellitus and other categories of\\nglucose intolerance. Diabetes 1979; 28: 1039–57.\\n3. World Health Organizat ion. Diabetes Mellitus: Report\\nof a WHO Study Group . Geneva: WHO, 1985.\\nTechnical Report Series 727.\\n4. The Expert Committee on the Diagnosis and'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 39, 'page_label': '40'}, page_content='Classification of Diabetes Mellitus. Report of the Expert\\nCommittee on the Diagnosis and Classification of\\nDiabetes Mellitus. Diabetes Care 1997; 20: 1183–97.\\n5. Alberti KGMM, Zimmet PZ for the WHO Consultation.\\nDefinition, diagnosis and classification of diabetes\\nmellitus and its complications. Part 1: diagnosis and\\nclassification of diabetes mellitus. Provisional report of\\na WHO Consultation. Diabetic Medicine  1998; 15:\\n539–553.\\n6. McCance DR, Hanson RL, Charles MA, Jacobsson'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 39, 'page_label': '40'}, page_content='LTH, Pettitt DJ, Bennett PH et al. Comparison of tests\\nfor glycated haemoglobin and fasting and two hour\\nplasma glucose concentrations as diagnostic methods\\nfor diabetes. BMJ 1994; 308: 1323–28.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 40, 'page_label': '41'}, page_content='35\\n7. Finch CF, Zimmet PZ, Alberti KGMM. Determining\\ndiabetes prevalence: a rational basis for the use of\\nfasting plasma glucose concentrations?  Diabetic\\nMedicine 1990; 7: 603–10.\\n8. Engelgau MM, Thompson TJ, Herman WH, Boyle JP,\\nAubert RE, Kenny SJ et al. Comparison of fasting and\\n2–hour glucose and HbA1c levels for diagnosing\\ndiabetes: diagnostic criteria and performance revisited.\\nDiabetes Care 1997; 20: 785–91.\\n9. Charles MA, Balkau B, Vauzelle–Kervoeden F, Thibult'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 40, 'page_label': '41'}, page_content='N, Eschwège E. Revision of diagnostic criteria for\\ndiabetes (Letter). Lancet 1996; 348: 1657–58.\\n10. DECODE Study Group on behalf of the European\\nDiabetes Epidemiology Study Group. Will new\\ndiagnostic criteria for diabetes mellitus change\\nphenotype of patients with diabetes? Reanalysis of\\nEuropean epidemiological data. BMJ 1998; 317: 371–\\n375.\\n11. De Vegt F, Dekker JM, Stehouwer CDA, Nijpels G,\\nBouter LM, Heine RJ. The 1997 American Diabetes\\nAssociation criteria versus the 1985 World Health'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 40, 'page_label': '41'}, page_content='Organization criteria for the diagnosis of abnormal\\nglucose tolerance: poor agreement in the Hoorn Study.\\nDiabetes Care 1998; 21: 1686–1690.\\n12. Wahl PW, Savage PJ, Psaty BM, Orchard TJ, Robbins\\nJA, Tracy RP. Diabetes in older adults: comparison of\\n1997 American Diabetes Association classification of\\ndiabetes mellitus with 1985 WHO classification. Lancet\\n1998; 352: 1012–1015.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 41, 'page_label': '42'}, page_content='36\\n13. Harris MI, Eastman RC, Cowie CC, Flegal KM,\\nEberhardt MS. Comparison of diabetes diagnostic\\ncategories in the US population according to 1997\\nAmerican Diabetes Association and 1980–1985 World\\nHealth Organization diagnostic criteria. Diabetes Care\\n1997; 20: 1859–62.\\n14. Ramachandran A, Snehalatha C, Latha E, Vijay V.\\nEvaluation of the use of fasting plasma glucose as a\\nnew diagnostic criterion for diabetes in Asian Indian\\npopulation (Letter). Diabetes Care 1998; 21: 666–67.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 41, 'page_label': '42'}, page_content='15. Kuzuya T, Matsuda A. Classification of diabetes on the\\nbasis of etiologies versus degree of insulin deficiency.\\nDiabetes Care 1997; 20: 219–20.\\n16. Hoet JJ, Tripathy BB, Rao RH, Yajnik CS. Malnutrition\\nand diabetes in the tropics. Diabetes Care 1996; 19:\\n1014–17.\\n17. Tripathy BB, Samal KC. Overview and consensus\\nstatement on diabetes in tropical areas. Diabetes\\nMetab Rev 1997; 13: 63–76.\\n18. Shaw JE, Zimmet PZ, de Courten M, Dowse GK,\\nGareeboo H, Hemraj F et al. IFG or IGT: what best'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 41, 'page_label': '42'}, page_content='predicts future diabetes?  A view of the new ADA\\nrecommendations. Diabetes Care 1999 (In press)\\n19. Larsson H, Berglund G, Lindgärde F, Ahrén B.\\nComparison of ADA and WHO criteria for diagnosis of\\ndiabetes and glucose intolerance. Diabetologia  1998;\\n41: 1124–1125.\\n20. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H.\\nCoronary heart disease risk and impaired glucose\\ntolerance: the Whitehall Study. Lancet 1980; i: 1373–\\n76.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 42, 'page_label': '43'}, page_content='37\\n21. Alberti KGMM. The clinical implications of Impaired\\nGlucose Tolerance. Diabet Med 1996; 13: 927–37.\\n22. Reaven GM. Role of insulin resistance in human\\ndisease. Diabetes 1988; 37: 1595–607.\\n23. McCance DR, Hanson RL, Pettitt DJ, Bennett PH,\\nHadden DR, Knowler WC. Diagnosing diabetes\\nmellitus – do we need new criteria?  Diabetologia\\n1997; 40: 247–55.\\n24. Zimmet PZ, Tuomi T, Mackay R, Rowley MJ, Knowles\\nW, Cohen M et al. Latent autoimmune diabetes'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 42, 'page_label': '43'}, page_content='mellitus in adults (LADA): the role of antibodies to\\nglutamic acid decarboxylase in diagnosis and\\nprediction of insulin dependency. Diabetic Med  1994;\\n11: 299–303.\\n25. Humphrey ARG, McCarty DJ, Mackay IR, Rowley MJ,\\nDwyer T, Zimmet P. Autoantibodies to glutamic acid\\ndecarboxylase and phenotypic features associated\\nwith early insulin treatment in individuals with adult–\\nonset diabetes mellitus. Diabetic Med  1998; 15: 113–\\n19.\\n26. Japan and Pittsburgh Childhood Diabetes Research'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 42, 'page_label': '43'}, page_content='Groups. Coma at onset of young insulin–dependent\\ndiabetes in Japan: the result of a nationwide survey.\\nDiabetes 1985; 34: 1241–46.\\n27. Zimmet PZ. The pathogenesis and prevention of\\ndiabetes in adults. Diabetes Care 1995; 18: 1050–64.\\n28. Willis JA, Scott RS, Brown LJ, Forbes LV, Schmidli RS,\\nZimmet PZ et al. Islet cell antibodies and antibodies\\nagainst glutamic acid decarboxylase in newly\\ndiagnosed adult–onset diabetes mellitus. Diabetes Res\\nClin Pract 1996; 33: 89–97.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 43, 'page_label': '44'}, page_content='38\\n29. Hother–Nielsen O, Faber O, Sørensen NS, Beck–\\nNielsen H. Classification of newly diagnosed diabetic\\npatients as insulin–requiring or non–insulin–requiring\\nbased on clinical and biochemical variables. Diabetes\\nCare 1988; 11: 531–37.\\n30. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo\\nM, Jackson RA et al. Predicting type I diabetes in first–\\ndegree relatives using a combination of insulin, GAD,\\nand ICA512bdc/IA–2 autoantibodies. Diabetes 1996;\\n45: 926–33.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 43, 'page_label': '44'}, page_content='45: 926–33.\\n31. Mølbak AG, Christau B, Marner B, Borch–Johnsen K,\\nNerup J. Incidence of insulin–dependent diabetes\\nmellitus in age groups over 30 years in Denmark.\\nDiabet Med 1994; 11: 650–55.\\n32. Betterle C, Zanette F, Pedini B, Presotto F, Rapp LB,\\nMonsciotti CM et al. Clinical and subclinical organ–\\nspecific autoimmune manifestations in type 1 (insulin–\\ndependent) diabetic patients and their first–degree\\nrelatives. Diabetologia  1983; 26: 431–36.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 43, 'page_label': '44'}, page_content='33. McLarty DG, Athaide I, Bottazzo GF, Swai ABM,\\nAlberti KGMM. Islet cell antibodies are not specifically\\nassociated with insulin–dependent diabetes in rural\\nTanzanian Africans. Diabetes Res Clin Pract  1990; 9:\\n219–24.\\n34. Ahrén B, Corrigan CB. Intermittent need for insulin in a\\nsubgroup of diabetic patients in Tanzania. Diabet Med\\n1984; 2: 262–64.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 44, 'page_label': '45'}, page_content='39\\n35. DeFronzo RA, Bonadonna RC, Ferrannini E.\\nPathogenesis of NIDDM. In: Alberti KGMM, Zimmet P,\\nDeFronzo RA, eds. International Textbook of Diabetes\\nMellitus. 2nd edn. Chichester: John Wiley, 1997: pp\\n635–712.\\n36. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE,\\nRavussin E et al. Insulin resistance and insulin\\nsecretory dysfunction as precursors of non–insulin–\\ndependent diabetes. Prospective Study of Pima\\nIndians. N Engl J Med 1993; 329: 1988–92.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 44, 'page_label': '45'}, page_content='37. Mooy JM, Grootenhuis PA, de Vries H, Valkenburg HA,\\nBouter LM, Kostense PJ et al. Prevalence and\\ndeterminants of glucose intolerance in a Dutch\\npopulation. The Hoorn Study. Diabetes Care 1995; 18:\\n1270–73.\\n38. Harris MI. Undiagnosed NIDDM; clinical and public\\nhealth issues. Diabetes Care 1993; 16: 642–52.\\n39. Campbell PJ, Carlson MG. Impact of obesity on insulin\\naction in NIDDM. Diabetes 1993; 42: 405–10.\\n40. Bogardus C, Lillioja S, Mott DM, Hollenbeck C, Reaven'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 44, 'page_label': '45'}, page_content='G. Relationship between degree of obesity and in vivo\\ninsulin action in man. Am J Physiol  1985; 248: E286–\\nE291.\\n41. Kissebah AH, Vydelingum N, Murray R, Evans DF,\\nHartz AJ, Kalkhoff RK et al. Relationship of body fat\\ndistribution to metabolic complications of obesity. J Clin\\nEndocrinol Metab  1982; 54: 254–60.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 45, 'page_label': '46'}, page_content='40\\n42. Banerji MA, Chaiken RI, Huey H, Tuomi T, Norin AJ,\\nMacKay IR et al. GAD antibody negative NIDDM in\\nadult black subjects with diabetic ketoacidosis and\\nincreased frequency of human leukocyte antigen DR3\\nand DR4: flatbush diabetes. Diabetes 1994; 43: 741–\\n45.\\n43. Umpierrez GE, Casals MMC, Gebhardt SSP, Mixon\\nPS, Clark WS, Phillips LS. Diabetic ketoacidosis in\\nobese African–Americans. Diabetes 1995; 44: 790–95.\\n44. Polonsky KS, Sturis J, Bell GI. Non–insulin–dependent'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 45, 'page_label': '46'}, page_content='diabetes mellitus: a genetically programmed failure of\\nthe beta cell to compensate for insulin resistance. N\\nEngl J Med 1996; 334: 777–84.\\n45. Simonson DC, Ferrannini E, Bevilacqua S, Smith D,\\nBarrett E, Carlson R et al. Mechanism of improvement\\nin glucose metabolism after chronic glyburide therapy.\\nDiabetes 1984; 33: 838–45.\\n46. Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe\\nR, Bergman RN. Caloric restriction per se is a\\nsignificant factor in improvements in glycemic control'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 45, 'page_label': '46'}, page_content='and insulin sensitivity during weight loss in obese\\nNIDDM patients. Diabetes Care 1994; 17: 30–36.\\n47. Zimmet PZ. Kelly West Lecture 1991: challenges in\\ndiabetes epidemiology: from West to the rest. Diabetes\\nCare 1992; 15: 232–52.\\n48. Harris MI, Cowie CC, Stern MP, Boyko E S, Reiber GE,\\nBennett PH, eds. Diabetes in America . 2nd edn.\\nWashington DC: US Government Printing Office, 1995\\n(NIH publ. No. 95–1468).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 46, 'page_label': '47'}, page_content='41\\n49. Valle T, Tuomilehto J, Eriksson J. Epidemiology of\\nNIDDM in Europids. In: Alberti KGMM, Zimmet P,\\nDeFronzo RA, eds. International Textbook of Diabetes\\nMellitus. 2nd edn. Chichester: John Wiley, 1997: pp\\n125–42.\\n50. de Courten M, Bennett PH, Tuomilehto J, Zimmet P.\\nEpidemiology of NIDDM in Non–Europids. In: Alberti\\nKGMM, Zimmet P, DeFronzo RA, eds. International\\nTextbook of Diabetes Mellitus . 2nd edn. Chichester:\\nJohn Wiley, 1997: pp 143–70.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 46, 'page_label': '47'}, page_content='51. Knowler WC, Nelson RG, Saad M, Bennett PH, Pettitt\\nDJ. Determinants of diabetes mellitus in the Pima\\nIndians. Diabetes Care 1993; 16: 216–27.\\n52. Byrne MM, Sturis J, Menzel S, Y amagata K, Fajans\\nSS, Dronsfield MJ et al. Altered insulin secretory\\nresponse to glucose in diabetic and nondiabetic\\nsubjects with mutations in the diabetes susceptibility\\ngene MODY 3 on chromosome 20. Diabetes 1996; 45:\\n1503–10.\\n53. Clement K, Pueyo ME, V axillaire M, Rakotoambinina'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 46, 'page_label': '47'}, page_content='B, Thuillier F, Passa P et al. Assessment of insulin\\nsensitivity in glucokinase–deficient subjects.\\nDiabetologia  1996; 39: 82–90.\\n54. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H,\\nVaxillaire M et al. Mutations in the hepatocyte nuclear\\nfactor–1\" gene in maturity–onset diabetes of the young\\n(MODY 3). Nature 1996; 384: 455–58.\\n55. Froguel P, Vaxillaire M, Sun F, Velho G, Zouali H,\\nButel MO et al. Close linkage of glucokinase locus on\\nchromosome 7p to early–onset non–insulin–dependent'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 46, 'page_label': '47'}, page_content='diabetes. Nature 1992; 356: 162–64.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 47, 'page_label': '48'}, page_content='42\\n56. Vionnet N, Stoffel M, Takeda J, Yasuda K, Bell GI,\\nZouali H et al. Nonsense mutation in the glucokinase\\ngene causes early–onset non–insulin–dependent\\ndiabetes. Nature 1992; 356: 721–22.\\n57. Yamagata K, Furuta H, Oda N, Kaisaki PJ, Menzel S,\\nCox NJ et al. Mutations in the hepatocyte nuclear\\nfactor–4\" gene in maturity–onset diabetes of the young\\n(MODY 1). Nature 1996; 384: 458–60.\\n58. Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early–\\nonset type–II diabetes mellitus (MODY4) linked to'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 47, 'page_label': '48'}, page_content='IPF1. Nature Genetics  1997; 117: 138–39.\\n59. Walker M, Turnbull DM.  Mitochondrial related diabetes:\\na clinical perspective. Diabet Med 1997; 14: 1007–09.\\n60. Johns DR. Mitochondrial DNA and disease. N Engl J\\nMed 1995; 333: 638–44.\\n61. Gruppuso PA, Gorden P, Kahn CR, Cornblath M,\\nZeller WP, Schwartz R. Familial hyperproinsulinemia\\ndue to a proposed defect in conversion of proinsulin to\\ninsulin. N Engl J Med  1984; 311: 629–34.\\n62. Robbins DC, Shoelson SE, Rubenstein AH, Tager HS.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 47, 'page_label': '48'}, page_content='Familial hyperproinsulinemia: two cohorts secreting\\nindistinguishable type II intermediates of proinsulin\\nconversion. J Clin Invest 1984; 73: 714–19.\\n63. Haneda M, Polonsky KS, Bergenstal RM, Jaspan JB,\\nShoelson SE, Blix PM et al. Familial hyperinsulinemia\\ndue to a structurally abnormal insulin. Definition of an\\nemerging new clinical syndrome. N Engl J Med  1984;\\n310: 1288–94.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 48, 'page_label': '49'}, page_content='43\\n64. Sanz N, Karam JH, Horita S, Bell GI. Prevalence of\\ninsulin–gene mutations in non–insulin–dependent\\ndiabetes mellitus. N Engl J Med  1986; 314: 1322–23.\\n65. Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P,\\nMartin MM et al. The syndromes of insulin resistance\\nand acanthosis nigricans. N Engl J Med  1976; 294:\\n739–45.\\n66. Taylor SI. Lilly Lecture: molecular mechanisms of\\ninsulin resistance: lessons from patients with mutations\\nin the insulin–receptor gene. Diabetes 1992; 41: 1473–\\n90.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 48, 'page_label': '49'}, page_content='90.\\n67. Gullo L, Pezzilli R, Morselli–Labate AM, and the Italian\\nPancreatic Cancer Study Group. Diabetes and the risk\\nof pancreatic cancer. N Engl J Med  1994; 331: 81–84.\\n68. Larsen S, Hilsted J, Tronier B, Worning H. Metabolic\\ncontrol and B cell function in patients with insulin–\\ndependent diabetes mellitus secondary to chronic\\npancreatitis. Metabolism  1987; 36: 964–67.\\n69. Permert J, Larsson J, Westermark GT, Herrington MK,\\nChristmanson L, Pour PM et al. Islet amyloid'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 48, 'page_label': '49'}, page_content='polypeptide in patients with pancreatic cancer and\\ndiabetes. N Engl J Med 1994; 330: 313–18.\\n70. Moran A, Pyzdrowski KL, Weinreb J, Kahn BB, Smith\\nSA, Adams KS et al. Insulin sensitivity in cystic fibrosis.\\nDiabetes 1994; 43: 1020–26.\\n71. Phelps G, Chapman I, Hall P, Braund W, Mackinnon\\nM. Prevalence of genetic haemochromatosis among\\ndiabetic patients. Lancet 1989; ii: 233–34.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 49, 'page_label': '50'}, page_content='44\\n72. Yajnik CS, Shelgikar KM, Naik SS, Kanitkar SV,\\nOrskov H, Alberti KGMM et al. The ketoacidosis–\\nresistance in fibro–calculous–pancreatic–diabetes.\\nDiabetes Res Clin Pract 1992; 15: 149–56.\\n73. MacFarlane IA. Endocrine diseases and diabetes\\nmellitus. In: Pickup JC, Williams G, eds. Textbook of\\nDiabetes. 2nd edn. Oxford: Blackwell, 1997: pp 64.1–\\n64.20.\\n74. Krejs GJ, Orci L, Conlon JM, Ravazzola M, Davis GR,\\nRaskin P et al. Somatostatinoma syndrome. N Engl J\\nMed 1979; 301: 285–92.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 49, 'page_label': '50'}, page_content='75. Conn JW. Hypertension, the potassium ion and\\nimpaired carbohydrate tolerance. N Engl J Med  1965;\\n273: 1135–43.\\n76. Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris\\nAN. Drug–induced disorders of glucose tolerance. Ann\\nIntern Med 1993; 118: 529–40.\\n77. O’Byrne S, Feely J. Effects of drugs on glucose\\ntolerance in non–insulin–dependent diabetes (parts I\\nand II). Drugs 1990; 40: 203–19.\\n78. Gallanosa AG, Spyker DA, Curnow RT. Diabetes\\nmellitus associated with autonomic and peripheral'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 49, 'page_label': '50'}, page_content='neuropathy after Vacor poisoning: a review. Clin\\nToxicol 1981; 18: 441–49.\\n79. Esposti MD, Ngo A, Myers MA. Inhibition of\\nmitochondrial complex I may account for IDDM induced\\nby intoxication with rodenticide Vacor. Diabetes 1996;\\n45: 1531–34.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 50, 'page_label': '51'}, page_content='45\\n80. Assan R, Perronne C, Assan D, Chotard L, Mayaud C,\\nMatheron S et al. Pentamidine–induced derangements\\nof glucose homeostasis. Diabetes Care 1995; 18: 47–\\n55.\\n81. Forrest JA, Menser MA, Burgess JA. High frequency of\\ndiabetes mellitus in young patients with congenital\\nrubella. Lancet 1971; ii: 332–34.\\n82. King ML, Bidwell D, Shaikh A, Voller A, Banatvala JE.\\nCoxsackie–B–virus–specific IgM responses in children\\nwith insulin–dependent (juvenile–onset; type 1)'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 50, 'page_label': '51'}, page_content='diabetes mellitus. Lancet 1983; i: 1397–99.\\n83. Karjalainen J, Knip M, Hyoty H, Linikki P, Ilonen J,\\nKaar M–L et al. Relationship between serum insulin\\nantibodies, islet cell antibodies and Coxsackie–B4 and\\nmumps virus–specific antibodies at the clinical\\nmanifestation of type 1 (insulin–dependent) diabetes.\\nDiabetologia  1988; 31: 146–52.\\n84. Pak CY, Eun H, McArthur RG, Yoon J. Association of\\ncytomegalovirus infection with autoimmune type 1\\ndiabetes. Lancet 1988; ii: 1–4.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 50, 'page_label': '51'}, page_content='85. Hirata Y, Ishizu H, Ouchi N et al. Insulin autoimmunity\\nin a case of spontaneous hypoglycaemia. J Jpn Diabet\\nSoc 1970; 13: 312–20.\\n86. Bodansky HJ, Grant PJ, Dean BM, McNally J, Bottazzo\\nGF, Hambling MH et al. Islet–cell antibodies and insulin\\nautoantibodies in association with common viral\\ninfections. Lancet 1986; ii: 1351–53.\\n87. Solimena M, De Camilli P. Autoimmunity to glutamic\\nacid decarboxylase (GAD) in Stiff–Man syndrome and\\ninsulin–dependent diabetes mellitus. Trends Neurosci'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 50, 'page_label': '51'}, page_content='1991; 14: 452–57.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 51, 'page_label': '52'}, page_content='46\\n88. Fabris P, Betterle C, Floreani A, Greggio NA, de\\nLazzari F, Naccarato R et al. Development of type 1\\ndiabetes mellitus during interferon alfa therapy for\\nchronic HCV hepatitis (Letter). Lancet 1992; 340: 548.\\n89. Flier JS. Lilly Lecture: syndromes of insulin resistance:\\nfrom patient to gene and back again. Diabetes 1992;\\n41: 1207–19.\\n90. Kahn CR, Baird KL, Flier JS, Jarrett DB. Effects of\\nautoantibodies to the insulin receptor on isolated\\nadipocytes. J Clin Invest 1977; 60: 1094–106.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 51, 'page_label': '52'}, page_content='91. Tsokos GC, Gorden P, Antonovych T, Wilson CB,\\nBalow JE. Lupus nephritis and other autoimmune\\nfeatures in patients with diabetes mellitus due to\\nautoantibody to insulin receptors. Ann Intern Med\\n1985; 102: 176–81.\\n92. Barrett TG, Bundey SE, Macleod AF.\\nNeurodegeneration and diabetes: UK nationwide study\\nof Wolfram (DIDMOAD) syndrome. Lancet 1995; 346:\\n1458–63.\\n93. Stern MP. The insulin resistance syndrome. In: Alberti\\nKGMM, Zimmet P, DeFronzo RA, eds. International'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 51, 'page_label': '52'}, page_content='Textbook of Diabetes Mellitus . 2nd edn. Chichester:\\nJohn Wiley, 1997: pp 255–83.\\n94. Haffner SM, Valdez RA, Hazuda HP , Mitchell BD,\\nMorales PA, Stern MP. Prospective analysis of the\\ninsulin resistance syndrome (Syndrome X). Diabetes\\n1992; 41: 715–22.\\n95. Kaplan NM. The deadly quartet: upper body adiposity,\\nglucose intolerance, hypertriglyceridaemia and\\nhypertension. Arch Intern Med  1989; 149: 1514–20.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 52, 'page_label': '53'}, page_content='47\\n96. European Arterial Risk Policy Group on behalf of the\\nInternational Diabetes Federation (European Region).\\nA strategy for arterial risk assessment and\\nmanagement in Type 2 (non–insulin–dependent)\\ndiabetes. Diabet Med 1997; 14: 611–21.\\n97. Mykkänen L, Kuusisto J, Pyörälä K, Laakso M.\\nCardiovascular disease risk factors as predictors of\\nType 2 (non–insulin–dependent) diabetes mellitus in\\nelderly subjects. Diabetologia  1993; 36: 553–59.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 52, 'page_label': '53'}, page_content='98. Eriksson KF, Lindegärde F. Prevent ion of Type 2 (non–\\ninsulin–dependent) diabetes mellitus by diet and\\nphysical exercise. Diabetologia  1991; 34: 891–98.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 53, 'page_label': '54'}, page_content='48\\nAnnex 1\\nThe Oral Glucose Tolerance Test\\nThe oral glucose tolerance test (OGTT) is principally used for\\ndiagnosis when blood glucose levels are equivocal, during\\npregnancy, or in epidemiological studies.\\nThe OGTT should be administered in the morning after at least\\nthree days of unrestricted diet (greater than 150 g of carbohydrate\\ndaily) and usual physical activity. Recent evidence suggests that a\\nreasonable (30–50g) carbohydrate containing meal should be'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 53, 'page_label': '54'}, page_content='consumed on the evening before the test. The test should be\\npreceded by an overnight fast of 8–14 hours, during which water\\nmay be drunk. Smoking is not permitted during the test. The\\npresence of factors that influence interpretation of the results of the\\ntest must be recorded (e.g. medications, inactivity, infection, etc.).\\nAfter collection of the fasting blood sample, the subject should\\ndrink 75 g of anhydrous glucose or 82.5 g of glucose monohydrate'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 53, 'page_label': '54'}, page_content='(or partial hydrolysates of starch of the equivalent carbohydrate\\ncontent) in 250–300 ml of water over the course of 5 minutes. For\\nchildren, the test load should be 1.75 g of glucose per kg body\\nweight up to a total of 75 g of glucose. Timing of the test is from the\\nbeginning of the drink. Blood samples must be collected 2 hours\\nafter the test load.\\nUnless the glucose concentration can be determined immediately,\\nthe blood sample should be collected in a tube containing sodium'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 53, 'page_label': '54'}, page_content='fluoride (6 mg per ml whole blood) and immediately centrifuged to\\nseparate the plasma; the plasma should be frozen until the glucose\\nconcentration can be estimated. For interpretation of results, refer\\nto Table 1.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 54, 'page_label': '55'}, page_content='49\\nAnnex 2\\nMethods for measuring substances in blood and urine\\nMeasurement of glucose in blood\\nReductiometric methods (the Somogyi–Nelson, the ferricyanide\\nand neocuprine autoanalyser methods) are still in use for blood\\nglucose measurement. The o–toluidine method also remains in use\\nbut enzyme–based methods are widely available, for both\\nlaboratory and near–patient use. Highly accurate and rapid (1–2\\nmin) devices are now available based on immobilized glucose'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 54, 'page_label': '55'}, page_content='oxidase electrodes. Hexokinase and glucose dehydrogenase\\nmethods are used for reference.\\nWhole blood samples preserved with fluoride show an initial rapid\\nfall in glucose of up to 10 % at room temperature, but subsequent\\ndecline is slow; centrifugation prevents the initial fall. Whole blood\\nglucose values are 15 % lower than corresponding plasma values\\nin patients with a normal haematocrit reading, and arterial values\\nare about 7 % higher than corresponding venous values.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 54, 'page_label': '55'}, page_content='The use of reagent–strip glucose oxidase methods has made\\nbedside estimation of blood glucose very popular. However, the\\ncost of the reagent–strips remains high. Some methods still require\\npunctilious technique, accurate timing, and storage of strips in\\nairtight containers. Reasonably quantitative results can be obtained\\neven with visual colour–matching techniques. Electrochemical and\\nreflectance meters can give coefficients of variation of well under 5'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 54, 'page_label': '55'}, page_content='%. Reagent–strip methods have been validated under tropical\\nconditions, but are sensitive to extreme climatic conditions.\\nDiabetes may be strongly suspected from the results of reagent–\\nstrip glucose estimation, but the diagnosis cannot be confidently\\nexcluded by the use of this method. Confirmation of diagnosis\\nrequires estimation by laboratory methods.\\nPatients can easily collect small blood samples themselves (either\\nin specially prepared plastic or glass capillary tubes or on'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 55, 'page_label': '56'}, page_content='50\\nfilter–paper), and self–monitoring using glucose reagent–strips\\nwith direct colour–matching or meters is now widely practised.\\nPatients should be properly trained in the appropriate techniques\\nto avoid inaccurate or misleading results.\\nThe insulin–treated patient is commonly requested to build up a\\n“glycaemic profile” by self–measurement of blood glucose at\\nspecific times of the day (and night). A “7–point profile” is useful,\\nwith samples taken before and 90 min after breakfast, before'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 55, 'page_label': '56'}, page_content='and 90 min after lunch, before and 90 min after an evening\\nmeal, and just before going to bed. Occasionally patients may\\narrange to wake at 0300 h to collect and measure a nocturnal\\nsample. The complete profile rarely needs to be collected within\\na single 24–hour period, and it may be compiled from samples\\ncollected at different times over several days.\\nMeasurement of glucose in urine\\nInsulin–treated patients who do not have access to facilities for'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 55, 'page_label': '56'}, page_content='self–measurement of blood glucose should test urine samples\\npassed after rising, before main meals, and before going to bed.\\nNon–insulin–dependent patients do not need to monitor their\\nurine so frequently. Urine tests are of somewhat limited value,\\nhowever, because of the great variation in urine glucose\\nconcentration for given levels of blood glucose. The correlation\\nbetween blood and urine glucose may be improved a little by\\ncollecting short–term fractions (15–30 min) of the urine output.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 55, 'page_label': '56'}, page_content='Benedict’s quantitative solution or self–boiling, caustic\\nsoda/copper sulphate tablets may be used or the more\\nconvenient, but costly, semi–quantitative enzyme–based test–\\nstrips.\\nKetone bodies in urine and blood\\nThe appearance of persistent ketonuria associated with\\nhyperglycaemia or high levels of glycosuria in the diabetic\\npatient points to an unacceptably severe level of metabolic\\ndisturbance and indicates an urgent need for corrective action.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 55, 'page_label': '56'}, page_content='The patient should be advised to test for ketone bodies (acetone\\nand aceto–acetic acid) when tests for glucose are'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 56, 'page_label': '57'}, page_content='51\\nrepeatedly positive, or when there is substantial disturbance of\\nhealth, particularly with infections. Rothera’s sodium nitroprusside\\ntest may be used or, alternatively, reagent–strips that are sensitive\\nto ketones. In emergency situations such as diabetic ketoacidosis,\\na greatly raised concentration of plasma ketones can be detected\\nwith a reagent–strip and roughly quantified by serial 1 in 2 dilution\\nof plasma with water.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 57, 'page_label': '58'}, page_content='52\\nTable 1.   Values for diagnosis of diabetes mellitus and other categories of hyperglycaemia\\nGlucose concentration, mmol l–1  (mg dl–1 )\\nWhole blood Plasma*\\nVenous Capillary Venous\\n Diabetes Mellitus:\\n   Fasting  ≥ 6.1 (≥ 110)  ≥ 6.1 (≥ 110)  ≥ 7.0 (≥ 126)\\n   or\\n   2-h post glucose load\\n   or both\\n ≥ 10.0 (≥ 180)  ≥ 11.1 (≥ 200)  ≥ 11.1 (≥ 200)\\n   or both\\n Impaired Glucose Tolerance (IGT):\\n   Fasting (if measured)  < 6.1 (< 110)  < 6.1 (< 110)  < 7.0 (< 126)\\n   and'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 57, 'page_label': '58'}, page_content='and\\n   2-h post glucose load  ≥ 6.7 (≥ 120) and  ≥ 7.8 (≥ 140) and  ≥ 7.8 (≥ 140) and\\n   < 10.0 (< 180)    < 11.1 (< 200)    < 11.1 (< 200)\\n Impaired Fasting Glycaemia (IFG):\\n   Fasting  ≥ 5.6 (≥ 100) and  ≥ 5.6 (≥ 100) and  ≥ 6.1 (≥ 110) and\\n   < 6.1 (< 110)    < 6.1 (< 110)    < 7.0 (< 126)\\n   and (if measured)\\n   2-h post glucose load  < 6.7 (< 120)  < 7.8 (< 140)  < 7.8 (< 140)'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 57, 'page_label': '58'}, page_content='* Corresponding values for capillary plasma are: for Diabetes Mellitus, fasting ≥ 7.0 (≥ 126), 2-h ≥ 12.2 (≥ 220); for Impaired Glucose Tolerance,fasting < 7.0 (< 126) and\\n2-h ≥ 8.9 (≥ 160) and < 12.2 (< 220); and for Impaired Fasting Glycaemia ≥ 6.1 (≥ 110) and < 7.0 (< 126) and if measured, 2-h < 8.9 (< 160).\\nFor epidemiological or population screening purposes, the fasting or 2-h value after 75 g oral glucose may be used alone. For clinical purposes, the diagnosis of diabetes'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 57, 'page_label': '58'}, page_content='should always be confirmed by repeating the test on another day unless there is unequivocal hyperglycaemia with acute metabolic decompensation or obvious\\nsymptoms.\\nGlucose concentrations should not be determined on serum unless red cells are immediately removed, otherwise glycolysis will result in an\\nunpredictable under-estimation of the true concentrations. It should be stressed that glucose preservatives do not totally prevent glycolysis.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 57, 'page_label': '58'}, page_content='If whole blood is used, the sample should be kept at 0-4 °C or centrifuged immediately, or assayed immediately.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 58, 'page_label': '59'}, page_content='53\\nTable 2. Aetiological Classification of Disorders of\\nGlycaemia*\\n––––––––––––––––––––––––––––––––––––––––––––––––\\nType 1 (beta-cell destruction, usually leading to absolute\\ninsulin deficiency)\\nAutoimmune\\nIdiopathic\\nType 2  (may range from predominantly insulin resistance\\nwith relative insulin deficiency to a predominantly\\nsecretory defect with or without insulin resistance)\\nOther specific types   (see Table 3)\\nGenetic defects of beta-cell function\\nGenetic defects in insulin action'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 58, 'page_label': '59'}, page_content='Diseases of the exocrine pancreas\\nEndocrinopathies\\nDrug- or chemical-induced\\nInfections\\nUncommon forms of immun e-mediated diabetes\\nOther genetic syndromes sometimes associated with\\ndiabetes\\nGestational diabetes**\\n––––––––––––––––––––––––––––––––––––––––––––––––\\n*As additional subtypes are discovered it is anticipated that\\nthey will be reclassified within their own specific category.\\n**Includes the former categories of gestational impaired\\nglucose tolerance and gestational diabetes.'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 59, 'page_label': '60'}, page_content='54\\nTable 3 Other Specific Types of Diabetes\\n––––––––––––––––––––––––––––––––––––––––––––––––\\nGenetic defects of beta-cell function\\nChromosome 20, HNF4 α (MODY1)\\nChromosome 7, glucokinase (MODY2)\\nChromosome 12, HNF1 α (MODY3)\\nChromosome 13, IPF-1 (MODY4)\\nMitochondrial DNA 3243 mutation\\nOthers\\nGenetic defects in insulin action\\nType A insulin resistance\\nLeprechaunism\\nRabson-Mendenhall syndrome\\nLipoatrophic diabetes\\nOthers\\nDiseases of the exocrine pancreas\\nFibrocalculous pancreatopathy\\nPancreatitis'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 59, 'page_label': '60'}, page_content=\"Pancreatitis\\nTrauma / pancreatectomy\\nNeoplasia\\nCystic fibrosis\\nHaemochromatosis\\nOthers\\nEndocrinopathies\\nCushing's syndrome\\nAcromegaly\\nPhaeochromocytoma\\nGlucagonoma\\nHyperthyroidism\\nSomatostatinoma\\nOthers\\n––––––––––––––––––––––––––––––––––––––––––––––––\\n(Continued on page 55 )\"),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 60, 'page_label': '61'}, page_content='55\\nTable 3 (continued)\\n––––––––––––––––––––––––––––––––––––––––––––––––\\nDrug- or chem ical-induced  (see Table 4)\\nInfections\\nCongenital rubella\\nCytomegalovirus\\nOthers\\nUncommon forms of immune-mediated diabetes\\nInsulin autoimmune syndrome (antibodies to insulin)\\nAnti-insulin receptor antibodies\\n\"Stiff Man\" syndrome\\nOthers\\nOther genetic syndromes   (see Table 5)\\n––––––––––––––––––––––––––––––––––––––––––––––––'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 61, 'page_label': '62'}, page_content='56\\nTable 4. Drug- or Chemical-induced Diabetes\\n–––––––––––––––––––––––––––––––––––––––––––––––\\nNicotinic acid\\nGlucocorticoids\\nThyroid hormone\\nAlpha-adrenergic agonists\\nBeta-adrenergic agonists\\nThiazides\\nDilantin\\nPentamidine\\nVacor\\nInterferon-alpha therapy\\nOthers\\n–––––––––––––––––––––––––––––––––––––––––––––––'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 62, 'page_label': '63'}, page_content=\"57\\nTable 5. Other Genetic Syndromes Sometimes\\nAssociated with Diabetes\\n–––––––––––––––––––––––––––––––––––––––––––––––\\nDown's syndrome\\nFriedreich's ataxia\\nHuntington's chorea\\nKlinefelter's syndrome\\nLawrence-Moon-Biedel syndrome\\nMyotonic dystrophy\\nPorphyria\\nPrader-Willi syndrome\\nTurner's syndrome\\nWolfram's syndrome\\nOthers\\n–––––––––––––––––––––––––––––––––––––––––––––––\"),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 63, 'page_label': '64'}, page_content='58\\nFigure 1:   Unstandardized (casual, random) blood glucose values in the diagnosis of diabetes in\\nmmol l-1 (mg dl-1).  Taken from the 1985 WHO Study Group Report (3).'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 64, 'page_label': '65'}, page_content='59\\nFigure 2:  Disorders of glycaemia: aetiological types and clinical stages.\\nStages Normoglycaemia Hyperglycaemia\\nNormal glucose\\ntolerance\\nImpaired glucose\\nregulation\\nDiabetes Mellitus\\nTypes\\nIGT and/or IFG Not\\ninsulin\\nrequiring\\nInsulin\\nrequiring\\nfor\\ncontrol\\nInsulin\\nrequiring\\nfor\\nsurvival\\nType 1\\n• Autoimmune\\n• Idiopathic\\nType 2*\\n• Predominantly\\ninsulin resistance\\n• Predominantly\\ninsulin secretory\\ndefects\\nOther specific\\ntypes*\\nGestational\\ndiabetes*'),\n",
       " Document(metadata={'producer': 'Acrobat PDFWriter 4.0 for Windows', 'creator': 'Microsoft Word - WHO_DIAGNOSI_11gW97.doc', 'creationdate': 'D:20000209211438', 'title': 'WHO_DIAGNOSI_11gW97', 'moddate': '2000-02-09T21:58:13+00:00', 'source': 'data\\\\medical_book.pdf', 'total_pages': 65, 'page': 64, 'page_label': '65'}, page_content='diabetes*\\n* In rare instances patients in these categories (e.g. Vacor Toxicity, Type 1\\npresenting in pregnancy, etc.) may require insulin for survival.')]"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "text_chunks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "39b9d498",
   "metadata": {},
   "outputs": [],
   "source": [
    "#download embeding model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "41f8dc2c",
   "metadata": {},
   "outputs": [],
   "source": [
    "def download_huggingface_embedding():\n",
    "    embeddings = HuggingFaceBgeEmbeddings(model_name=\"sentence-transformers/all-MiniLM-L6-v2\")\n",
    "    return embeddings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "07fe57ac",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\USER\\AppData\\Local\\Temp\\ipykernel_11220\\732167232.py:2: LangChainDeprecationWarning: The class `HuggingFaceBgeEmbeddings` was deprecated in LangChain 0.2.2 and will be removed in 1.0. An updated version of the class exists in the :class:`~langchain-huggingface package and should be used instead. To use it run `pip install -U :class:`~langchain-huggingface` and import as `from :class:`~langchain_huggingface import HuggingFaceEmbeddings``.\n",
      "  embeddings = HuggingFaceBgeEmbeddings(model_name=\"sentence-transformers/all-MiniLM-L6-v2\")\n"
     ]
    }
   ],
   "source": [
    "embeddings = download_huggingface_embedding()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "0864830c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "HuggingFaceBgeEmbeddings(client=SentenceTransformer(\n",
       "  (0): Transformer({'max_seq_length': 256, 'do_lower_case': False, 'architecture': 'BertModel'})\n",
       "  (1): Pooling({'word_embedding_dimension': 384, 'pooling_mode_cls_token': False, 'pooling_mode_mean_tokens': True, 'pooling_mode_max_tokens': False, 'pooling_mode_mean_sqrt_len_tokens': False, 'pooling_mode_weightedmean_tokens': False, 'pooling_mode_lasttoken': False, 'include_prompt': True})\n",
       "  (2): Normalize()\n",
       "), model_name='sentence-transformers/all-MiniLM-L6-v2', cache_folder=None, model_kwargs={}, encode_kwargs={}, query_instruction='Represent this question for searching relevant passages: ', embed_instruction='', show_progress=False)"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "embeddings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "8f97c37d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Length 384\n"
     ]
    }
   ],
   "source": [
    "query_result = embeddings.embed_query(\"Hello world\")\n",
    "print(\"Length\",len(query_result))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "db4ac317",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[-0.010300815105438232,\n",
       " 0.18307922780513763,\n",
       " 0.03081119991838932,\n",
       " 0.0044528404250741005,\n",
       " -0.0273361224681139,\n",
       " -0.033562567085027695,\n",
       " 0.03763148933649063,\n",
       " -0.031573336571455,\n",
       " -0.003391013015061617,\n",
       " -0.008950837887823582,\n",
       " 0.03803616017103195,\n",
       " -0.05129104107618332,\n",
       " 0.0003682934329845011,\n",
       " -0.023727091029286385,\n",
       " 0.0927102193236351,\n",
       " -0.027795813977718353,\n",
       " -0.035152580589056015,\n",
       " -0.003224145621061325,\n",
       " -0.0768178328871727,\n",
       " -0.05761215463280678,\n",
       " 0.07257603853940964,\n",
       " 0.11128544807434082,\n",
       " 0.01605846732854843,\n",
       " 0.015908440575003624,\n",
       " -0.08232704550027847,\n",
       " 0.00700728502124548,\n",
       " 0.02901311218738556,\n",
       " 0.0011386689729988575,\n",
       " 0.1167173683643341,\n",
       " -0.032327331602573395,\n",
       " -0.032271552830934525,\n",
       " -0.0012590086553245783,\n",
       " 0.10591629147529602,\n",
       " 0.023600876331329346,\n",
       " 0.009664947167038918,\n",
       " 0.09834080189466476,\n",
       " 0.042936310172080994,\n",
       " -0.019547604024410248,\n",
       " 0.019267888739705086,\n",
       " -0.06417104601860046,\n",
       " 0.023923343047499657,\n",
       " -0.05288001894950867,\n",
       " -0.026469500735402107,\n",
       " 0.00554870767518878,\n",
       " -0.017025191336870193,\n",
       " -0.030232669785618782,\n",
       " -0.0903533399105072,\n",
       " 0.05418829619884491,\n",
       " 0.03278318792581558,\n",
       " -0.038491811603307724,\n",
       " -0.1629096120595932,\n",
       " -0.05710044130682945,\n",
       " -0.06604953855276108,\n",
       " -0.014481844380497932,\n",
       " 0.04974620044231415,\n",
       " -0.010199349373579025,\n",
       " -0.06685128808021545,\n",
       " -0.0010847249068319798,\n",
       " 0.028305642306804657,\n",
       " -0.021520234644412994,\n",
       " -0.035317711532115936,\n",
       " 0.02593114599585533,\n",
       " -0.01971501298248768,\n",
       " 0.06278971582651138,\n",
       " 0.0917641744017601,\n",
       " -0.10229229927062988,\n",
       " 0.037035271525382996,\n",
       " 0.02054443210363388,\n",
       " -0.07321774959564209,\n",
       " -0.03843872994184494,\n",
       " -0.10208169370889664,\n",
       " -0.021372707560658455,\n",
       " -0.04500991478562355,\n",
       " -0.018804119899868965,\n",
       " -0.13577796518802643,\n",
       " -0.03678477555513382,\n",
       " -0.03485994413495064,\n",
       " -0.03833593800663948,\n",
       " -0.01651901751756668,\n",
       " -0.031229348853230476,\n",
       " 0.06781851500272751,\n",
       " 0.020737282931804657,\n",
       " 0.011971945874392986,\n",
       " 0.0718044638633728,\n",
       " -0.004278053529560566,\n",
       " 0.02494547702372074,\n",
       " 0.016518963500857353,\n",
       " -0.06834040582180023,\n",
       " 0.049031734466552734,\n",
       " -0.006629342213273048,\n",
       " -0.07006296515464783,\n",
       " -0.09807819128036499,\n",
       " 0.03884943202137947,\n",
       " 0.011759771034121513,\n",
       " -0.010465777479112148,\n",
       " 0.0517449676990509,\n",
       " 0.0499442033469677,\n",
       " 0.021490367129445076,\n",
       " 0.0220781322568655,\n",
       " 0.11860286444425583,\n",
       " 0.08999451249837875,\n",
       " 0.03394394740462303,\n",
       " 0.08883435279130936,\n",
       " 0.02232237718999386,\n",
       " -0.022453973069787025,\n",
       " 0.011377076618373394,\n",
       " -0.10129454731941223,\n",
       " 0.06914234161376953,\n",
       " 0.014844372868537903,\n",
       " -0.04821128770709038,\n",
       " -0.09350986033678055,\n",
       " -0.05377848073840141,\n",
       " -0.038114599883556366,\n",
       " -0.10190244764089584,\n",
       " 0.040902283042669296,\n",
       " -0.06833642721176147,\n",
       " 0.02250685915350914,\n",
       " 0.015452065505087376,\n",
       " -0.02008035220205784,\n",
       " 0.035998232662677765,\n",
       " -0.024194862693548203,\n",
       " -0.008909281343221664,\n",
       " -0.007182062137871981,\n",
       " 0.03651837632060051,\n",
       " -0.03508392721414566,\n",
       " -0.017105218023061752,\n",
       " -0.020168807357549667,\n",
       " -2.284261213807171e-33,\n",
       " 0.09506476670503616,\n",
       " 0.006660005077719688,\n",
       " 0.02188521809875965,\n",
       " 0.09388472139835358,\n",
       " -0.03544974699616432,\n",
       " -0.0033221703488379717,\n",
       " -0.04450336471199989,\n",
       " 0.04256828874349594,\n",
       " 0.0298566035926342,\n",
       " -0.013110686093568802,\n",
       " 0.007181514985859394,\n",
       " 0.02030738815665245,\n",
       " 0.0015097877476364374,\n",
       " 0.02846389077603817,\n",
       " -0.05009438470005989,\n",
       " -0.03787592053413391,\n",
       " -0.06964105367660522,\n",
       " 0.01916494593024254,\n",
       " -0.06952053308486938,\n",
       " 0.07272636145353317,\n",
       " -0.014777947217226028,\n",
       " -0.015872715041041374,\n",
       " 0.0013891526032239199,\n",
       " 0.02643933892250061,\n",
       " 0.06056539714336395,\n",
       " 0.005688129924237728,\n",
       " 0.011080402880907059,\n",
       " -0.08853623270988464,\n",
       " 0.025121835991740227,\n",
       " 0.021633902564644814,\n",
       " 0.03881046175956726,\n",
       " -0.04513125494122505,\n",
       " -0.0461919941008091,\n",
       " -0.042806725949048996,\n",
       " 0.06965950131416321,\n",
       " 0.09090016782283783,\n",
       " -0.013691006228327751,\n",
       " -0.08157449960708618,\n",
       " -0.06711916625499725,\n",
       " -0.05557231605052948,\n",
       " -0.04676034674048424,\n",
       " 0.039633430540561676,\n",
       " 0.07059668004512787,\n",
       " 0.00581582635641098,\n",
       " 0.030685964971780777,\n",
       " 0.02797587402164936,\n",
       " -0.055435970425605774,\n",
       " 0.005270813591778278,\n",
       " -0.0005426345742307603,\n",
       " 0.08524660766124725,\n",
       " -0.020388618111610413,\n",
       " 0.07555054873228073,\n",
       " -0.09101557731628418,\n",
       " -0.028498036786913872,\n",
       " 0.05228203907608986,\n",
       " 0.048482876271009445,\n",
       " -0.028915319591760635,\n",
       " 0.06852048635482788,\n",
       " -0.043926920741796494,\n",
       " 0.07083982229232788,\n",
       " -0.009455116465687752,\n",
       " 0.008037054911255836,\n",
       " 0.04271795228123665,\n",
       " 0.05201654136180878,\n",
       " -0.037631191313266754,\n",
       " -0.01975356787443161,\n",
       " -0.026938606053590775,\n",
       " -0.022774627432227135,\n",
       " 0.045056287199258804,\n",
       " 0.0026522025000303984,\n",
       " -0.03637433052062988,\n",
       " -0.0016245422884821892,\n",
       " -0.009545039385557175,\n",
       " 0.08428999036550522,\n",
       " -0.033165521919727325,\n",
       " -0.004807292949408293,\n",
       " 0.005520858336240053,\n",
       " -0.043771229684352875,\n",
       " -0.007754708174616098,\n",
       " -0.06770294904708862,\n",
       " -0.006248037796467543,\n",
       " 0.008232739754021168,\n",
       " 0.029952414333820343,\n",
       " 0.05353198200464249,\n",
       " 0.07379398494958878,\n",
       " -0.07401298731565475,\n",
       " 0.045438166707754135,\n",
       " -0.1214526891708374,\n",
       " 0.006786940153688192,\n",
       " 0.023229101672768593,\n",
       " -0.02505349926650524,\n",
       " 0.0705210268497467,\n",
       " -0.002563547110185027,\n",
       " -0.10330289602279663,\n",
       " -0.061434704810380936,\n",
       " -4.5545495765178443e-35,\n",
       " 0.09373200684785843,\n",
       " 0.016521798446774483,\n",
       " -0.05128544196486473,\n",
       " -0.0075631095096468925,\n",
       " -0.05882898345589638,\n",
       " -0.010721035301685333,\n",
       " -0.03885474056005478,\n",
       " 0.06002236530184746,\n",
       " 0.005357761867344379,\n",
       " 0.08408883959054947,\n",
       " -0.01162257045507431,\n",
       " 0.01050450187176466,\n",
       " 0.13890966773033142,\n",
       " -0.01399277150630951,\n",
       " -0.07269318401813507,\n",
       " -0.04701683670282364,\n",
       " 0.10752871632575989,\n",
       " -0.003004295751452446,\n",
       " 0.01007448136806488,\n",
       " 0.06560282409191132,\n",
       " 0.0039940509013831615,\n",
       " 0.010955668054521084,\n",
       " -0.09632878750562668,\n",
       " -0.02518204227089882,\n",
       " 0.015337620861828327,\n",
       " 0.0705656111240387,\n",
       " 0.08489099144935608,\n",
       " -0.025677915662527084,\n",
       " -0.07766714692115784,\n",
       " 0.008598231710493565,\n",
       " 0.009575297124683857,\n",
       " 0.007218610495328903,\n",
       " -0.09409841150045395,\n",
       " 0.04147094860672951,\n",
       " -0.04565494880080223,\n",
       " -0.007441775407642126,\n",
       " 0.014582683332264423,\n",
       " 0.006933530326932669,\n",
       " 0.0029329366516321898,\n",
       " -0.05206771567463875,\n",
       " 0.0027411114424467087,\n",
       " 0.02147791162133217,\n",
       " 0.011189433746039867,\n",
       " 0.06323125213384628,\n",
       " -0.0821591392159462,\n",
       " -0.005953987594693899,\n",
       " -0.026612356305122375,\n",
       " 0.06312452256679535,\n",
       " -0.00956495851278305,\n",
       " -0.028025902807712555,\n",
       " -0.037277400493621826,\n",
       " -0.03191063180565834,\n",
       " 0.04313572496175766,\n",
       " -0.08780158311128616,\n",
       " -0.05951862037181854,\n",
       " -0.022808043286204338,\n",
       " -0.06337302923202515,\n",
       " -0.04372796788811684,\n",
       " 0.02640071138739586,\n",
       " -0.03103046864271164,\n",
       " 0.004854693077504635,\n",
       " 0.036866798996925354,\n",
       " 0.0022788250353187323,\n",
       " 0.05558505654335022,\n",
       " 0.02213161252439022,\n",
       " -0.07549655437469482,\n",
       " 0.009231260977685452,\n",
       " 0.07583917677402496,\n",
       " 0.021181747317314148,\n",
       " -0.08696744590997696,\n",
       " -0.009340710006654263,\n",
       " -0.07346437126398087,\n",
       " -0.040603797882795334,\n",
       " -0.016280800104141235,\n",
       " -0.014284392818808556,\n",
       " 0.05343625321984291,\n",
       " 0.036426763981580734,\n",
       " -0.06934577971696854,\n",
       " -0.02606288529932499,\n",
       " 0.044529158622026443,\n",
       " 0.03905070945620537,\n",
       " 0.002251173136755824,\n",
       " -0.053449321538209915,\n",
       " 0.019616803154349327,\n",
       " 0.03297467902302742,\n",
       " -0.017909832298755646,\n",
       " -0.004217404872179031,\n",
       " 0.05406989902257919,\n",
       " 0.025197861716151237,\n",
       " 0.02336159162223339,\n",
       " -0.04513731226325035,\n",
       " 0.015319793485105038,\n",
       " -0.060902178287506104,\n",
       " -0.010311366058886051,\n",
       " 0.005022996570914984,\n",
       " -2.2991844872422007e-08,\n",
       " -0.07419109344482422,\n",
       " 0.023530110716819763,\n",
       " -0.038048431277275085,\n",
       " 0.0368015430867672,\n",
       " 0.036406587809324265,\n",
       " 0.03847786411643028,\n",
       " 0.05947579815983772,\n",
       " -0.03988250344991684,\n",
       " -0.0797484815120697,\n",
       " 0.02500234916806221,\n",
       " 0.03533363342285156,\n",
       " 0.08019212633371353,\n",
       " -0.05820675939321518,\n",
       " -0.02403559535741806,\n",
       " 0.06849478930234909,\n",
       " 0.06681929528713226,\n",
       " -0.008757541887462139,\n",
       " -0.06276895105838776,\n",
       " -0.06686685979366302,\n",
       " 0.0013597350334748626,\n",
       " 0.07438520342111588,\n",
       " 0.06266903132200241,\n",
       " -0.022049138322472572,\n",
       " 0.015178668312728405,\n",
       " -0.04246604070067406,\n",
       " 0.04371560364961624,\n",
       " -0.0029684093315154314,\n",
       " 0.03230779990553856,\n",
       " -0.07244178652763367,\n",
       " -0.00845311488956213,\n",
       " 0.02477753348648548,\n",
       " 0.10374249517917633,\n",
       " -0.0886213406920433,\n",
       " 0.00780540332198143,\n",
       " -0.040527161210775375,\n",
       " 0.004687707405537367,\n",
       " -0.08092763274908066,\n",
       " 0.0018340604146942496,\n",
       " 0.050583865493535995,\n",
       " -0.055485405027866364,\n",
       " 0.006174121052026749,\n",
       " 0.08420974016189575,\n",
       " 0.01147595327347517,\n",
       " -0.0007286232430487871,\n",
       " 0.03322442248463631,\n",
       " 0.015147857367992401,\n",
       " 0.015199857763946056,\n",
       " 0.009150282479822636,\n",
       " -0.04391647130250931,\n",
       " -0.05456811562180519,\n",
       " -0.08241592347621918,\n",
       " -0.0029428794514387846,\n",
       " 0.05940462648868561,\n",
       " -0.002933190669864416,\n",
       " 0.022355984896421432,\n",
       " 0.05346654728055,\n",
       " 0.024953072890639305,\n",
       " 0.0515102818608284,\n",
       " -0.01908126287162304,\n",
       " 0.020930206403136253,\n",
       " 0.15390370786190033,\n",
       " 0.03994995355606079,\n",
       " 0.027571862563490868,\n",
       " -0.02796812728047371]"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "query_result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "20df1e69",
   "metadata": {},
   "outputs": [
    {
     "ename": "PineconeApiException",
     "evalue": "(400)\nReason: Bad Request\nHTTP response headers: HTTPHeaderDict({'content-type': 'text/plain; charset=utf-8', 'access-control-allow-origin': '*', 'vary': 'origin,access-control-request-method,access-control-request-headers', 'access-control-expose-headers': '*', 'x-pinecone-api-version': '2025-04', 'x-cloud-trace-context': '1020a2b8211b4793d5e14927293ceabb', 'date': 'Wed, 02 Jul 2025 11:18:46 GMT', 'server': 'Google Frontend', 'Content-Length': '200', 'Via': '1.1 google', 'Alt-Svc': 'h3=\":443\"; ma=2592000,h3-29=\":443\"; ma=2592000'})\nHTTP response body: {\"error\":{\"code\":\"INVALID_ARGUMENT\",\"message\":\"Bad request: Your free plan does not support indexes in the us-west-2 region of aws. To create indexes in this region, upgrade your plan.\"},\"status\":400}\n",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mPineconeApiException\u001b[39m                      Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[21]\u001b[39m\u001b[32m, line 8\u001b[39m\n\u001b[32m      5\u001b[39m index_name = \u001b[33m\"\u001b[39m\u001b[33mmedical-chatbot2\u001b[39m\u001b[33m\"\u001b[39m  \u001b[38;5;66;03m# ✅ all lowercase and hyphen\u001b[39;00m\n\u001b[32m      7\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m index_name \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;129;01min\u001b[39;00m pc.list_indexes().names():\n\u001b[32m----> \u001b[39m\u001b[32m8\u001b[39m     \u001b[43mpc\u001b[49m\u001b[43m.\u001b[49m\u001b[43mcreate_index\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m      9\u001b[39m \u001b[43m        \u001b[49m\u001b[43mname\u001b[49m\u001b[43m=\u001b[49m\u001b[43mindex_name\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m     10\u001b[39m \u001b[43m        \u001b[49m\u001b[43mdimension\u001b[49m\u001b[43m=\u001b[49m\u001b[32;43m384\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m  \u001b[49m\u001b[38;5;66;43;03m# for all-MiniLM-L6-v2\u001b[39;49;00m\n\u001b[32m     11\u001b[39m \u001b[43m        \u001b[49m\u001b[43mmetric\u001b[49m\u001b[43m=\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mcosine\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m     12\u001b[39m \u001b[43m        \u001b[49m\u001b[43mspec\u001b[49m\u001b[43m=\u001b[49m\u001b[43mServerlessSpec\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcloud\u001b[49m\u001b[43m=\u001b[49m\u001b[33;43m'\u001b[39;49m\u001b[33;43maws\u001b[39;49m\u001b[33;43m'\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mregion\u001b[49m\u001b[43m=\u001b[49m\u001b[33;43m'\u001b[39;49m\u001b[33;43mus-west-2\u001b[39;49m\u001b[33;43m'\u001b[39;49m\u001b[43m)\u001b[49m\n\u001b[32m     13\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m     15\u001b[39m index = pc.Index(index_name)\n",
      "\u001b[36mFile \u001b[39m\u001b[32me:\\AI\\AI,ML Career\\Medical-chatbot-using-Liama-2\\medicalChatbot\\Lib\\site-packages\\pinecone\\pinecone.py:334\u001b[39m, in \u001b[36mPinecone.create_index\u001b[39m\u001b[34m(self, name, spec, dimension, metric, timeout, deletion_protection, vector_type, tags)\u001b[39m\n\u001b[32m    323\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mcreate_index\u001b[39m(\n\u001b[32m    324\u001b[39m     \u001b[38;5;28mself\u001b[39m,\n\u001b[32m    325\u001b[39m     name: \u001b[38;5;28mstr\u001b[39m,\n\u001b[32m   (...)\u001b[39m\u001b[32m    332\u001b[39m     tags: Optional[Dict[\u001b[38;5;28mstr\u001b[39m, \u001b[38;5;28mstr\u001b[39m]] = \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[32m    333\u001b[39m ) -> \u001b[33m\"\u001b[39m\u001b[33mIndexModel\u001b[39m\u001b[33m\"\u001b[39m:\n\u001b[32m--> \u001b[39m\u001b[32m334\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mdb\u001b[49m\u001b[43m.\u001b[49m\u001b[43mindex\u001b[49m\u001b[43m.\u001b[49m\u001b[43mcreate\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    335\u001b[39m \u001b[43m        \u001b[49m\u001b[43mname\u001b[49m\u001b[43m=\u001b[49m\u001b[43mname\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    336\u001b[39m \u001b[43m        \u001b[49m\u001b[43mspec\u001b[49m\u001b[43m=\u001b[49m\u001b[43mspec\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    337\u001b[39m \u001b[43m        \u001b[49m\u001b[43mdimension\u001b[49m\u001b[43m=\u001b[49m\u001b[43mdimension\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    338\u001b[39m \u001b[43m        \u001b[49m\u001b[43mmetric\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmetric\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    339\u001b[39m \u001b[43m        \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    340\u001b[39m \u001b[43m        \u001b[49m\u001b[43mdeletion_protection\u001b[49m\u001b[43m=\u001b[49m\u001b[43mdeletion_protection\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    341\u001b[39m \u001b[43m        \u001b[49m\u001b[43mvector_type\u001b[49m\u001b[43m=\u001b[49m\u001b[43mvector_type\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    342\u001b[39m \u001b[43m        \u001b[49m\u001b[43mtags\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtags\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    343\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32me:\\AI\\AI,ML Career\\Medical-chatbot-using-Liama-2\\medicalChatbot\\Lib\\site-packages\\pinecone\\utils\\require_kwargs.py:14\u001b[39m, in \u001b[36mrequire_kwargs.<locals>.wrapper\u001b[39m\u001b[34m(*args, **kwargs)\u001b[39m\n\u001b[32m      9\u001b[39m     param_names = \u001b[38;5;28mlist\u001b[39m(inspect.signature(func).parameters.keys())[\u001b[32m1\u001b[39m:]  \u001b[38;5;66;03m# Skip self\u001b[39;00m\n\u001b[32m     10\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mTypeError\u001b[39;00m(\n\u001b[32m     11\u001b[39m         \u001b[33mf\u001b[39m\u001b[33m\"\u001b[39m\u001b[38;5;132;01m{\u001b[39;00mfunc.\u001b[34m__name__\u001b[39m\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m() requires keyword arguments. \u001b[39m\u001b[33m\"\u001b[39m\n\u001b[32m     12\u001b[39m         \u001b[33mf\u001b[39m\u001b[33m\"\u001b[39m\u001b[33mPlease use \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mfunc.\u001b[34m__name__\u001b[39m\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m(\u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[33m'\u001b[39m\u001b[33m, \u001b[39m\u001b[33m'\u001b[39m.join(\u001b[33mf\u001b[39m\u001b[33m'\u001b[39m\u001b[38;5;132;01m{\u001b[39;00mname\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m=value\u001b[39m\u001b[33m'\u001b[39m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mfor\u001b[39;00m\u001b[38;5;250m \u001b[39mname\u001b[38;5;250m \u001b[39m\u001b[38;5;129;01min\u001b[39;00m\u001b[38;5;250m \u001b[39mparam_names)\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m)\u001b[39m\u001b[33m\"\u001b[39m\n\u001b[32m     13\u001b[39m     )\n\u001b[32m---> \u001b[39m\u001b[32m14\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mfunc\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32me:\\AI\\AI,ML Career\\Medical-chatbot-using-Liama-2\\medicalChatbot\\Lib\\site-packages\\pinecone\\db_control\\resources\\sync\\index.py:81\u001b[39m, in \u001b[36mIndexResource.create\u001b[39m\u001b[34m(self, name, spec, dimension, metric, timeout, deletion_protection, vector_type, tags)\u001b[39m\n\u001b[32m     59\u001b[39m \u001b[38;5;129m@require_kwargs\u001b[39m\n\u001b[32m     60\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mcreate\u001b[39m(\n\u001b[32m     61\u001b[39m     \u001b[38;5;28mself\u001b[39m,\n\u001b[32m   (...)\u001b[39m\u001b[32m     70\u001b[39m     tags: Optional[Dict[\u001b[38;5;28mstr\u001b[39m, \u001b[38;5;28mstr\u001b[39m]] = \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[32m     71\u001b[39m ) -> IndexModel:\n\u001b[32m     72\u001b[39m     req = PineconeDBControlRequestFactory.create_index_request(\n\u001b[32m     73\u001b[39m         name=name,\n\u001b[32m     74\u001b[39m         spec=spec,\n\u001b[32m   (...)\u001b[39m\u001b[32m     79\u001b[39m         tags=tags,\n\u001b[32m     80\u001b[39m     )\n\u001b[32m---> \u001b[39m\u001b[32m81\u001b[39m     resp = \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_index_api\u001b[49m\u001b[43m.\u001b[49m\u001b[43mcreate_index\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcreate_index_request\u001b[49m\u001b[43m=\u001b[49m\u001b[43mreq\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m     83\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m timeout == -\u001b[32m1\u001b[39m:\n\u001b[32m     84\u001b[39m         \u001b[38;5;28;01mreturn\u001b[39;00m IndexModel(resp)\n",
      "\u001b[36mFile \u001b[39m\u001b[32me:\\AI\\AI,ML Career\\Medical-chatbot-using-Liama-2\\medicalChatbot\\Lib\\site-packages\\pinecone\\openapi_support\\endpoint.py:102\u001b[39m, in \u001b[36mEndpoint.__call__\u001b[39m\u001b[34m(self, *args, **kwargs)\u001b[39m\n\u001b[32m     91\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34m__call__\u001b[39m(\u001b[38;5;28mself\u001b[39m, *args, **kwargs):\n\u001b[32m     92\u001b[39m \u001b[38;5;250m    \u001b[39m\u001b[33;03m\"\"\"This method is invoked when endpoints are called\u001b[39;00m\n\u001b[32m     93\u001b[39m \u001b[33;03m    Example:\u001b[39;00m\n\u001b[32m     94\u001b[39m \n\u001b[32m   (...)\u001b[39m\u001b[32m    100\u001b[39m \n\u001b[32m    101\u001b[39m \u001b[33;03m    \"\"\"\u001b[39;00m\n\u001b[32m--> \u001b[39m\u001b[32m102\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mcallable\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32me:\\AI\\AI,ML Career\\Medical-chatbot-using-Liama-2\\medicalChatbot\\Lib\\site-packages\\pinecone\\core\\openapi\\db_control\\api\\manage_indexes_api.py:322\u001b[39m, in \u001b[36mManageIndexesApi.__init__.<locals>.__create_index\u001b[39m\u001b[34m(self, create_index_request, **kwargs)\u001b[39m\n\u001b[32m    320\u001b[39m kwargs = \u001b[38;5;28mself\u001b[39m._process_openapi_kwargs(kwargs)\n\u001b[32m    321\u001b[39m kwargs[\u001b[33m\"\u001b[39m\u001b[33mcreate_index_request\u001b[39m\u001b[33m\"\u001b[39m] = create_index_request\n\u001b[32m--> \u001b[39m\u001b[32m322\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mcall_with_http_info\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32me:\\AI\\AI,ML Career\\Medical-chatbot-using-Liama-2\\medicalChatbot\\Lib\\site-packages\\pinecone\\openapi_support\\endpoint.py:134\u001b[39m, in \u001b[36mEndpoint.call_with_http_info\u001b[39m\u001b[34m(self, **kwargs)\u001b[39m\n\u001b[32m    124\u001b[39m params = EndpointUtils.gather_params(\n\u001b[32m    125\u001b[39m     attribute_map=\u001b[38;5;28mself\u001b[39m.attribute_map,\n\u001b[32m    126\u001b[39m     location_map=\u001b[38;5;28mself\u001b[39m.location_map,\n\u001b[32m   (...)\u001b[39m\u001b[32m    129\u001b[39m     kwargs=kwargs,\n\u001b[32m    130\u001b[39m )\n\u001b[32m    132\u001b[39m HeaderUtil.prepare_headers(headers_map=\u001b[38;5;28mself\u001b[39m.headers_map, params=params)\n\u001b[32m--> \u001b[39m\u001b[32m134\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mapi_client\u001b[49m\u001b[43m.\u001b[49m\u001b[43mcall_api\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    135\u001b[39m \u001b[43m    \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43msettings\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mendpoint_path\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    136\u001b[39m \u001b[43m    \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43msettings\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mhttp_method\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    137\u001b[39m \u001b[43m    \u001b[49m\u001b[43mpath_params\u001b[49m\u001b[43m=\u001b[49m\u001b[43mparams\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mpath\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    138\u001b[39m \u001b[43m    \u001b[49m\u001b[43mquery_params\u001b[49m\u001b[43m=\u001b[49m\u001b[43mparams\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mquery\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    139\u001b[39m \u001b[43m    \u001b[49m\u001b[43mheader_params\u001b[49m\u001b[43m=\u001b[49m\u001b[43mparams\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mheader\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    140\u001b[39m \u001b[43m    \u001b[49m\u001b[43mbody\u001b[49m\u001b[43m=\u001b[49m\u001b[43mparams\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mbody\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    141\u001b[39m \u001b[43m    \u001b[49m\u001b[43mpost_params\u001b[49m\u001b[43m=\u001b[49m\u001b[43mparams\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mform\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    142\u001b[39m \u001b[43m    \u001b[49m\u001b[43mfiles\u001b[49m\u001b[43m=\u001b[49m\u001b[43mparams\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mfile\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    143\u001b[39m \u001b[43m    \u001b[49m\u001b[43mresponse_type\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43msettings\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mresponse_type\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    144\u001b[39m \u001b[43m    \u001b[49m\u001b[43mauth_settings\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43msettings\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mauth\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    145\u001b[39m \u001b[43m    \u001b[49m\u001b[43masync_req\u001b[49m\u001b[43m=\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43masync_req\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    146\u001b[39m \u001b[43m    \u001b[49m\u001b[43masync_threadpool_executor\u001b[49m\u001b[43m=\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m.\u001b[49m\u001b[43mget\u001b[49m\u001b[43m(\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43masync_threadpool_executor\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mNone\u001b[39;49;00m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    147\u001b[39m \u001b[43m    \u001b[49m\u001b[43m_check_type\u001b[49m\u001b[43m=\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43m_check_return_type\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    148\u001b[39m \u001b[43m    \u001b[49m\u001b[43m_return_http_data_only\u001b[49m\u001b[43m=\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43m_return_http_data_only\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    149\u001b[39m \u001b[43m    \u001b[49m\u001b[43m_preload_content\u001b[49m\u001b[43m=\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43m_preload_content\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    150\u001b[39m \u001b[43m    \u001b[49m\u001b[43m_request_timeout\u001b[49m\u001b[43m=\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43m_request_timeout\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    151\u001b[39m \u001b[43m    \u001b[49m\u001b[43m_host\u001b[49m\u001b[43m=\u001b[49m\u001b[43m_host\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    152\u001b[39m \u001b[43m    \u001b[49m\u001b[43mcollection_formats\u001b[49m\u001b[43m=\u001b[49m\u001b[43mparams\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mcollection_format\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    153\u001b[39m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32me:\\AI\\AI,ML Career\\Medical-chatbot-using-Liama-2\\medicalChatbot\\Lib\\site-packages\\pinecone\\openapi_support\\api_client.py:306\u001b[39m, in \u001b[36mApiClient.call_api\u001b[39m\u001b[34m(self, resource_path, method, path_params, query_params, header_params, body, post_params, files, response_type, auth_settings, async_req, async_threadpool_executor, _return_http_data_only, collection_formats, _preload_content, _request_timeout, _host, _check_type)\u001b[39m\n\u001b[32m    285\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m.threadpool_executor.submit(\n\u001b[32m    286\u001b[39m         \u001b[38;5;28mself\u001b[39m.__call_api,\n\u001b[32m    287\u001b[39m         resource_path,\n\u001b[32m   (...)\u001b[39m\u001b[32m    302\u001b[39m         _check_type,\n\u001b[32m    303\u001b[39m     )\n\u001b[32m    305\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m async_req:\n\u001b[32m--> \u001b[39m\u001b[32m306\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m__call_api\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    307\u001b[39m \u001b[43m        \u001b[49m\u001b[43mresource_path\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    308\u001b[39m \u001b[43m        \u001b[49m\u001b[43mmethod\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    309\u001b[39m \u001b[43m        \u001b[49m\u001b[43mpath_params\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    310\u001b[39m \u001b[43m        \u001b[49m\u001b[43mquery_params\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    311\u001b[39m \u001b[43m        \u001b[49m\u001b[43mheader_params\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    312\u001b[39m \u001b[43m        \u001b[49m\u001b[43mbody\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    313\u001b[39m \u001b[43m        \u001b[49m\u001b[43mpost_params\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    314\u001b[39m \u001b[43m        \u001b[49m\u001b[43mfiles\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    315\u001b[39m \u001b[43m        \u001b[49m\u001b[43mresponse_type\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    316\u001b[39m \u001b[43m        \u001b[49m\u001b[43mauth_settings\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    317\u001b[39m \u001b[43m        \u001b[49m\u001b[43m_return_http_data_only\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    318\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcollection_formats\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    319\u001b[39m \u001b[43m        \u001b[49m\u001b[43m_preload_content\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    320\u001b[39m \u001b[43m        \u001b[49m\u001b[43m_request_timeout\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    321\u001b[39m \u001b[43m        \u001b[49m\u001b[43m_host\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    322\u001b[39m \u001b[43m        \u001b[49m\u001b[43m_check_type\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    323\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    325\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m.pool.apply_async(\n\u001b[32m    326\u001b[39m     \u001b[38;5;28mself\u001b[39m.__call_api,\n\u001b[32m    327\u001b[39m     (\n\u001b[32m   (...)\u001b[39m\u001b[32m    344\u001b[39m     ),\n\u001b[32m    345\u001b[39m )\n",
      "\u001b[36mFile \u001b[39m\u001b[32me:\\AI\\AI,ML Career\\Medical-chatbot-using-Liama-2\\medicalChatbot\\Lib\\site-packages\\pinecone\\openapi_support\\api_client.py:182\u001b[39m, in \u001b[36mApiClient.__call_api\u001b[39m\u001b[34m(self, resource_path, method, path_params, query_params, header_params, body, post_params, files, response_type, auth_settings, _return_http_data_only, collection_formats, _preload_content, _request_timeout, _host, _check_type)\u001b[39m\n\u001b[32m    180\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m PineconeApiException \u001b[38;5;28;01mas\u001b[39;00m e:\n\u001b[32m    181\u001b[39m     e.body = e.body.decode(\u001b[33m\"\u001b[39m\u001b[33mutf-8\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m--> \u001b[39m\u001b[32m182\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m e\n\u001b[32m    184\u001b[39m \u001b[38;5;28mself\u001b[39m.last_response = response_data\n\u001b[32m    186\u001b[39m return_data = response_data\n",
      "\u001b[36mFile \u001b[39m\u001b[32me:\\AI\\AI,ML Career\\Medical-chatbot-using-Liama-2\\medicalChatbot\\Lib\\site-packages\\pinecone\\openapi_support\\api_client.py:170\u001b[39m, in \u001b[36mApiClient.__call_api\u001b[39m\u001b[34m(self, resource_path, method, path_params, query_params, header_params, body, post_params, files, response_type, auth_settings, _return_http_data_only, collection_formats, _preload_content, _request_timeout, _host, _check_type)\u001b[39m\n\u001b[32m    161\u001b[39m url = build_request_url(\n\u001b[32m    162\u001b[39m     config=config,\n\u001b[32m    163\u001b[39m     processed_path_params=path_params_tuple,\n\u001b[32m    164\u001b[39m     resource_path=resource_path,\n\u001b[32m    165\u001b[39m     _host=_host,\n\u001b[32m    166\u001b[39m )\n\u001b[32m    168\u001b[39m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m    169\u001b[39m     \u001b[38;5;66;03m# perform request and return response\u001b[39;00m\n\u001b[32m--> \u001b[39m\u001b[32m170\u001b[39m     response_data = \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    171\u001b[39m \u001b[43m        \u001b[49m\u001b[43mmethod\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    172\u001b[39m \u001b[43m        \u001b[49m\u001b[43murl\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    173\u001b[39m \u001b[43m        \u001b[49m\u001b[43mquery_params\u001b[49m\u001b[43m=\u001b[49m\u001b[43mprocessed_query_params\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    174\u001b[39m \u001b[43m        \u001b[49m\u001b[43mheaders\u001b[49m\u001b[43m=\u001b[49m\u001b[43mheaders_tuple\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    175\u001b[39m \u001b[43m        \u001b[49m\u001b[43mpost_params\u001b[49m\u001b[43m=\u001b[49m\u001b[43mprocessed_post_params\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    176\u001b[39m \u001b[43m        \u001b[49m\u001b[43mbody\u001b[49m\u001b[43m=\u001b[49m\u001b[43mbody\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    177\u001b[39m \u001b[43m        \u001b[49m\u001b[43m_preload_content\u001b[49m\u001b[43m=\u001b[49m\u001b[43m_preload_content\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    178\u001b[39m \u001b[43m        \u001b[49m\u001b[43m_request_timeout\u001b[49m\u001b[43m=\u001b[49m\u001b[43m_request_timeout\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    179\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    180\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m PineconeApiException \u001b[38;5;28;01mas\u001b[39;00m e:\n\u001b[32m    181\u001b[39m     e.body = e.body.decode(\u001b[33m\"\u001b[39m\u001b[33mutf-8\u001b[39m\u001b[33m\"\u001b[39m)\n",
      "\u001b[36mFile \u001b[39m\u001b[32me:\\AI\\AI,ML Career\\Medical-chatbot-using-Liama-2\\medicalChatbot\\Lib\\site-packages\\pinecone\\openapi_support\\api_client.py:386\u001b[39m, in \u001b[36mApiClient.request\u001b[39m\u001b[34m(self, method, url, query_params, headers, post_params, body, _preload_content, _request_timeout)\u001b[39m\n\u001b[32m    376\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m.rest_client.OPTIONS(\n\u001b[32m    377\u001b[39m         url,\n\u001b[32m    378\u001b[39m         query_params=query_params,\n\u001b[32m   (...)\u001b[39m\u001b[32m    383\u001b[39m         body=body,\n\u001b[32m    384\u001b[39m     )\n\u001b[32m    385\u001b[39m \u001b[38;5;28;01melif\u001b[39;00m method == \u001b[33m\"\u001b[39m\u001b[33mPOST\u001b[39m\u001b[33m\"\u001b[39m:\n\u001b[32m--> \u001b[39m\u001b[32m386\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mrest_client\u001b[49m\u001b[43m.\u001b[49m\u001b[43mPOST\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    387\u001b[39m \u001b[43m        \u001b[49m\u001b[43murl\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    388\u001b[39m \u001b[43m        \u001b[49m\u001b[43mquery_params\u001b[49m\u001b[43m=\u001b[49m\u001b[43mquery_params\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    389\u001b[39m \u001b[43m        \u001b[49m\u001b[43mheaders\u001b[49m\u001b[43m=\u001b[49m\u001b[43mheaders\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    390\u001b[39m \u001b[43m        \u001b[49m\u001b[43mpost_params\u001b[49m\u001b[43m=\u001b[49m\u001b[43mpost_params\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    391\u001b[39m \u001b[43m        \u001b[49m\u001b[43m_preload_content\u001b[49m\u001b[43m=\u001b[49m\u001b[43m_preload_content\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    392\u001b[39m \u001b[43m        \u001b[49m\u001b[43m_request_timeout\u001b[49m\u001b[43m=\u001b[49m\u001b[43m_request_timeout\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    393\u001b[39m \u001b[43m        \u001b[49m\u001b[43mbody\u001b[49m\u001b[43m=\u001b[49m\u001b[43mbody\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    394\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    395\u001b[39m \u001b[38;5;28;01melif\u001b[39;00m method == \u001b[33m\"\u001b[39m\u001b[33mPUT\u001b[39m\u001b[33m\"\u001b[39m:\n\u001b[32m    396\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m.rest_client.PUT(\n\u001b[32m    397\u001b[39m         url,\n\u001b[32m    398\u001b[39m         query_params=query_params,\n\u001b[32m   (...)\u001b[39m\u001b[32m    403\u001b[39m         body=body,\n\u001b[32m    404\u001b[39m     )\n",
      "\u001b[36mFile \u001b[39m\u001b[32me:\\AI\\AI,ML Career\\Medical-chatbot-using-Liama-2\\medicalChatbot\\Lib\\site-packages\\pinecone\\openapi_support\\rest_utils.py:146\u001b[39m, in \u001b[36mRestClientInterface.POST\u001b[39m\u001b[34m(self, url, headers, query_params, post_params, body, _preload_content, _request_timeout)\u001b[39m\n\u001b[32m    136\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mPOST\u001b[39m(\n\u001b[32m    137\u001b[39m     \u001b[38;5;28mself\u001b[39m,\n\u001b[32m    138\u001b[39m     url,\n\u001b[32m   (...)\u001b[39m\u001b[32m    144\u001b[39m     _request_timeout=\u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[32m    145\u001b[39m ):\n\u001b[32m--> \u001b[39m\u001b[32m146\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    147\u001b[39m \u001b[43m        \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mPOST\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m    148\u001b[39m \u001b[43m        \u001b[49m\u001b[43murl\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    149\u001b[39m \u001b[43m        \u001b[49m\u001b[43mheaders\u001b[49m\u001b[43m=\u001b[49m\u001b[43mheaders\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    150\u001b[39m \u001b[43m        \u001b[49m\u001b[43mquery_params\u001b[49m\u001b[43m=\u001b[49m\u001b[43mquery_params\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    151\u001b[39m \u001b[43m        \u001b[49m\u001b[43mpost_params\u001b[49m\u001b[43m=\u001b[49m\u001b[43mpost_params\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    152\u001b[39m \u001b[43m        \u001b[49m\u001b[43m_preload_content\u001b[49m\u001b[43m=\u001b[49m\u001b[43m_preload_content\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    153\u001b[39m \u001b[43m        \u001b[49m\u001b[43m_request_timeout\u001b[49m\u001b[43m=\u001b[49m\u001b[43m_request_timeout\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    154\u001b[39m \u001b[43m        \u001b[49m\u001b[43mbody\u001b[49m\u001b[43m=\u001b[49m\u001b[43mbody\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    155\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32me:\\AI\\AI,ML Career\\Medical-chatbot-using-Liama-2\\medicalChatbot\\Lib\\site-packages\\pinecone\\openapi_support\\rest_urllib3.py:267\u001b[39m, in \u001b[36mUrllib3RestClient.request\u001b[39m\u001b[34m(self, method, url, query_params, headers, body, post_params, _preload_content, _request_timeout)\u001b[39m\n\u001b[32m    264\u001b[39m     \u001b[38;5;66;03m# log response body\u001b[39;00m\n\u001b[32m    265\u001b[39m     logger.debug(\u001b[33m\"\u001b[39m\u001b[33mresponse body: \u001b[39m\u001b[38;5;132;01m%s\u001b[39;00m\u001b[33m\"\u001b[39m, r.data)\n\u001b[32m--> \u001b[39m\u001b[32m267\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mraise_exceptions_or_return\u001b[49m\u001b[43m(\u001b[49m\u001b[43mr\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32me:\\AI\\AI,ML Career\\Medical-chatbot-using-Liama-2\\medicalChatbot\\Lib\\site-packages\\pinecone\\openapi_support\\rest_utils.py:49\u001b[39m, in \u001b[36mraise_exceptions_or_return\u001b[39m\u001b[34m(r)\u001b[39m\n\u001b[32m     46\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[32m500\u001b[39m <= r.status <= \u001b[32m599\u001b[39m:\n\u001b[32m     47\u001b[39m         \u001b[38;5;28;01mraise\u001b[39;00m ServiceException(http_resp=r)\n\u001b[32m---> \u001b[39m\u001b[32m49\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m PineconeApiException(http_resp=r)\n\u001b[32m     51\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m r\n",
      "\u001b[31mPineconeApiException\u001b[39m: (400)\nReason: Bad Request\nHTTP response headers: HTTPHeaderDict({'content-type': 'text/plain; charset=utf-8', 'access-control-allow-origin': '*', 'vary': 'origin,access-control-request-method,access-control-request-headers', 'access-control-expose-headers': '*', 'x-pinecone-api-version': '2025-04', 'x-cloud-trace-context': '1020a2b8211b4793d5e14927293ceabb', 'date': 'Wed, 02 Jul 2025 11:18:46 GMT', 'server': 'Google Frontend', 'Content-Length': '200', 'Via': '1.1 google', 'Alt-Svc': 'h3=\":443\"; ma=2592000,h3-29=\":443\"; ma=2592000'})\nHTTP response body: {\"error\":{\"code\":\"INVALID_ARGUMENT\",\"message\":\"Bad request: Your free plan does not support indexes in the us-west-2 region of aws. To create indexes in this region, upgrade your plan.\"},\"status\":400}\n"
     ]
    }
   ],
   "source": [
    "from pinecone import Pinecone, ServerlessSpec\n",
    "\n",
    "pc = Pinecone(api_key=PINECONE_API_KEY)\n",
    "\n",
    "index_name = \"medical-chatbot2\"  # ✅ all lowercase and hyphen\n",
    "\n",
    "if index_name not in pc.list_indexes().names():\n",
    "    pc.create_index(\n",
    "        name=index_name,\n",
    "        dimension=384,  # for all-MiniLM-L6-v2\n",
    "        metric=\"cosine\",\n",
    "        spec=ServerlessSpec(cloud='aws', region='us-west-2')\n",
    "    )\n",
    "\n",
    "index = pc.Index(index_name)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "588eadf5",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
